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Abstract 
 
Introduction: Sympathetic nerve activity (SNA) undergoes physiological modulation 
by respiration but it remains unclear whether this process is altered by age and 
hypertension. 
Aims: To establish relationship between respiration and neural regulation of the 
cardiovascular system in aging and hypertension.  
Methods: Multiunit muscle SNA, BP, respiratory parameters and heart rate were 
recorded at rest in young and older healthy men and hypertensive patients, then repeated 
in hypertensive group after acute and long-term device-guided slow deep-breathing 
(SDB) training. 
Results: Muscle SNA was higher in older subjects but showed similar modulation by 
respiration in both age groups. In young acute SDB reduced SNA, with no effect on 
sympathetic and cardiac baroreflex sensitivity. The sympathoinhibition was not related 
to changes in baroreflex sensitivity, but it reflected increases in lung inflation afferent 
input and/or reduction in central respiratory-sympathetic coupling. Long-term SDB 
training inhibited muscle SNA in hypertensive patients and led to acute increase in heart 
rate variability and longer-term BP reduction. There were no changes in baroreflex 
sensitivity, cardiac structure/function or arterial stiffness in response to SDB training.  
Conclusions: The study provides new mechanistic insights into sympathetic regulatory 
pathways in hypertension and aging, which may help to establish anti-hypertensive 
strategy based on respiratory modulation. 
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CHAPTER I. INTRODUCTION 
 
Hypertension is a major cardiovascular risk factor. It affects approximately 1 billion 
people worldwide with less than half being able to achieve desirable blood pressure 
(BP) control with treatment.1-5 Hypertension has a major impact on health and longevity 
and puts a huge strain on national healthcare services. Strikingly, each 2 mmHg increase 
in systolic BP translates into a 7% increase in mortality from ischemic heart disease and 
a 10% increase from a stroke.6  
 
The sympathetic nervous system plays a key role in the maintenance of homeostasis, 
including the regulation of the functional status of the cardiovascular, respiratory, 
gastrointestinal and genitourinary systems. The sympathetic nervous system has a 
complex neuroanatomy and it closely interacts with, and receives inputs from, multiple 
other organs and systems. This reflects its status as a global regulator of bodily function. 
However, the chronic activation of the sympathetic nervous system can lead to a 
number of cardiovascular risk factors and pathologies. These disorders include ischemic 
heart disease, myocardial infarction, and heart failure.7-10 Studies performed on patients 
with hypertension have demonstrated the relevance of sympathetic activation to the 
pathogenesis of hypertension starting from its early manifestations and extending to its 
advanced stages and development of complications. The degree of BP increase has been 
shown to parallel the magnitude of the sympathetic activation.11, 12 In fact, data indicate 
that heightened sympathetic activation often precedes hypertension.13 In a longitudinal 
observational study with a 20-year follow up, high arterial adrenaline levels strongly 
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predicted future occurrence of hypertension.13 Sympathetic hyperactivity in 
hypertension leads to development of left ventricle (LV) hypertrophy and presence of 
LV hypertrophy in hypertensive patients.14-17 Moreover high sympathetic nerve activity 
(SNA) is associated with LV diastolic dysfunction independently of BP levels18, 19 
Taken together, these observations indicate that the sympathetic nervous system may 
play a role in the initiation, development, and worsening of hypertension. 
 
Aging is commonly associated with increased cardiovascular morbidity, higher 
prevalence of hypertension20, 21 and it is reasonable to probe potential changes in 
sympathetic system status in older people and possible factors modulating the system’s 
activity. Furthermore, healthy older people have raised plasma catecholamine 
concentrations, elevated noradrenaline spillover from the heart, brain, kidneys, and 
increased sympathetic neural drive to vasculature of the skeletal muscles (i.e., muscle 
SNA).22, 23 These autonomic alterations have been related to abnormalities in vascular 
structure and function, including impairment of the elastic properties of the large 
arteries and vasomotor endothelial function.24, 25 The mechanistic basis for the age-
related elevation in sympathetic neural firing remains unknown. 
 
Respiration has been long known to modulate SNA. The links between breathing and 
SNA are mediated by central neuronal circuits with the regulatory feedback signals 
from cardiorespiratory sensory afferents (e.g., lung-stretch receptors, baroreceptors, 
peripheral chemoreceptors).26-33 Spontaneous shallow breathing (decreased tidal 
volume) has been associated with an increase in sympathetic activity in patients with 
heart failure, likely a consequence of diminished inhibition of SNA by pulmonary 
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stretch receptors32, 34. During normal breathing in young healthy individuals muscle 
SNA is inhibited during mid-inspiration, reaching a nadir when lung volume is at its 
highest (peak inspiration), and it peaks when lung volume is at its lowest (end-
expiration).27-30, 33 It is possible that an impairment in the normal inspiratory inhibition 
of muscle SNA explains the increase in the tonic level of muscle SNA and thus elevated 
BP with age. However, to date it is unknown whether the respiratory modulation of 
muscle SNA is changed as a consequence of healthy human ageing. In light of this 
background, the first experimental chapter (Chapter 4), aimed to establish the effect of 
age on respiratory related bursting of muscle SNA and on the association between the 
rhythmic fluctuations in muscle SNA and BP that occur with respiration in humans.  
 
The use of breathing techniques for management of hypertension has a long history.35, 36 
Recently, the potential of the hypotensive effect of device-guided slow deep breathing 
have been demonstrated in several trials,37-43 although such findings have not always 
been consistent.44-47 Recently home-based device-guided training has been 
recommended by the American Heart Association.48 Despite several trials investigating 
the effect of slow deep breathing on BP few studies assessed mechanisms of the acute 
and especially long-term effects of the technique. However, the physiological 
mechanisms leading to the BP lowering effects of device-guided slow deep breathing 
and the potential for associated effects on neural regulation, cardiovascular structure 
and function remain unclear. 
 
It has been reported that acute slow deep breathing increases cardiovagal baroreflex 
sensitivity in young healthy individuals, children with obesity and patients with heart 
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failure and hypertension.49-54 However, data are lacking on acute and longer-term effect 
of slow deep breathing on arterial baroreflex control of muscle SNA.55 This response is 
important to establish because cardiovagal baroreflex sensitivity and arterial baroreflex 
control of muscle SNA are differentially controlled and do not always change in 
parallel.55 It is known that slow deep breathing acutely inhibits increased SNA in 
hypertensive patients,44, 56 but there are no published data on muscle SNA response to 
the acute slow deep breathing in healthy young subjects.49, 50, 57  
 
Analysis of heart rate (HR) variability allows insight into cardiac parasympathetic 
activity, but limited knowledge is available on how this activity is influenced by device-
guided slow deep breathing. Acute effect on cardiac parasympathetic fluctuations has 
only been tested in a group of healthy middle age volunteers with borderline elevated 
BP.58 That study was not able to demonstrate a significant increase in parameters of the 
cardiac parasympathetic drive.58 Also, the acute effect of device-guided slow deep 
breathing on HR variability in hypertensive patients was not studied, neither HR 
variability response was evaluated in hypertensive cohort without concomitant 
pathologies longer term.59 
 
In this thesis, I aimed to obtain further information on influences of slow deep breathing 
on sympathetic and parasympathetic activity in carefully selected young healthy 
individuals and patients with established hypertension (Chapters 5 and 6, respectively). 
The hypothesis was tested that acute slow deep breathing would reduce BP and muscle 
SNA in young healthy and hypertensive groups, and to assess the underlying 
mechanisms of autonomic neural effect. I also aimed to provide a comprehensive 
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assessment of the long-term training effects of home-based device-guided slow deep 
breathing on autonomic regulation in hypertension reflected by muscle SNA, arterial 
baroreflex control of muscle SNA, parameters of HR variability and effect on 
hypertension target organ damage (e.g. heart, vessels, kidney).  
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CHAPTER II. LITERATURE REVIEW 
 
2.1. Hypertension: clinical significance and epidemiology 
 
Hypertension is a major global health problem due to the large number of patients 
affected and its strong association with an increased risk of coronary artery disease, 
myocardial infarction, stroke, renal dysfunction, and death.60 The clinical importance of 
hypertension is highlighted by estimates that it contributes to a third of all cases of 
myocardial infarctions and strokes, and half of all cases of heart failure.61 Hypertension 
is also the leading course of kidney failure.20 
 
Hypertension is usually defined as systolic BP equal or above 140 mmHg or diastolic 
BP equal or above 90 mmHg.20 However, in some patient populations, such as in those 
with complicated renal dysfunction even lower BP levels may merit treatment. It is 
estimated that about 1 billion people are affected by hypertension worldwide and that it 
affects approximately every third individual in developed countries.1-3 Currently, 
hypertension is also a growing problem in the developing world with the number of 
affected individuals expected to rise further with improving detection and increasing 
urbanization.62 
 
In fact, even those high numbers may underestimate the genuine rate of hypertension as 
it often remains undetected until the patient develops severe and often disabling 
complications. Identification and appropriate management of high BP are of particular 
clinical importance as interventions directed to BP reduction bring significant health 
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benefits. It has been shown that every 5 mm Hg decrease in systolic BP in the general 
population is associated with a 9% to 14% decrease in cardiovascular mortality.63 
Nevertheless, despite the availability of a wide range of pharmacological and non-
pharmacological interventions to reduce BP, recent data show poor hypertension control 
in every second patient.5 This fact partly reflects the substantial diversity and 
heterogeneity of pathogenic mechanisms of hypertension, which still remain 
insufficiently understood. Available and emerging data clearly suggest the intimate role 
of the sympathetic nervous system in the pathophysiology of hypertension. 
 
In this section of the thesis, I aim to provide an overview of the structure of the 
autonomic nervous system, with a particular focus on the sympathetic nervous system. 
The methods available for the assessment of the sympathetic nervous system will be 
discussed along with their advantages and limitations. Following that, I will review 
current knowledge of the pathways involved in the sympathetic regulation of BP per se 
and the pathogenesis of hypertension. The section will conclude with an overview of the 
available therapeutic and lifestyle approaches to improve BP control via modulation of 
the sympathetic nervous system. 
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2.2. Autonomic nervous system: organization and regulation 
 
2.2.1. Introduction 
 
The autonomic nervous system plays a key role in the unconscious regulation of many 
bodily actions and is composed of sympathetic, parasympathetic and enteric divisions. 
The enteric nervous system, an intrinsic nervous system of the gastrointestinal tract, 
appears to have little role in BP control. It possesses complete reflex circuits 
functioning to detect homeostatic changes within gastrointestinal organs to provide 
outputs to keep intestinal motility, fluid exchange balance and gut circulation within the 
desirable range.64 The enteric nervous system contains two nerve plexuses that continue 
along the entire length of the gastrointestinal tract. The system also has extensive links 
with other parts of the central nervous system that allow interactions with and 
adjustment for the state of the entire body. 
  
Sympathetic and parasympathetic nervous systems play a crucial role in the regulation 
of maintenance of bodily homeostasis, including the regulation of the functional status 
of the cardiovascular, respiratory, gastrointestinal and genitourinary systems, but also 
pupillary responses and thermoregulation (Table 2.1). The autonomic nervous system 
has a complex structure, and it regulates a variety of parameters implicated in BP 
control, which will be discussed below in more detail. 
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Table 2.1. Overview of sympathetic and parasympathetic nervous system actions 
Effector 
organ 
Sympathetic Parasympathetic 
Heart é Contractility and heart rate  ê Contractility and heart rate 
Blood vessels Vasoconstriction - 
Pupils Dilation Constriction 
Lungs Bronchial dilation Bronchial constriction 
Bladder Inhibits voiding Promotes voiding 
Gastro-
intestinal tract 
Inhibits digestion and secretion 
Stimulates digestion and 
secretion 
Kidneys 
é Secretion of 
noradrenaline   
- 
Salivary and 
lacrimation 
glands 
- é Salvation and tear production 
Liver 
éGlucose production and 
release 
é Bile release 
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2.2.2. Central regulation 
 
Figure 2.1 provides a simplified overview of the central regulation of sympathetic 
outflow. The medulla oblongata is a region of the brainstem that has a particularly 
important role in the control of autonomic function, and thus regulation of the 
respiratory, cardiovascular and gastrointestinal systems.65 It contains several smaller 
specialised areas that are of importance for the generation and regulation of sympathetic 
outflow. The rostral ventrolateral medulla (RVLM) is a site of central sympathetic 
outflow, which receives both excitatory and inhibitory inputs. It is commonly 
recognised as the pressor area of the brain and functions as the primary regulator of the 
sympathetic nervous outflow to the heart and vasculature (Figure 2.1).65 Excitatory 
catecholaminergic neurones project from the RVLM to the sympathetic preganglionic 
neurones in the intermediolateral (IML) cell column of the spinal cord via reticulospinal 
tract. Also, as evident from retrogradely transported tracer studies, IML preganglionic 
neurones receive direct input from other brain centres (e.g. hypothalamic nuclei, pontine 
structures, ventromedial medulla).66 In addition inhibitory γ- amino butyric acid 
(GABA) receptors expressed in IML.67, 68 The RVLM is considered to be a site at which 
central (e.g. pons, hypothalamus, amygdala) and peripheral (e.g. afferent inputs, 
including baroreflex input) receptor pathways converge. RVLM neurones possess both 
excitatory glutamate neurones and inhibitory GABA neurones.69-71 The RVLM 
glutamatergic neurones differ neurochemically. Some of the neurones contain the 
phenylethanolamine-N-methyltransferase enzyme (PNMT), which is involved in the 
catecholamine synthesis.72 These neurones form the C1 cell population73, 74 and in one 
experiment, the retrograde labelling of C1 neurones in the IML showed that 79% of the 
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C1 bulbospinal neurones are glutamatergic.75 Additionally, the C1 cells expressed 
substance P, enkephalin, pituitary adenylate cyclase activating polypeptide, vasoactive 
intestinal peptide, and neuropeptide Y.76-78 The C1 neurones have two types of 
terminals, containing either glutamate79, 80 or PNMT81, 82 and both types of the 
terminals, synapse with sympathetic preganglionic neurones in the IML. Recent work 
by Guyenet and colleagues has provided insight into the functional role of C1 neurones 
using new experimental approaches. Activation of C1 cells using photostimulation 
evoked an increase in BP83 while selective partial lesioning of the C1 cells diminished 
the pressor effects.83 In another experiment by Guyenet and colleagues, a lentivirus 
expressing channelrhodopsin-2 (ChR2) under the control of the catecholaminergic 
neuron preferring promoter PRSx8, was used to powerfully and selectively activate C1 
neurones in the RVLM. This led to a prominent sympathoactivation and a marked 
increase in BP.84 Earlier work had shown that the destruction of C1 neurones by spinal 
microinjections of an anti-dopamine-beta-hydroxylase antibody conjugated to the 
ribosomal toxin, saporin (80-85% depletion)85-87 reduced the sympathetic activation 
mediated by activation of the baroreflex, carotid chemoreflex, and somatic pressor 
reflex.85-87 In contrast, the parasympathetic branch of the baroreflex function was not 
affected by C1 neuron destruction as the reduction in HR in response to an increase in 
BP was preserved.87 Taken together, these experiments provide unambiguous and 
sophisticated evidence that C1 neurones are an important regulator of sympathetic 
cardiovascular function. AT(1) receptors for angiotensin II are also expressed in 
RVLM, as evident with quantitative in vitro autoradiography.88 The RVLM also 
contains nitric oxide (NO) synthase (NOS)-producing neurones, which can be activated 
through sympathoexcitatory cardiac reflexes.89 Although the region contains all 3 
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isoforms of the NOS (i.e., neuronal NOS (nNOS), inducible NOS (iNOS), and 
endothelial NOS (eNOS)) only nNOS has been reported to mediate the cardiac 
sympathetic response, as evident from the attenuation of sympathoexcitatory reflexes 
only after specific inhibition of nNOS.89  
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Figure 2.1. Simplified diagram showing organization of the brain regions involved 
in the generation and modulation of the sympathetic flow 
CVLM, caudal ventrolateral medulla; IML, intermediolateral cell column; NTS, nucleus 
tractus solitarius; PVN, paraventricular nucleus; RVLM, rostral ventrolateral medulla. 
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The supramedullary paraventricular nucleus (PVN) in the hypothalamus is a well-
recognised area providing direct descending excitatory inputs to IML of the spinal cord 
and RVLM.90 The activity of PVN neurones can be modulated by circulating 
angiotensin II and by renal afferent signals nerves delivered through the NTS.91-93 Both 
NO and GABA are known to provide inhibitory inputs to the PVN and are thus 
involved in the control of sympathetic outflow.91-93 Indeed, in rats, the microinjection of 
a NO donor (sodium nitroprusside) into the PVN resulted in a dose dependant reduction 
in renal sympathetic activity, with no response in the presence GABA blockade with 
bicuculline.91 When the production of NO was inhibited with L-NAME renal 
sympathetic activity was increased, this excitatory effect was eliminated by activation 
of the GABA system with muscimol. Negative feedback of NO on the glutamate system 
within the PVN is responsible for the balance of the sympathetic drive both 
physiological and pathological states.92 
 
The nucleus tractus solitarius (NTS) constitutes a vertical column of grey matter within 
the medulla oblongata. The NTS serves as the primary integrative centre for arterial 
baroreceptor and peripheral afferents and from the NTS projections travel to many other 
parts of the brain (e.g., preganglionic neurones, hypothalamus and thalamus).94 In 
particular, NTS neurones project to the GABAergic barosensitive interneurones of the 
caudal ventrolateral medulla (CVLM) (as demonstrated by retrograde fluorescent 
tracing), which send inhibitory impulses directly to the RVLM.95 NO amplifies 
glutamatergic transmission in the NTS, where blockade of NOS activity inhibits 
baroreflexes and cardiopulmonary reflexes.96 
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The sympathetic preganglionic neurones are the most peripheral location at which the 
central nervous system may modulate sympathetic outflow. The soma of the 
sympathetic preganglionic neurones are located in the lateral horns and central regions 
of the spinal cord.97 Although the majority of the neuron bodies are placed at the 
thoracic and lumbar spine levels, some are situated at cervical level VIII.98, 99 Axons of 
the sympathetic preganglionic neurones mainly project towards postganglionic neurones 
via the ventral root, but also to the adrenal medulla and accessory peripheral nerves.100, 
101 Retrograde labelling of sympathetic nerves and ganglia using Fluoro-gold was 
utilized to establish distribution of sympathetic preganglionic neurones in rats.102 A 
large number of sympathetic preganglionic neurones (i.e., 1000-2000 neurones per 
ganglion) have been identified within the ganglia involved in regulation of the head or 
chest organs. This is in contrast to the relatively small number of sympathetic 
preganglionic neurones (i.e., 100-400 neurone per ganglion) in the ganglia that control 
abdominal and pelvic organs, including the kidneys. It has been suggested that this 
observation likely reflects differences in the regulatory contribution of the sympathetic 
preganglionic neurones to these organs.102 The sympathetic preganglionic neurones 
receive modulatory inputs from afferent feedback, descending influences, and 
interneurones. Important advances in the understanding of the inputs to sympathetic 
preganglionic neurones have been made using rat experiments employing transneuronal 
labelling with pseudorabies virus.103 After the injections into various sympathetic 
ganglia and the adrenal gland, the infection affected neurones of the RVLM, A5, raphe, 
and hypothalamus, which identified five brain cell clusters responsible for the 
regulation of the sympathetic outflow.66, 104 On the virus expansion the label was further 
found in some sympathetic ganglia, mainly superior cervical and stellate ganglia. In 
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addition, for the first time, the virus labelling targeted spinal cord interneurones in 
laminae VII and X, one of the important components of the spinal cord.66, 104 
Sympathetic preganglionic neurones can also be excited by stimulation of visceral or 
somatic afferents.105-108 These afferent inputs and some descending inputs are further 
modulated by the spinal interneurones.109, 110 Taken together, these experiments 
demonstrate that sympathetic preganglionic neurones not only receive descending 
modulatory signals but also interact with local influences to produce functionally 
appropriate changes in sympathetic outflow to body tissues and organs. This view 
advances the previous simplistic perception of the sympathetic preganglionic neurones 
as relay neurones translating central influences without significant modulation by local 
neuronal feedback. 
 
New information has been provided by functional magnetic resonance imaging (fMRI) 
regarding the central regulation of sympathetic outflow in humans. King et al. were the 
first to report activation in the insular and medial prefrontal cortex and the thalamus in 
response to changes in HR and BP caused by maximal inspiration, Valsalva manoeuvre 
or isometric handgrip exercise.111 An ‘activation likelihood estimation meta-analysis’ of 
the neuroimaging experiments identified several consistently activated human brain 
areas involved in the autonomic regulation. These areas included left amygdala, right 
anterior and left posterior insula and midcingulate cortices.112 Although the insular 
cortex has attracted substantial attention in animal studies, analysis of this brain area in 
humans initially proved challenging due to the limited spatial resolution of available 
neuroimaging techniques. However, work by Macey et al. has provided further insight 
into the role of this area in humans using newer fMRI techniques and reported that five 
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different areas within the insular cortex display distinct responses to various autonomic 
challenges.113 Subsequently, Shoemaker and colleagues reported activation of the 
posterior insular cortex in response to the graded handgrip, thus indicating the role of 
this particular part of the insular cortex in autonomic regulation.114, 115 These 
observations were supported by a human study showing that stimulation of the forearm 
muscles activated the posterior insular cortex but decreased the activation of the anterior 
insular, which might be suggestive of intra-insular connections.115 Activation of the 
posterior insula was also noted during the baroreflex unloading with lower body 
negative pressure.116, 117 In these studies, application of the more pronounced lower 
body negative pressure and higher HR response correlated with higher activity in the 
posterior insula, but also in the frontoparietal cortex and left cerebellum. During the 
same experiments, diminished activity was noted in the anterior insular cortices, right 
anterior cingulate, orbitofrontal cortex, amygdala, midbrain and mediodorsal nucleus of 
the thalamus.  Deactivation of the ventral medial prefrontal cortex was evident during 
the handgrip challenges.114, 115 The deactivation of the ventral medial prefrontal cortex 
was more prominent when participants completed a higher intensity exercise that 
resulted in a larger HR increase. The above studies support the role of these cortical 
regions in the modulation of efferent parasympathetic outflow to the heart. The 
consistent involvement of the insular and ventral medial prefrontal cortex in the 
cardiovascular reflex responses suggests a possibility that these two regions may link 
regulation of the sympathetic and parasympathetic systems. 
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2.2.3. Arterial baroreflex 
 
The arterial baroreceptors are a key regulator of cardiovascular autonomic activity. The 
arterial baroreflex serves to provide a negative feedback regulation of BP and thus help 
to maintain circulatory homeostasis. Via the baroreflex mechanism, fluctuations in BP 
may be buffered, and desirable BP levels established to meet hemodynamic demand.118 
Baroreceptor afferents respond to the mechanical deformation of their receptive fields at 
the medial-adventitial border in the aortic arch and carotid sinuses.119 The principle 
mechanism of baroreceptor activation is the opening of stretch-activated ion channels, 
but they can be further modulated by functional status of potassium channels and the 
sodium-potassium pump.120 The magnitude by which baroreceptor activity is altered 
further depends on a variety of paracrine factors, such as reactive oxygen species, 
prostacyclin, and factors released from aggregating platelets.120 Baroreceptor afferents 
travel via vagal and glossopharyngeal nerves to the NTS where the information is 
processed and autonomic efferent activity to the heart and vessels modulated.94 An 
increase in BP and the associated increase in baroreceptor afferent activity results in a 
reflex-mediated decrease in SNA to the heart and the blood vessels and an increase in 
cardiac parasympathetic activity. Conversely, a fall in BP decreases baroreceptor 
afferent activity and leads to an increase in SNA and decrease in parasympathetic 
activity. Via this mechanism the adjustment of the sympathetic and parasympathetic 
activity maintain BP around an appropriate operating point level.118 
 
Of note, efferent SNA outflow is dependent upon the type of baroreceptor afferent 
discharge. In the presence of pulse phasic afferent baroreceptor discharge, SNA remains 
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inhibited.120 In contrast, continuous, nonphasic baroreceptor discharge leads to a 
reduction in the afferent activity and elevation of the SNA.120 Baroreflex inhibition of 
the sympathetic activity is controlled by the input from the aortic arch and carotid 
sinuses baroreceptors.121 But strength and occurrence of the sympathetic discharges are 
modulated differentially in both animal122, 123 and human124 investigations. 
 
2.2.4. Peripheral chemoreflex 
 
The peripheral chemoreceptors are situated in the aortic arch and carotid bodies and 
powerfully increase sympathetic activity in response to hypoxemia and hypercapnia. 
Carotid bodies contain glomus cells that respond to hypoxia by releasing various 
neurotransmitters, such as serotonin, acetylcholine, substance P and adenosine 
triphosphate. These neurotransmitters activate afferent neurones within the carotid sinus 
nerve that connect carotid bodies and NTS.125, 126 The activation of the peripheral 
chemoreceptors increasing the SNA and causing arterial constriction within the renal, 
splanchnic and skeletal muscle circulations, and consequently increases BP.125 The 
mechanism aims to compensate for a deficiency in perfusion/oxygen saturation by 
increasing systemic vascular tone.127 Where the restoration of the global circulatory 
homeostasis cannot be achieved the mechanism facilitates the redistribution of the blood 
flow towards critical organs. 
 
Sympathetic stimuli to the heart are also triggered by stimulation of chemoreceptors, 
which evokes both cardiac chronotropic and inotropic effects.125 In contrast, stimulation 
of the chemoreceptors (a mixture of 8% O2 and 92% N2 given for 30 s) inhibits 
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sympathetic outflow to the adipose tissue, which has a biological role in counteracting 
hypoxia via reduction overall oxygen requirements.128 Importantly, arterial chemoreflex 
activation also leads to increase in phrenic nerve activity, that enhances ventilation.129 
 
The magnitude of the sympathetic response to chemoreflex activation is modified by 
breathing rate. Higher breathing rates increase the sympathetic response to stimulation 
of the chemoreceptors,130 whereas at lower respiratory rates the scale of sympathetic 
response to chemoreceptor stimulation is diminished.131 Chemoreceptor mediated 
sympathetic drive is also reduced when respiratory tidal volume is augmented due to an 
enhanced inhibitory response arising from pulmonary stretch receptors.132 
 
2.2.3. Efferent pathways 
 
Several levels of neurones mediate transmission of central sympathetic stimuli. The 
sympathetic preganglionic neurones are located in the thoracolumbar section of the 
spinal cord (from T1 to L2) with their axons in most cases spreading to paravertebral 
ganglia. The next level of postganglionic neurones distributes the sympathetic stimuli to 
the target cells through unmyelinated nerves.64 Adrenergic receptors are the main 
receptors of the sympathetic system and they include alpha receptors, activation of 
which leads to peripheral vasoconstriction; beta 1 receptors, which increase cardiac 
contractility and HR, and beta 2 receptors, which activation cause relaxation of smooth 
muscle in peripheral vasculature, bronchi, gastrointestinal organs, and genitourinary 
system.64 
 
 21 
2.2.4. Parasympathetic nervous system 
 
The parasympathetic nervous system often serves as a counterpart of the sympathetic 
nervous system, however this is not always the case.133 The main biological function of 
the system is to maintain body functions under homeostatic (resting) state as opposed to 
the role of the sympathetic nervous system to adapt to ‘threats’ by providing appropriate 
changes to the resting homeostasis. 
 
Cranial nerve X (vagus) is the principle component of the parasympathetic nervous 
system that links the brain with peripheral organs such as the heart. The preganglionic 
vagal motorneurones arise from the nucleus ambiguous of the medulla oblongata. 
Parasympathetic activity (‘vagal tone’) helps to sustain stable homeostasis of cardiac, 
respiratory, gastrointestinal, genitourinary and endocrine systems among other 
functions. The parasympathetic nervous system also includes neurones in cranial nerves 
III (oculomotor nerve), VII (facial nerve) and IX (glossopharyngeal nerve). 
Preganglionic axons are mostly myelinated, and they synapse with postganglionic 
neurones in ganglia that are located near the end organs.134 The parasympathetic 
nervous system rapidly and powerfully modulates HR. An increase in vagal tone 
reduces HR via inhibition of sinoatrial node discharge. The level of cardiac 
parasympathetic activity at a given instance is dependent upon a multitude of 
influences, such as excitatory central inputs from baroreceptors and the local 
modulatory effects of SNA. Respiration also strongly modulates HR with an inhibition 
of vagal activity and increase in HR observable during inspiration with the opposite 
dynamics seen during expiration. In the absence of direct recordings, the study of such 
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respiratory sinus arrhythmia (e.g., HR variability) can provide a valuable insight into 
cardiac parasympathetic activity in health and disease. This is discussed in detail below 
(2.3.5).  
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2.3. Assessment of autonomic nervous system 
 
2.3.1. Introduction 
 
Accurate quantification of the activity of the sympathetic and parasympathetic branches 
of the autonomic nervous system is essential to assess its impact in the pathogenesis of 
morbid states (e.g., hypertension) and to determine the effectiveness of therapeutical 
strategies targeting the autonomic nervous system. Several methods have been 
described, but all have limitations, which need to be considered when deciding to 
choose a study method. 
 
2.3.2. Plasma catecholamine concentration 
 
Assessment of plasma noradrenaline concentration, the principle neurotransmitter of the 
sympathetic nervous system, provides an accessible and well-validated method of 
quantifying global SNA. High-performance liquid chromatography is a relatively 
inexpensive and widely available technique, which can be employed in clinical settings. 
Advantages of the method also include simplicity of sampling (i.e., venous blood) and a 
possibility of postponed batched sample analysis. It has been demonstrated that forearm 
venous plasma noradrenaline concentration is correlated with central sympathetic 
outflow to the skeletal muscle vasculature in healthy individuals (r=0.65, P<0.01), 
aging populations and disease states (e.g., in hypertension r=0.64, P<0.01).135-137 
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Despite several benefits, the assessment of sympathetic activity using plasma 
noradrenaline concentration has significant limitations. For instance, plasma 
noradrenaline concentrations from venous samples represent only a minor portion of 
secreted neurotransmitter from sympathetic nerve terminals with a substantial part of 
the norepinephrine being taken back up by nerve terminals without spilling into 
plasma.138-140 The proportion of noradrenaline reaching the peripheral circulation may 
vary among different individuals and within individuals, thus affecting the 
reproducibility of the method. It has been shown that reproducibility of venous plasma 
noradrenaline measurements by high-performance liquid chromatography is inferior to 
the reproducibility of microneurography technique (described in detail below).141-143 It 
has also been suggested that the reproducibility could be improved by averaging several 
measurements from the same sample.144, 145 
 
2.3.3. Radiolabeled noradrenaline tracers (noradrenaline spillover) 
 
The assessment of noradrenaline spillover using radiolabelled tracers provides valuable 
and accurate quantitative information on SNA. The procedure involves the infusion of 
small doses of radiolabelled noradrenaline and the placement of a catheter for selective 
blood sampling from particular organs or the whole body.138, 143, 146 The former 
approach allows measurement of regional sympathetic outflow to selected organs, from 
which direct recordings are not possible in humans (e.g., kidneys and heart). In healthy 
subjects, spillover of noradrenaline from the heart correlates well with muscle SNA 
burst frequency at rest (r=0.70, P=0.03).147 Single unit recordings from sympathetic 
nerves in hypertensive patients revealed an association between firing rates of 
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sympathetic bursts and cardiac noradrenaline spillover.148 The value of making regional 
measures of noradrenaline spillover is that a heterogeneous sympathetic activation 
between organs can occur, for example in obese but otherwise healthy individuals 
kidney noradrenaline spillover is elevated while in contrast cardiac spillover is 
decreased.149  
 
Several studies have reported that both cardiac and renal noradrenaline spillover is 
increased in untreated essential hypertension.150-153 In addition, in patients undergoing 
renal denervation a significant reduction of renal noradrenaline spillover rate post 
catheter renal denervation has been reported, that is paralleled by a 50% reduction in 
renin activity and an increase in renal blood flow.154, 155 However more recent studies 
have reported less prominent impact of renal denervation on noradrenaline spillover 
with highly variable results among different patients thus challenging reliability of the 
renal denervation.156 
 
2.3.4. Microneurography 
 
The microneurography technique was developed in the 1960s by Hagbarth and 
Vallbo157 and permitted the first direct recordings of sympathetic action potentials in 
awake humans158. This method brought multiple advantages, such as the real-time 
registration of SNA. Microneurography since has been widely used in a variety of 
experimental settings, contributing to better understanding of the role of sympathetic 
nervous activity in normal physiology and different disease states.159 
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Recordings can be directly obtained from sympathetic nerve efferent activity to either 
the skin or muscle vasculature. Those two types of nerve activity have characteristic 
differences, with muscle SNA having a pulse-synchronous pattern and skin SNA an 
arrhythmic, not cardiac linked discharge. Many studies have been focused on the 
investigation of the activity of sympathetic fibers supplying skeletal muscle 
vasculature.143, 160 These studies provided valuable information on different aspects of 
regulation of cardiovascular functions, including BP control. 
 
The direct recording of efferent muscle SNA is minimally invasive with the peroneal 
nerve being a common choice for such examination.160, 161 The method involves the 
insertion of a unipolar tungsten microelectrode into a sympathetic fascicle at the level of 
fibular head and a reference electrode inserted percutaneously at a site 2-3cm distally. 
The raw signal undergoes amplification (x100000), band-pass filtering (bandwidth 700 
– 2000 Hz), rectification and integration (0.1 s time constant). Acceptance of the 
multiunit muscle SNA neurogram is based on pulse rhythmicity of spontaneous signal 
bursts, with a signal-to-noise ratio of at least 3:1.162 Verification of the recordings can 
assisted by the utilisation of an end-expiratory breath-hold or Valsalva manoeuvre.162 
The integrated neurogram contains information on frequency and activity of the 
sympathetic bursts. The frequency is quantified by counting the number of sympathetic 
bursts per one minute (burst frequency) and by a number of bursts per 100 heart beats 
per minute (burst incidence). The strength of the signal is determined from the 
amplitude or area of the sympathetic bursts. 
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Microneurography provides a direct measurement of central sympathetic outflow to the 
periphery, accurately reflecting changes in sympathetic activity due to neural 
(dys)function. Although there is noticeable inter-individual variability of muscle SNA, 
the method shows excellent reproducibility over repeated measurements.143, 163, 164 The 
limitation of microneurography is that it does not provide a direct measurement of the 
sympathetic activity of the heart and kidney, two key organs involved in blood pressure 
homeostasis. Nevertheless, in healthy subjects, there is a strong association between 
muscle SNA from the peroneal nerve and sympathetic outflow from the heart (r=0.70, 
P=0.03) and kidneys (r=0.76, P<0.01).143, 147, 165 Such an association is less well 
established in disease states. Since muscle SNA provides a measurement of sympathetic 
outflow to vascular smooth muscle cells, it is related to the level of vascular 
resistance.160, 166, 167 Moreover a correlation has been established between muscle SNA 
and the level of plasma markers of sympathetic activity, such as plasma 
noradrenaline.135, 137 
 
Additional parameters obtainable from the single-unit method include information on 
firing frequency, firing probability, the probability of multiple firing (e.g. the number of 
bursts per cardiac interval), recruitment (the number of active fibers) and frequency 
modulation.168, 169 This approach can provide a more comprehensive evaluation of the 
potential for sympathoexcitation in pathological conditions.170-173 
 
Direct recordings from sympathetic nerves in animal studies are usually done acutely on 
anesthetized models.174 More advanced methods involve implantation of electrodes to 
allow longer-term recordings. These were first performed in rabbits171, 175, 176 and now 
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extended to rats177, 178 and mice.179 This provides an opportunity for follow up data 
recordings in animal models of disease states. Such continuous recordings in rat have 
been obtained for periods longer than 3 weeks, which brings clear advantage for 
autonomic control research.180 
 
2.3.5. Heart rate variability 
 
HR variability provides a useful marker of cardiac autonomic control and a tool for 
prediction of outcomes in human studies. For example, in middle age and elderly men 
low HR variability predicts all cause mortality.181, 182 In addition, post-myocardial 
infraction183, 184 and chronic heart failure185, a diminished HR variability has been 
shown to be an independent predictor of mortality.183, 184 Many clinical conditions, 
including ageing and hypertension, are associated with reduced HR variability.186-188 
HR variability supplies indirect information on the cardiac autonomic regulation of 
sinus node, at baseline and in response to different physiological maneuvers. 
Admittedly, the precise contribution of the sympathetic and parasympathetic branches 
of the autonomic nervous system to HR variability has not been firmly established.189 
 
Two main approaches are usually applied to evaluate HR variability: time domain 
methods and frequency domain methods.190 Statistical and geometric approaches are 
both time domain methods. Only QRS complexes from individuals in sinus rhythm can 
be used to calculate successive normal-to-normal R-R intervals. One of the statistical 
parameters that can be calculated is the standard deviation of the normal-to-normal 
intervals (SDNN). SDNN is calculated as the square root of the variance in successive 
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normal-to-normal R-R intervals and equivalent to total power obtained from the 
frequency domain methods.190 SDNN is influenced by the duration of recordings, only 
the same length record should be compared (5 min or 24 hours are commonly 
recommended), and it provides information on overall HR variability. Two other 
common parameters obtained from interval differences are the square root of the mean 
of the sum of successive differences in the normal-to-normal interval (RMSSD) and 
proportion of the number of successive normal-to-normal intervals that differ by more 
than 50 ms (pNN50%). Both RMSSD and pNN50% are considered as markers of 
parasympathetic activity.190, 191 
 
The frequency domain method of HR variability provides information on the 
distribution of power (statistical variance) over the frequencies. The commonly used 
approach is based on fast Fourier transformation. Using short (5 min) recordings, three 
main frequencies determined: very low frequency range (<0.04Hz), low frequency (LF) 
range (0.04–0.15 Hz), high frequency (HF) range (0.15-0.4 Hz) and between (0.0-0.4 
Hz) total power (TP). Interpretation of the very LF is much less robustly defined 
especially using 5 min recordings 190, 192 LF and HF components are described in 
absolute power spectral density and normalized units.  Normalized units calculated as 
the proportion of each component to the TP minus very low frequency range. The HF 
component is principally a marker of parasympathetic activity,190, 193, 194 while the LF is 
a marker of the interaction of sympathetic and parasympathetic activity.191, 195, 196 There 
are data showing that the LF component does not relate to the spillover of noradrenaline 
from the heart and/or muscle SNA.143 However some groups consider LF data to be 
reflective of the level of sympathetic activity.197 In hypertensive patients, an increase in 
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LF and decrease in HF as compared to normotensives has been interpreted as an 
enhanced cardiac sympathetic activity and a reduced parasympathetic activity.198 Beta-
adrenergic blockade for 2 weeks with atenolol in hypertension resulted in a significant 
reduction in LF.198 HR variability assessed using frequency domain methods have been 
proposed as a convenient non-invasive technique for monitoring of dynamic changes in 
sympatho-vagal balance in hypertension.198 Spectral analysis of HR variability can also 
be used to evaluate the effect of antihypertensive agents on sympatho-vagal balance.199 
 
 The ratio of LF to HF is considered as an index of sympatho-vagal balance, with higher 
numbers indicating increased sympathetic activity and/or decreased parasympathetic 
activity.200-202 It needs to be mentioned that some groups do not entirely agree with such 
interpretation of the ratio.203, 204 Admittedly interpretation of results of HR variability 
findings could be ambiguous, partly due to the on-going dispute on the physiological 
meaning of changes in LF and HF.203, 205 It is commonly agreed that the HR variability 
approach has important limitations to be considered as a straightforward and reliable 
tool for assessment of autonomic nervous status. 
 
2.3.6. Summary 
 
Despite several techniques being available to quantify the status of the autonomic 
nervous system, each approach has significant limitations and utilization of several 
methods can be recommended (if plausible) to provide more robust conclusions. Among 
the available techniques microneurography clearly benefits from being a minimally 
invasive method for direct assessment of sympathetic activity in real time. This method 
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is suitable for repeated measurement for monitoring of disease progression and response 
to therapeutic interventions. 
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2.4. Heightened sympathetic activity in disease 
 
A number of cardiovascular disorders, and risk factors for their development have been 
associated with the heightened activation of the sympathetic nervous system. These 
conditions include myocardial infarction,7 congestive heart failure,8-10 metabolic 
syndrome,206 and obstructive sleep apnoea.207-209 Studies conducted on patients with 
essential hypertension confirmed the involvement of sympathetic system starting from 
the early stages of hypertension and persisting through its progression to severe and 
complicated forms. It was noted that there is an increase in noradrenaline spillover from 
the heart, kidneys, and brain in many patients with essential hypertension.150, 151, 210-213 
In addition, muscle SNA is elevated in individuals with borderline hypertension,214 as 
well as in those with white coat hypertension215 and sustained essential hypertension.9, 
140, 216-218 The degree of the sympathetic hyperactivation was related to the magnitude of 
the blood pressure raise.11, 12 These observations imply pathogenic role of sympathetic 
system in hypertension. In fact, data indicate that heightened sympathetic activation 
often precedes hypertension.13 In a longitudinal observational study with 20 year follow 
up, a high arterial adrenaline concentration strongly predicted future occurrence of 
hypertension.13 
 
Evidence for the significant role of the sympathetic nervous system activation in the 
initiation and development of hypertension is vast.9, 140, 214, 216-222 However, this theory is 
not universally accepted due to some inconsistency on the magnitude of sympathetic 
hyperactivity among different cohorts of hypertensive patients.167 136, 223-225 This could 
partly be due limitations of the methods used for quantification of sympathetic 
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parameters, varying degree of imbalance of central vs. peripheral sympathetic 
hyperactivity. This is also due to the fact that a multitude of other factors is involved in 
the regulation of BP, such as cardiac output, endothelial function, neurohumoral status, 
salt sensitivity, and vascular adrenergic responsiveness.226 Individual contribution of all 
those factors in a particular patient is often difficult to assess, and there is a complex 
network of excitatory and inhibitory mechanisms linking those pathogenic factors. The 
single unit recordings of the muscle SNA add knowledge to explain this inconsistency. 
Single unit recordings revealed that there is a significant increment in sympathetic 
activation in patients with early and mild hypertension than in severe hypertension, 
while increased multiunit muscle SNA was not different between hypertension 
stages.173 Importance of local activity of the sympathetic system in organs implicated in 
BP control has been particularly highlighted in elderly hypertensive subjects who had 
consistently elevated muscle SNA by microneurography but did not always show 
elevated renal noradrenaline spillover.146, 153, 218 This also emphasizes the importance of 
the direct sympathetic measurements as quantification of ‘systemic’ sympathetic 
activity might be misleading in some cases.  
 
In summary, it is likely there is a causative association between increased SNA and 
hypertension (Figure 2.2).221, 227 Good understanding of intimate details of pathways 
linking the heighten SNA and development of hypertension is important for establishing 
therapeutic targets and development of effective treatments. 
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Figure 2.2. Schematic drawing of the potential mechanisms and consequences of 
sympathetic activation in essential hypertension 
LVH, left ventricle hypertrophy; RAAS, renin-angiotensin aldosterone system. 
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2.5. Physiological and pathophysiological consequences of heightened sympathetic 
activity 
 
2.5.1. Sympathetic nerve activity and the vasculature  
 
Heightened vascular sympathetic nerve activity evokes complex structural and 
functional consequences. Chronic sympathetic activation can lead to arterial stiffening, 
vascular and cardiac hypertrophy and hypertension. Structural changes, such as vascular 
remodeling, reflect the long-term status of the SNA.228, 229 Increased vascular smooth 
muscle tone secondary to high SNA activity increases arterial stiffness and aortic BP, 
and promotes deposition of collagen fibers.230, 231 In addition, hypertrophy of vascular 
smooth muscle cells and functional and structural changes in endothelial cells occur. 
This results in increased wall-to-lumen ratio with unfavorable consequences to systemic 
hemodynamics, elevated resistance to flow, increased endothelial shear stress and 
ultimately atherogenesis.24, 229  
 
Although high BP per se could mediate a catecholamine-related vascular hypertrophy, 
BP independent changes in the vasculature as a direct consequence of heightened SNA 
are now well acknowledged.229, 232 Morphological studies conducted on animals 
confirmed that chronic sympathetic drive leads to structural changes of vascular smooth 
muscle cells (i.e., hypertrophy and proliferation) even despite maintenance of normal 
BP.232 Moreover these effects could be inhibited by sympathetic denervation. 
Exogenous administration of norepinephrine for 2 weeks in rats increased vascular 
production of collagen and elastin.233 Antagonism of endothelial A receptors promptly 
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and effectively reversed norepinephrine-induced aortic structural and compositional 
changes, suggesting a central role of endothelin in mediating this response.233 These 
data indicate that SNA-related vascular effects are partly attributed to stimulation of 
endothelin, a potent vasopressor and regulator of multiple functional pathways within 
the vascular wall. 
  
Along with changes in vascular structure, studies in humans show that sympathetic 
activity reduces arterial distensibility. Higher sympathetic activity in postmenopausal 
women was positively correlated with increased arterial stiffness assessed by 
augmentation index.234 A similar association was also confirmed in a study of young 
men.235 Stiffening of large elastic arteries impairs the buffering function of the arterial 
system and predisposes to cardiovascular disease.236 In addition, the increased stiffness 
of larger arteries is associated with the age-related impairment of cardiovagal baroreflex 
sensitivity and arterial baroreflex control of muscle SNA in both men and women.237 In 
this study a lower level of arterial baroreflex control of muscle SNA was particularly 
prominent in older women, which may be implicated in the higher prevalence of 
hypertension in this age-gender category.237 
 
High carotid-femoral pulse wave velocity (PWV), an index of central arterial stiffness, 
is a strong independent predictor of cardiovascular morbidity and mortality. In the 
Framingham Heart Study, the addition of PWV to the cardiovascular risk stratification 
models improved risk prediction compared to conventional risk factors used alone.236 
PWV thus represents a useful and easy to obtain marker of risk of cardiovascular 
disease.236 In healthy men, high muscle SNA predicted increased PWV independently 
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of age, BP and body mass index.238 Of note, individuals with abnormally high PWV had 
significantly higher muscle SNA compared to individuals with normal PWV despite 
similar systolic BP.238 There was a significant inverse association between muscle SNA 
and arterial stiffness in patients with systolic heart failure.25 Furthermore, activation of 
sympathetic system in this population by cigarette smoking or phenylephrine 
significantly decreased radial artery distensibility.25  
 
The acute removal of SNA, by direct anesthesia of the sympathetic nerves of upper and 
lower extremities in healthy subjects and pathological conditions, leads to increased 
arterial distensibility with no alteration in BP or HR, and no change in the properties of 
the contralateral control artery.24 Clinical support of these observations comes from a 
study of patients undergoing hand transplant,239 where radial artery distensibility was 
observed to be much higher in the transplanted and thus denervated radial artery, than in 
the contralateral radial artery. However, radial artery distensibility increased to match 
those in the contralateral hand 4 months after the surgery, once signs of reinnervation 
appeared.239 These data accord with animal studies demonstrating that both surgical and 
pharmacological disruption of sympathetic innervation led to significant improvement 
in parameters of arterial distensibility.240, 241 
 
Acute increases in sympathetic activity, secondary to mental stress or other triggers of 
sympathetic discharge (e.g., cold pressor test or lower body negative pressure) increased 
arterial stiffness in healthy volunteers.242, 243 These observations are also relevant to the 
cardiovascular morbid states associated with increased sympathetic drive, such as heart 
failure.25 However, acute effects of catecholamines (e.g., infusion of phentolamine or 
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application of negative pressure to lower body) on arterial stiffness appear to be less 
prominent in older healthy individuals.244, 245 This likely reflects more prominent 
background arterial stiffness in older subjects with larger deposition of connective 
tissue/collagen and consequently lesser contribution of catecholamine-dependent 
smooth muscle tone to the overall stiffness. 
 
In addition to the structural composition of the blood vessel, endothelial function is an 
important determinant of arterial stiffness. The endothelium plays a key role in the 
regulation of multiple biological processes related to vascular function. For example, 
endothelium-derived signals are involved in regulation of balance of vasodilatation vs. 
vasoconstriction, inflammatory and anti-inflammatory processes, pro- and 
antithrombotic actions. The interactions between endothelial activity and the 
sympathetic nervous system are often less appreciated but (patho)physiologically and 
clinically relevant.246, 247 In a healthy and relatively young normotensive cohort the 
reactive hyperemic index (an index of endothelial function) was significantly and 
inversely associated with muscle SNA.248 
 
Given that arterial stiffness is dependent on arterial smooth muscle tone, endothelium-
dependent regulation of vascular tone has a direct implication on the arterial elastic 
properties. These effects are perpetuated by a vicious circle of increased vascular tone 
and endothelial dysfunction leading to increased arterial stiffness and increased arterial 
stiffness further contributing to endothelial dysfunction. The invasive assessment of 
arterial compliance and measurement of PWV in young healthy individuals have 
confirmed the capacity of NO to improve elastic characteristics of peripheral arteries.249 
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Although acute NO-dependent effects on arterial elastic properties are primarily related 
to changes in smooth muscle tone, impairment of endothelium-dependent function is 
also involved in sustained arterial stiffening.247 For example, diminished NO 
availability is related to higher platelet activity that stimulates accumulation of 
proinflammatory leukocytes and smooth muscle cell proliferation. 
 
The interaction of endothelial dysfunction and heightened sympathetic activation is 
likely to be of considerable clinical significance although direct assessment of those 
interactions in clinical settings is complicated by the multiple other factors involved. 
Vast amounts of data highlight the importance of endothelial dysfunction in 
pathogenesis and prognostication in cardiovascular disease, particularly in heart 
failure.250-252 The magnitude of endothelial dysfunction in coronary arteries parallels the 
degree of left ventricle (LV) hypertrophy, a cumulative surrogate parameter of duration 
and severity of hypertension.253-255 Several studies have also demonstrated the presence 
of endothelial dysfunction in patients with hypertension, a recognised risk factor for 
both ischemic heart disease and heart failure.256-259 Of interest, presence of endothelial 
dysfunction of peripheral arteries often precedes occurrence of overt cardiovascular 
pathology.260-262 
 
Another mechanism that links excessive SNA and endothelial dysfunction to 
atherogenesis and hypertension are the increased arterial shear stress due to 
vasoconstriction promoted by sympathetic hyperactivity.247 Vasoconstriction puts an 
additional strain on the endothelium to provide adequate vasodilation. This may be 
critical at sites with naturally occurring higher shear stress, such as at arterial 
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bifurcations/branching points. These parts of the arterial tree are particularly prone to 
development of the atherosclerotic plaques. Among a group of young healthy males a 
higher muscle SNA was shown to be associated with more prominent NO generation.263 
It has thus been speculated that an inability to sufficiently enhance NO production in 
settings of sympathetic hyperactivity could be responsible for the net impairment of the 
vasomotor responses, resulting in abnormal peripheral resistance and hypertension.263 
Increased SNA induced by sympatho-excitatory maneuvers impairs flow mediated 
endothelial-dependent vasodilatation in healthy subjects264, 265 and patients with chronic 
heart failure.266 Furthermore, in vivo animal experiments show that NO can directly 
inhibit SNA.267 In healthy subjects, systemic inhibition of NO production by NG-
Monomethyl-L-arginine, monoacetate salt (L-NMMA) resulted in rise in peripheral 
resistance and a dose-dependent elevation in BP and reflector decreased in SNA and 
cardiac output.268 The mediated BP elevation was particularly prominent in individuals 
who already had tendency towards the higher BP at baseline. 
 
The magnitude of involvement of endothelial dysfunction in the pathogenesis of 
hypertension has not been firmly established. Some data indicate that endothelial 
dysfunction precedes developments of hypertension and may be one of the pathogenic 
mechanisms of essential hypertension.269 However, a causative relationship between 
essential hypertension and flow-mediated dilation has not been firmly established. For 
example, the Framingham Heart study failed to confirm the causation.270 This 
discrepancy may at least partly be due to the presence of other modulators of 
endothelial and overall vascular function. Heightened sympathetic tone is likely to be a 
major contributor to the net impact of endothelial dysfunction to the development of 
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hypertension in an individual. Multiple other factors are known to affect the magnitude 
of flow-mediated dilation, including recognised cardiovascular risk factors, such as 
hypertension, smoking, hypercholesterolemia.271, 272 The multifactorial nature of 
endothelial dysfunction makes it difficult to firmly establish the independent 
pathophysiological role of endothelium in hypertension and precise impact of the 
sympathetic overactivation in this association. 
 
In summary, the available data support a direct role of high SNA in arterial stiffening, 
pathologic remodeling, and endothelial dysfunction. These effects likely contribute to 
the pathogenesis of various cardiovascular disorders, including atherosclerosis, heart 
failure, and hypertension. However, these interactions are complex and still not fully 
understood. 
 
2.5.2. Sympathetic nerve activity and the heart 
 
Excessive SNA has been shown to affect both cardiac structure and function. In vivo 
studies of even sub-pressor doses of noradrenaline show direct hypertrophic effect of 
catecholamines on cardiac myocytes and net increase in LV thickness and mass.273, 274 
Moreover, a strong independent association has been identified between high 
sympathetic activity, quantified either by measurements of the plasma catecholamines 
or muscle SNA, and the development of LV hypertrophy in subjects with essential 
hypertension.14-16 Interestingly, long-term (i.e., over 20 years) observational studies of 
middle age men with arterial plasma noradrenaline levels measured at baseline showed 
significant independent predictive value of high catecholamine levels with increased LV 
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mass, after accounting for systolic BP and body mass index.275 Similar observations 
have been made in studies of patients with chronic kidney disease; where higher 
baseline muscle SNA levels were associated with higher LV mass over a 9-year follow 
up, despite optimal BP control.276 
 
A study of normotensive siblings of hypertensive parents has provided further insight 
into the role of an imbalance in the autonomic system in hypertension by the 
demonstration that low parasympathetic activity, as well activation of sympathetic 
nervous system (assessed using HR variability analysis) were implicated in the 
progression of prehypertension into overt hypertension.277 These findings accord with a 
study showing that presence of LV hypertrophy in hypertension was linked with 
features of inhibition of the parasympathetic system (assessed using HR variability 
analysis) and thus relative dominance of the sympathetic drive in regulation of cardiac 
processes.17 
 
Collectively, these data have significant clinical implications given the well-
documented role of a LV hypertrophy in prognostication. For example, higher LV mass 
was independently related to occurrence of cardiovascular disease, cardiovascular and 
all-cause mortality in the Framingham Heart Study.278 
 
An abnormally high sympathetic activation can also have functional consequences for 
the heart. High muscle SNA is associated with LV diastolic dysfunction independently 
of BP levels18, 19 and arterial baroreflex control of muscle SNA is more greatly 
attenuated in hypertensive patients with diastolic dysfunction than in those with normal 
 43 
diastolic function.18 In view of the negative impact of LV diastolic dysfunction on 
cardiovascular morbidity and mortality in hypertension, detrimental effects of 
catecholamine on diastolic function likely represent another pathogenic mechanism of 
sympathetic hyperactivity. The mechanisms responsible for the sympathetically-
mediated diastolic dysfunction are not entirely clear but appear to be attributable to both 
increased myocardial stiffening and impaired (delayed) relaxation of 
cardiomyocytes.279, 280 Increased myocardial and arterial stiffness are secondary to (i) 
accelerated extracellular matrix turnover with collagen deposition, (ii) increased tone of 
the cardiomyocytes and (iii) cardiomyocyte hypertrophy.281 The therapeutic utility of 
these findings is still to be firmly established, as large-scale trials of sympatho-
inhibition on outcomes specifically in patients with hypertension and predominantly 
catecholamine related diastolic dysfunction are lacking. 
 
2.5.3. Sympathetic nerve activity and the kidney 
 
The kidneys play a major role in the regulation of BP, and they serve this purpose by 
complex coordination of neuro-humoral pathways. In addition to the production of renin 
and regulation of renin-angiotensin-aldosterone system the kidneys have a rich 
sympathetic innervation. Sympathetic hyperactivity is evident in many hypertensive 
patients with renal dysfunction and successful antihypertensive treatment in these 
individuals seems to parallel reductions in SNA.282 Recently the role of renal SNA in 
hypertension has attracted particular attention due to the initial success of renal 
denervation therapy.154, 155 Development of this treatment approach was based on strong 
evidence for the role of the sympathetic system in elevating renal vascular resistance in 
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hypertension, and direct involvement of renal afferent signaling to central nuclei, 
sympathetic activation, and up-regulation of the renin-angiotensin-aldosterone 
system.283 
 
The renin-aldosterone-angiotensin system is of particular importance in the 
pathogenesis of hypertension, and high plasma renin activity has been independently 
related to increase in muscle SNA.282 The renin-angiotensin-aldosterone system has 
become the key target for pharmacological intervention in hypertension and the 
contribution of the sympathetic system to kidney related BP increase is of paramount 
importance. For example, high sympathetic renal activity leads to constriction of 
afferent renal arterioles accompanied by a reduction in glomerular perfusion; changes in 
electrolyte handling by the kidneys, including increases in tubular reabsorption of 
sodium and water balance disturbances, leading to water retention.284, 285 All those 
changes invariably result in activation of the renin-angiotensin-aldosterone system and 
are further exacerbated by the sympathetic activation, thus completing the vicious 
cycle.286 This exaggerated interaction between the renin-angiotensin-aldosterone system 
and the sympathetic nervous system is an important mechanism responsible for the 
chronicity of the BP increase (i.e., hypertension). The pro-hypertensive interactions 
between the sympathetic nervous system and the kidneys are further amplified by direct 
damage to renal tissue related to the high SNA. For example, animal experiments show 
that pharmacological inhibition of the central sympatholytic drive reduces occurrence of 
glomerulosclerosis irrespectively of BP.287 
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The clinical utilization of renal denervation therapy was hampered by the disappointing 
results of the randomized SYMPLICITY HTN-3 trial.288, 289 Admittedly the trial results 
do not necessarily imply lack of relevance of the sympathetic inhibition in hypertensive 
patients but rather the need for identification of the appropriate candidates to such 
treatment and/or development of better treatment options (both interventional and non-
interventional).288, 290, 291 
 
2.5.4. Metabolic effects of sympathetic nervous system 
 
An association between abnormal sympathetic drive and presence of metabolic 
disturbances has been established. Associations have been found between the 
sympathetic system and presence of dyslipidemia and insulin resistance.292 Although 
mutual relationship between those factors are sophisticated it has been shown that high 
circulating levels of insulin in those with insulin resistance (e.g., in obesity) activate 
central sympathetic nervous system.293 
 
Given the well-known role of sympathetic activation in the pathogenesis of 
hypertension this pathway at least partly explains close association between the 
components of the metabolic syndrome, such as insulin resistance/diabetes, increased 
body mass index and hypertension. Muscle SNA is increased in overweight individuals, 
even if BP remains within the normal range.294 Activation of sympathetic nervous 
system in obesity is likely to have a pathogenic role in hypertension. For example, in 
the Framingham Heart study obesity was strongly predictive of future hypertension 
during 30-year follow up.295 The hypothesis that the sympathetic nervous system links 
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the metabolic syndrome and hypertension is further supported by studies in healthy 
humans showing that insulin infusion stimulates SNA independently of insulin’s 
vasodilatory effects.296, 297 
 
It is difficult to establish the precise reciprocal associations between the sympathetic 
system activation and metabolic abnormalities. It is likely that their impact is mutual 
with a ‘vicious circle’ of self-perpetuation existing and predisposing to hypertension.298 
In addition to the well-documented impact of metabolic abnormalities in evoking 
sympathetic activation, excessive catecholamine release increases pancreatic insulin 
production.299 In patients with metabolic syndrome muscle SNA promoted progression 
from impaired glucose tolerance to overt type two diabetes.300 
 
SNA may also contribute to insulin resistance by causing chronic vasoconstriction by 
skeletal muscles and consequently restricting glucose clearance by the muscles, which 
requires more insulin to be released to overcome the effect.298 In contrast, 
pharmacological vasodilation significantly improves insulin sensitivity.301, 302 However, 
clinical utilization of such approach is likely to be limited by a compensatory 
baroreflex-mediated increase in SNA in response to the vasodilatation. 
 
2.5.5. Interaction with the immune system 
 
The immune system plays a pivotal role in the regulation of inflammatory process, 
modulation of tissue remodeling and regulation of oxidative stress. To achieve this, the 
immune system interacts with humoral (e.g., hormones) and nervous (e.g., 
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catecholamines) systems. The complexity of those interactions allows fine adjustments 
of the system to meet the homeostatic needs. In this regard, the nervous control is 
particularly important for very fast changes as opposed to more prolonged responses 
mediated through humoral mechanisms. 
 
Mutual impact of the immune and autonomic nerve systems is increasingly recognized 
and a mechanism of ‘inflammatory reflex’ has been suggested. This term describes 
neural circuit that includes afferent and efferent neurones of the vagus nerve that 
contribute to regulation of immune responses.303 
 
The autonomic nervous system possesses mechanisms of sensing the presence of 
cytokines, bacteria and components of cell damage. Although not all details of this 
sensing are completely understood the receptor apparatus appears to be generally 
similar to that in the immune system per se. As such, immune cells (such as monocytes 
and lymphocytes) may serve as a link between the immune and neural interactions by 
producing cytokines and sensing catecholamines. It is also likely that the autonomic 
afferents can possess receptors that are sensitive to inflammatory molecules. However, 
the extent and variability of their expression need further investigation. Animal 
experiments clearly show that an up-regulation of circulating inflammatory cytokines 
leads to activation of the sympathetic system.304, 305 Once activated by immune stimuli, 
sympathetic signals rapidly spread to central regulatory nuclei allowing for a prompt 
response aimed at counteracting the pathological changes (e.g., tachycardia to increase 
cardiac output in the setting of peripheral vasodilation seen in sepsis). These 
homeostatic adjustments mediated by the sympathetic system are fast as compared to 
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many responses produced by the immune system. They give time for the immune 
system to provide more specific actions. These autonomic signals from the brainstem 
nuclei also provide efferent outflows to the organs of the immune system, such as the 
spleen, lymph nodes, and reticuloendothelial system. 
 
Catecholamines can also directly interact with specific receptors on cells of the innate 
and adaptive immune systems, such as monocytes/macrophages and lymphocytes. For 
example, lymph nodes and the spleen, reach in T-lymphocytes are have been shown to 
have dense innervation by nerves, and the sympathetic stimulation leads to T cell 
activation and prolipheration.306-311 High sympathetic activity can stimulate the 
generation of inflammatory cytokines. Animal experiments indicate that catecholamine 
induced inflammation is pathophysiologically linked to hypertension and development 
of heart failure.312, 313 In normal rats the subfornical organ of the brain has been shown 
to link central sympathetic activity and formation of inflammatory cytokines, such as 
tumor necrosis factor-α and interleukin-1β.314 
 
Inflammation in hypertension can be promoted by the renin-angiotensin-aldosterone 
system, with the particular role of angiotensin II. Angiotensin II promotes oxidative 
stress by triggering production of the reactive oxygen by nicotinamide adenosine 
dinucleotide phosphate (NADPH) in immune cells.315 Inflammation is also supported 
by angiotensin II.310 Delivery of T cells lacking angiotensin type I receptor or transfer of 
functional NADPH oxidase, reduced superoxide generation, and hypertension in 
response to high angiotensin II infusion. These findings suggest that the development of 
angiotensin II-mediated hypertension may be partly explained by activation of NADPH 
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oxidase and increased sympathetic activity.316 In T lymphocytes, NADPH oxidase also 
promotes their activation, cytokine production, and migration to tissues thus enhancing 
effects of sympatho-immune interactions.317, 318 
 
In summary, an abnormally high sympathetic drive and diminished parasympathetic 
activity may result in the pro-inflammatory milieu, which serves to further stimulate 
SNA. 
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2.6. Mechanisms for increased central sympathetic activity in hypertension 
 
2.6.1. Introduction 
 
The central nervous system is closely involved in regulation of sympathetic activity and 
BP and pathogenesis of hypertension.319 The sympathetic nervous system represents a 
principle mechanism mediating signals from the central nervous system and BP control. 
As discussed in previous sections different parts of the brain, including the brain stem, 
NTS, and the RVLM play a particularly important role in the regulation of BP via the 
sympathetic nervous system.320 The fact that majority of patients with hypertension are 
classified as having essential hypertension highlights the diversity of mechanisms and 
pathological pathways responsible for dysbalance in BP control. Many of those 
pathways are mutually linked and amplify pathological effects caused by other 
mechanisms. 
 
2.6.2. Role of central oxidative stress 
 
The role of brain oxidative stress in the pathogenesis of hypertension has been 
suggested by experiments in spontaneously hypertensive rats.320-322 Reactive oxygen 
species (ROS) in the RVLM have been shown to amplify glutamatergic-mediated 
excitation and reduce GABA-mediated inhibitory effects, thus enhancing overall 
sympathetic drive.320 Also, in salt-sensitive hypertension rat model excessive oxidative 
stress in the brain increased sympathetic activity and caused hypertension via activation 
of reduced nicotinamide-adenine dinucleotide phosphate oxidase (NAD(P)H)).323  
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Cytochrome oxidase activity is a parameter of longer-term brain neuronal activity that 
reflects local metabolism and oxidative capacity.324 Cytochrome oxidase activity is 
increased in spontaneously hypertensive mice, especially within the central autonomic 
network.324 Of note, there is a clear heterogeneity in the cerebral distribution of 
cytochrome oxidase activity, with areas responsible for high-order autonomic control, 
such as insular cortex and the hypothalamic nuclei, being particularly affected.324 
Superoxide dismutase represents another potent endogenous antioxidant. In rats 
administration of tempol, a superoxide dismutase mimetic, doubled vascular superoxide 
dismutase production in spontaneously hypertensive rats, such that it reached levels 
seen in normotensive animals.325 Accordingly, treatment with tempol reduced mean BP 
by 28%, HR by 16% and integrated renal SNA by 63% with the magnitude of these 
changes being significantly greater in hypertensive than in normotensive rats. Of note, 
in spontaneously hypertensive rats reductions in renal SNA during administration of 
superoxide dismutase mimetic, tempol, were strongly correlated with changes in mean 
BP (r=0.85, P<0.0001).325 
 
Tempol reduces BP when delivered either intravenously or intracerebroventricularly, 
but the mechanisms by which tempol lowers BP differs depending upon the mode of 
administration.326 For instance, tempol reduced norepinephrine secretion from the 
posterior hypothalamus and renal SNA when infused intracerebroventricularly but 
raised norepinephrine secretion from the posterior hypothalamus and increased renal 
SNA when infused intravenously.326 The effects of intravenous tempol on SNA were 
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inhibited by sinoaortic denervation indicating involvement of oxidative stress related 
changes in baroreflex function and the role of superoxide dismutase in its regulation.326 
 
Endogenous adrenomedullin is an antioxidant peptide that inhibits central sympathetic 
activation via its antioxidant properties.327 Hyperosmotic saline-induced ROS 
production in the hypothalamus was more pronounced in adrenomedullin knockout 
mice compared to wild-type animals.327 These data indicate presence of an intrinsic 
cerebral imbalance in pro- and anti-oxidative processes in spontaneously hypertensive 
mice and suggest the role of these abnormalities in sympathetic disturbances and BP 
elevation in this model.324 
 
Several experimental studies suggested the therapeutic potential of antioxidants in 
hypertension. For example, inhibition of the oxidative stress by chronic antioxidant 
treatment of rats with renovascular hypertension significantly decreased sympathetic 
activity and BP levels which were associated with diminished expression of angiotensin 
II type 1 (AT1) receptor.328 Furthermore, acute treatment with vitamin C in essential 
hypertension significantly reduced cardiac adrenergic activity and improved baroreflex 
sensitivity.329 However, the suitability (effectiveness and safety) of long-term 
antioxidant treatment in hypertension needs to be tested in controlled trials. 
 
Angiotensin system is involved in multiple pathogenic pathways in hypertension, 
including regulation of the ROS release. Peripheral and central oxidative stress are 
interacting and amplify the hypertensive effects of angiotensin.330 High levels of 
angiotensin II in the PVN generation of the ROS and enhance the cardiac sympathetic 
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afferent reflex.331 Angiotensin II administered into the lateral ventricle of the brain 
involved in the noradrenergic control of BP enhances oxidative stress, activates the 
sympathetic nervous system and increases BP,332 via an AT1 receptor mechanism.330 
 
In a rat model of renovascular hypertension decreases in BP by inhibition of AT1 
receptors with losartan, resulted in a reduction of oxidative stress in the RVLM.333 
Deletion of ACE2 gene was shown to enhance the age-related increase in ROS and led 
to autonomic dysfunction and hypertension.334 In contrast ACE2 gene therapy targeted 
to the PVN attenuated oxidative stress via inhibition of NADPH oxidase and 
improvement in cardiac autonomic function (defined by responsiveness in HR and BP 
to propranolol, atropine, and chlorisondamine).334 It is speculated that clinical benefits 
of AT1 receptor inhibitors could be partly attributable to the reduction of brain 
oxidative stress.321 Of note, angiotensin II stimulation also increases NO production that 
may limit angiotensin II-related sympathetic activation, thus represents an important 
regulatory negative-feedback mechanism.330 
 
NO can act as a central neurotransmitter and can regulate SNA and consequently BP.335 
Local NO deficiency may increase SNA and promote the development of 
hypertension.335 It has been demonstrated that interaction between NO and superoxide 
dismutase mimetic, tempol contributed to the biological effects of the drug.336 Tempol 
increased the levels of nNOS in the posterior hypothalamus, PVN, and locus coeruleus 
when infused intracerebro-ventricularly, but it decreased the levels of nNOS when 
infused intravenously.326 
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The available data support the hypothesis that ROS may raise BP via sympathetic 
nervous system activation. This effect is modulated by central angiotensin, nNOS, and 
NO availability.326 The discrepancies in responses to tempol may be attributable to the 
route of administration, with an inhibitory effect of the drug on SNA being evident 
when it is given intracerebrally, versus a vasodilatory response when given 
intravenously.326 
 
2.6.3. Role of central nitric oxide 
 
NO is a principle regulator of cardiovascular function and expresses its actions through 
a multitude of mechanisms. Peripheral vascular vasodilatory effects and antithrombotic 
properties have attracted particular attention. However, NO also plays a significant role 
in the central regulation of SNA.96 Endogenous NO provides a significant input in 
maintenance of basal sympathetic tone by contracting excitatory reflex responses.337 
 
NO is produced in a process involving NOS and the amino acid, L-arginine as a 
substrate. Several forms exist in both mammal animals and humans, which accounts for 
the diversity of NO functions and its activity within different organs. eNOS is localised 
within vascular endothelium and largely responsible for peripheral effects of the NO 
(e.g., vasodilation, antiplatelet and anti-inflammatory properties). nNOS is 
predominantly localised in brain structures with an uneven distribution and activity.338 
iNOS is not normally expressed under physiological conditions but its high levels are 
related to pathological states, such as sepsis, where it strongly contributes to the 
development of excessive oxidative stress. 
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The brain, particularly the medulla and hypothalamus, contains autonomic inhibitory 
(nitrergic) nerves, which transfer regulatory signals to the peripheral tissues, including 
heart and vessels.338 These signals strongly contribute to BP control.338 For example, 
stimulation of the nitrergic nerves that supply signals to the peripheral vasculature 
reduce arterial and venous resistance (especially targeting small calibre vessels) and 
lower BP.338 NO plays a major role in the adrenergic system by enhancing the activity 
of neuronal uptake of norepinephrine in sympathetic nerve terminals.339 
 
Cervical spinal cord transection inhibits abnormal sympathetic drive and reduces 
hypertension caused by NO inhibitors.340 This supports the hypothesis that in addition 
to its ability to reduce BP by peripheral vasorelaxation (i.e., peripheral effects) NO also 
has the ability to reduce BP via its effects on the central nervous system.340 As 
discussed above the central effects of NO are predominantly mediated by a reduction in 
sympathetic vascular tone.340 Two decades ago it was noted that acute central 
administration of a NOS inhibitor increased BP in rats, and this increase could be 
abolished by central administration of L-arginine.341 These data were complemented by 
finding that different endogenous NOS inhibitors (N(omega)-nitro-L-arginine methyl 
ester (L-NAME) and asymmetric dimethylarginine (ADMA)) significantly increase 
SNA.342 Long-term NOS inhibition achieved by administration L-NAME resulted in 
sodium-sensitive hypertension with increased SNA.343 However, brain sympathetic 
inhibition mediated by nNOS was in fact up-regulated in salt-sensitive hypertensive 
rats, which could probably precede baroreflex sympathetic inhibition in this model.344 
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Brain NO plays a principal role in inhibition of sympathetic vasoconstriction associated 
with baroreflex.345 NO-dependent central SNA modulates a magnitude of baroreflex-
mediated responses (i.e., in HR and BP).346, 347 However, there appear to be some highly 
specific pathways directing selected functions of the baroreceptors.346 In an anesthetized 
animal model basal NO release plays a significant role in the tonic BP regulation, but it 
does not seem to be important for the dynamic sympathetic modulation of BP or HR at 
least in this experimental model.348 Administration of either L-arginine or showed that 
NO modulates efferent SNA via central nervous system without changing the afferent 
or efferent pathways of the baroreceptor reflex arc.349 Also administration of L-arginine 
to healthy volunteers increased NO synthesis, reduced BP, but increased HR and SNA, 
thus supporting the role of NO in the tone of central sympathetic outflow in humans.350 
 
Accumulating data testing relation of inhibition of brain NO synthesis with the 
pathogenesis of hypertension reveal a complex network of interactions with the 
development of hypertension being largely renal nerve dependent and mediated by the 
integrity of the renal nerves.351 These findings are relevant to the recent (although 
somewhat controversial) success of the renal denervation therapy in patients with 
hypertension. Of interest, the sympathetic nervous system plays a role in the regulation 
of release of vascular NO thus representing an important feedback mechanism for fine 
tuned balance of pressor and depressor mechanisms.352 While administration of the 
NOS inhibitor increases BP and decreases renal SNA, treatment with an ACE inhibitor 
or an AT1 receptor blocker reduced BP and increased SNA, which was associated with 
blunted baroreceptor reflex function.353 
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2.6.4. Changes in rostral ventrolateral medulla in hypertension 
 
RVLM contains NOS-producing neurones, which can be activated through cardiac 
sympathetic excitatory reflexes.89 nNOS-derived NO is implicated in the transmission 
of sympathetic baroreflex in the RVLM, which is at least partly mediated by soluble 
guanylate cyclase-dependent, superoxide-independent mechanism.354 This neuronal 
NO-mediated suppression of tonic peripheral sympathetic drive is amplified by salt load 
in both salt-resistant and salt-sensitive rat models and the mechanisms are thus may be 
particularly relevant to salt-sensitive hypertension.355 
 
In contrast to nNOS, overexpression of iNOS in the RVLM increases BP through 
upregulation of oxidative stress and resultant sympathetic nervous system activation.356 
Although eNOS does not directly play a role in RVLM activity, eNOS gene transfer to 
the RVLM to induce eNOS overexpression in rats resulted in an inhibition of SNA, 
bradycardia and a lowering of BP.357, 358 These responses are mediated by an enhanced 
release of gamma-amino butyric acid (GABA) in the RVLM.358 In contrast to 
anesthetized rats, NOS activity facilitates renal SNA in conscious rats.359 The 
mechanism for the sympatho-excitatory effect of NO are not entirely clear but appear to 
be partly dependent on the activity of endogenous angiotensin II (in low-sodium 
animals only).359 In hypertension models angiotensin II also activates AT1 receptors in 
RVLM, while their inhibition led to a reduction in SNA and BP.88 Indication of that 
overactivity of the angiotensin system in the RVLM can be implicated in hypertension. 
Indeed, the bilateral injection of losartan into the RVLM in rats reduced both renal SNA 
and BP.360  
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The dorsomedial medulla is also involved in the pathogenesis of hypertension, but 
perhaps to a lesser extent than the RVLM. In animal experiments injection of glutamate 
into this brain area led to a hypertensive response which was paralleled by an increase 
in SNA.361 Vasopressor mechanisms induced by glutamate are regulated by changes in 
NO levels in the dorsomedial medulla and RVLM, indicating the role of NO glutamate-
activation pathways.361 Injection of glutamate into the dorsomedial medulla and RVLM 
increased BP and vertebral SNA.361 Vasopressor mechanisms induced by glutamate are 
regulated by changes in NO levels in the dorsomedial medulla and RVLM, indicating 
role of NO glutamate-activation pathways.361 
 
2.6.5. Changes in nucleus tractus solitarius in hypertension 
 
It has been shown that adenosine is involved in BP controlling baroreflex responses 
within the NTS with net effects of reduction of BP, HR, and renal SNA.362 These 
adenosine effects in the NTS are NO and eNOS-dependent, mediated by activation of 
mitogen-activated protein kinase/extracellular signal-regulated kinases 1 and 2 and can 
be inhibited by NOS blockers.362 In rats gene transfer induced overexpression of eNOS 
in the NTS inhibits SNA and reduces BP and HR.357, 363 
 
2.6.6. The paraventricular nucleus 
 
A negative feedback pathway between NO generation and glutamate-mediated system 
exists within the PVN, which has been implicated in regulation of the sympathetic drive 
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in both physiological and pathological conditions.92 However precise contribution of the 
PVN (as well other nuclei discussed above) in hypertension in humans has not been 
firmly established and it has not become a specific target for the currently available 
therapeutic interventions. 
 
2.6.7. Changes in sympathetic preganglionic neurones in the spinal cord in 
hypertension 
 
High NOS levels have been demonstrated within sympathetic preganglionic neurones in 
the spinal cord, where NO is released in the process of the synaptic activity.364 
Excitation of renal sympathetic neurones by descending inputs from the PVN, is 
modulated by the inhibitory effects of NO provided through glycine interneurones at a 
spinal level.364 
 
2.6.8. Role of arterial baroreflex in hypertension 
 
The primary function of the arterial baroreflex has traditionally been viewed as short-
term BP regulation. The role of arterial baroreflex in longer-term BP regulation is still 
debated, and a consensus has not been reached.365, 366 Excessive sympathetic stimulation 
can sensitize the arterial baroreceptors, but the importance of this for long-term BP 
elevation is not clear. Both animal and human studies have consistently documented 
that sustained high BP impairs baroreceptor function.367-372 Decreased baroreflex 
sensitivity may also occur as the result of structural changes in large arteries and 
baroreceptor resetting in aging, hypertension and atherosclerosis.373, 374 375 Changes in 
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baroreflex sensitivity could also reflect functional changes in the reflex arc at the level 
of the peripheral sensory receptors and within the central nervous system.376 Arterial 
baroreflex function is preserved in spontaneously hypertensive rats as compared to 
control rats and independent from BP level.377 
 
The association between hypertension and arterial baroreflex dysfunction can also be 
partly due to the fact that even physiological aging is accompanied by a significant 
reduction in the baroreflex buffering capacity.378 This phenomenon could be more 
prominent in hypertensive subjects of advanced age and affect responsiveness to 
antihypertensive treatment in this age category.379 Additionally, the efficiency of the 
baroreflex may be influenced by female sex hormones and potentially protective 
hormonal effects seen in young women may be aborted post menopause.380, 381 
 
It seems plausible that influences of baroreflex control on renal SNA may contribute to 
the pathogenesis of hypertension. Characteristics of arterial baroreflex control of renal 
SNA were similar in spontaneously hypertensive and normotensive rats.382 Although 
angiotensin II-induced hypertension in rabbits significantly affected cardiac baroreflex 
sensitivity, but no noticeable change was evident in the relationship between mean BP 
and renal SNA.383 Physiological baroreflex has opposing long-term effects on renal 
SNA to those produced by angiotensin II, but abnormalities in both systems are seen in 
hypertension.384 This latter observation does not, however, prove that baroreflex 
abnormalities have a primary or pathogenic role in hypertension. In fact, direct 
experiments showed that aldosterone does impair baroreflex function in normal 
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volunteers and baroreflex dysfunction in hypertension could thus be secondary to 
activation of the renin-angiotensin-aldosterone axis.385 
 
Experiments on rats with chronic intermittent hypoxia indicate that inappropriate 
resetting of the sympathetic and cardiac baroreflex control, rather than reduced 
baroreflex sensitivity can predispose to hypertension related to hypoxia, the setting 
commonly seen in hypertensive subjects with obstructive sleep apnea.386 
 
Baroreflex inhibition of muscle SNA was found to be diminished in adolescents with a 
family history of hypertension before they had any evidence of hypertension thus 
leading to a possibility that familial predisposition to hypertension might be partly 
related to insufficient sympatho-inhibition secondary to inherited baroreflex 
dysfunction.387 
 
The baroreflex plays a recognised role in the control of BP and its dysfunction may be 
involved in the pathogenesis of hypertension. This is important because reduced 
cardiovagal baroreflex sensitivity independently predicts all-cause mortality in 
hypertension as well as cardiac mortality after myocardial infarction, a condition 
associated with functional alterations in the autonomic nervous system.388, 389 However, 
cardiovagal baroreflex sensitivity and arterial baroreflex control of muscle SNA are 
differentially controlled and do not always change in parallel.55 This means that both 
arms of the baroreflex function have to be assessed in order to draw conclusions 
regarding the impairment or restoration of baroreflex sensitivity following a 
treatment/intervention. 
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As a summary, despite clear involvement of the arterial baroreflex in the regulation of 
BP and multiple lines of evidence showing impaired baroreflex function in 
hypertension, the causative relation between baroreflex abnormalities and long-term BP 
increase in essential hypertensions have not been unequivocally proven yet. Such 
information would be of clear benefit for the further development of new treatments for 
hypertension. 
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2.6.9. Role of chemoreflex in hypertension 
 
Abnormalities in peripheral chemoreceptor function have been linked to several 
cardiovascular conditions, including hypertension.390-393 Increased sensitivity of arterial 
chemoreceptors, particularly those located in carotid bodies, has been shown to increase 
muscle SNA, total peripheral resistance, renal vascular resistance and BP in patients 
with hypertension and animal hypertension models.367, 391, 393-397 Studies of human 
volunteers with borderline or established hypertension, and of spontaneously 
hypertensive rats, have shown the presence of hyperventilation at rest with its further 
augmentation and increase in SNA in response to hypoxia.393, 396 
 
The mechanisms by which chemoreceptor sensitivity increases in hypertension are still 
debated. Hypertrophy of the carotid bodies has been reported in spontaneously 
hypertensive rats and confirmed in patients with hypertension.398-400 One may speculate 
that these changes reflect an attempt to compensate for brain hypoxia secondary to 
hypertension related arterial remodeling and vasoconstriction. These changes may thus 
be adaptive in nature and, in fact, they resemble changes seen in individuals living at 
high altitude. 
 
In rats exposed to intermittent hypoxia, augmentation of basal and chemoreflex-
stimulated sympathetic outflow occurs, at least in part, via activation of the renin-
angiotensin system, whereas expression of neuronal nitric oxide synthase was 
reduced.401 Endothelin-1 may modulate chemosensitivity by evoking a potent 
vasoconstriction within the carotid body vasculature thus reducing the threshold for 
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chemoreceptor activation and increasing the magnitude of their response to hypoxia.402-
404 However, the relevance of these findings to the management of patients with 
hypertension and their independent predictive value for outcomes in these settings 
remain unclear. 
 
2.6.10. The ‘Selfish brain’ hypothesis 
 
The ’ selfish brain’ hypothesis suggests that the reduced perfusion of medulla oblongata 
causes a reflex increase in SNA, an increase in peripheral vascular resistance and 
hypertension.405 The brainstem responds to any reduction in blood flow to the 
cardiovascular control centers by activation of pathways (particularly sympathetic 
system) aiming to counteract the changes and maintain the homeostatic level of 
perfusion. Brainstem hypoperfusion is the key component of the Cushing’s mechanism 
in humans, whereby sympathetic constriction of peripheral arteries occurs in response to 
cerebral under-perfusion. Curiously, this mechanism is physiological for growing 
giraffes, when gravitational brain hypotension triggers vasoconstriction and increase in 
BP to provide adequate blood flow to the brain.405 
 
Details of the mechanism have been provided by data from animal experiments. 
Neurones within the RVLM and spinal cord have been found to be sensitive to hypoxia, 
and their resultant activation leads to sympatho-excitation.406, 407 In patients with arterial 
compression of the ventrolateral medulla, an area rich in efferent sympathetic neurones, 
increases in muscle SNA and hypertension can be reversed by surgical 
decompression.408, 409 The circulatory deficiency of the medulla oblongata can also be 
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secondary to concentric remodeling of the arterial wall. Increased arterial wall thickness 
with the reduced luminal area have been noted in the vertebral and basilar arteries of the 
spontaneously hypertensive rats even before they develop hypertension.410, 411 This 
indirectly indicates a possibility causative link between brain hypoperfusion and an 
increase in peripheral resistance leading to hypertension. Similar changes in the 
vertebral arteries were seen in patients with hypertension and were strongly correlated 
with increased vascular resistance and BP.412 These data support the hypothesis that 
abnormal SNA triggered by suboptimal brain circulation has an intrinsic protective role 
for the perfusion by the cost of peripheral perfusion, hypertension and increased risk of 
long-term complications.405, 410, 411, 413 
 
2.6.11. Respiratory-sympathetic coupling 
 
Appropriate respiratory-sympathetic coupling provides important regulatory inputs for 
the sympathetic drive. Alterations (e.g. reduction in respiratory sympathoinhibition) in 
respiratory-sympathetic coupling have been described in spontaneously hypertensive 
rats, even prior to the development of hypertension when they are at a neonatal or 
juvenile stage.414-416 These observations imply that these abnormalities of respiratory-
sympathetic coupling are not merely a consequence of hypertension but may be 
involved in pathogenesis of hypertension.414-416  
 
Attenuation of the normal inspiratory sympathoinhibition has been shown to underlie 
the increased sympathetic outflow in chronic heart failure patients.32 The same 
attenuation in inspiratory inhibition pattern of sympathetic activity was also described 
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in hypertensive obstructive sleep apnea patients, and was reversed by treatment with 
continuous positive airway pressure.417 But these findings were not observed, by the 
same group in patients with hypertension without obstructive sleep apnea.418 These 
discrepancies could be partly related to the difficulty with precise measurement of the 
rapidly changing characteristics of the sympathetic status in response to fluctuations of 
the respiratory output. Under physiological conditions central inspiratory drive often 
does not closely correlate with the centrally generated expiratory drive (e.g., post-
inspiration - reflected by recordings of respiratory motor outputs to the upper airway or 
late-expiratory activity/pre-inspiration –reflected by respiratory motor outputs to the 
abdominal muscles).419, 420 In the spontaneously hypertensive rat the respiratory pattern 
was found to be shifted towards domination of the enhanced respiratory motor activity 
with predominant control of upper airway resistance during pre- and post-inspiration 
phases, without any noticeable changes during the inspiration itself.419, 420  
 
In normotensive subjects late inspiration/early expiration phases (i.e., phases of 
maximal lung expansion) are associated with sympathoinhibition. However, those 
inhibitory effects disappear in hypertension.416 The phenomenon has been explained by 
experimental data in spontaneously hypertensive rats showing that respiratory neurones 
in the medulla oblongata in the settings of hypertension provide synaptic-mediated 
excitatory drive to RVLM pre-sympathetic neurones.421-424 These findings explain more 
potent phase-related respiratory modulation of sympathetic nerves in hypertension. 
 
However, significant gaps exist in our understanding of the influence of age and 
hypertension on respiratory mediated modulation of SNA in humans. Detailed 
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discussion on the respiratory-sympathetic modulation in healthy human ageing is 
provided in experimental Chapter 4. Alterations of respiratory modulations of SNA in 
hypertension is reviewed in Chapter 6. It would also be important to understand better 
the capacity of modulation of breathing patterns to improve BP control through 
inhibition of SNA (Chapter 5 and Chapter 6). 
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2.7. Therapeutic strategies  
 
In view of the vast amount of data on the implication of chronic heightened sympathetic 
activation in hypertension it is only natural that several classes of inhibitors/activators 
of different types of adreno-receptors have been introduced. Admittedly after the 
introduction of inhibitors of renin–angiotensin system and new generation calcium 
channel blockers agents, the therapeutic role of agents working through adrenergic 
receptors has diminished, and they do not play a dominant therapeutic role in 
hypertension at present. The potential of this therapeutic target for BP control is thus 
currently underutilized.425 
 
2.7.1. Agonists of central α2-adrenergic and imidazoline receptors 
 
The α2-adrenergic receptors are predominantly expressed in the medulla oblongata, and 
they inhibit release of noradrenaline in the brainstem and thus provide a negative 
feedback mechanism to reduce SNA. Centrally acting agonists of α2-adrenoreceptors, 
such as methyldopa and clonidine were among the first antihypertensive agents 
available for practice. They provide effective BP reduction, but their use is hampered by 
numerous and frequent side effects (Table 2.2).  
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Table 2.2. Pharmacological agents primarily acting through modulation of 
adrenergic receptors 
Pharmacological 
target 
Principle 
agents  
Principle 
mechanism of BP 
reduction 
Principle side effects 
Agonists of central 
α2-adrenergic 
Clonidine 
(also 
imidazoline 
receptor 
agonist) 
Stimulates 
presynaptic α2-
receptors in the 
brainstem, which 
reduces peripheral 
vascular resistance 
Dizziness, drop in BP upon 
standing, somnolence 
(drowsiness; dose-dependent), 
dry mouth, headache, fatigue, 
skin reactions 
Competitive 
inhibitor of the 
enzyme DOPA  
 
 
Methyldopa Inhibits conversion 
of L-DOPA into 
dopamine, which is 
a precursor for 
noradrenaline 
 
Depression, apathy, 
anhedonia, anxiety, impaired 
attention, decreased 
motivation, fatigue, lethargy, 
agitation, cognitive and 
memory impairment, 
impaired libido, dizziness, 
headache, bradycardia, 
hyperprolactinemia, 
hepatotoxicity, hemolytic 
anemia, myelotoxicity  
Agonists of Moxonidine Inhibits central Dry mouth, fatigue, dizziness, 
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imidazoline 
receptors 
Rilmenidine 
 
sympathetic activity headache, nausea, sleep 
disturbances intermittent 
facial oedema 
Beta-blockers 
Selective β1-
blockers 
 
Selective β1-
blocker with 
potentiating 
vasodilatory effect 
 
Non-selective 
β1/β2-blocker/α1-
blocker 
 
Bisoprolol 
Metoprolol 
 
Nebivolol  
 
 
 
 
Carvedilol 
Negative 
chronotropic and 
inotropic cardiac 
effect 
 
 
Nausea, diarrhea, 
bronchospasm, exacerbation 
of Raynaud's syndrome, 
bradycardia, heart block, 
hypotension, heart failure, 
alopecia abnormal vision, 
fatigue, dizziness, 
hallucinations, nightmares, 
sexual dysfunction, erectile 
dysfunction and/or alteration 
of glucose and lipid 
metabolism. 
Selective α1-
adrenergic 
blockers 
Doxazosin 
Prazosin 
Terazosin 
 
Relaxation of 
arterial smooth 
muscle cells 
Dizziness, headache, 
drowsiness, constipation, 
fatigue, nasal congestion or 
dry eyes 
 
As a result methyldopa, a α2-adrenorecoptor agonist is now almost exclusively used for 
the management of pregnancy related hypertension. Consequently selective (I1) 
imidazoline receptors have been developed with two, moxonidine and rilmenidine, 
approved for clinical use.  
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The antihypertensive effects of clonidine are partly attributed to the stimulation of 
subtype 1 (I1) imidazoline. Imidazoline I1 receptors are found in both the RVLM 
pressor and ventromedial depressor areas, and their activation inhibits the activity of the 
sympathetic nervous system in similar to α2-adrenergic receptors.426, 427 Administration 
of imidazoline I1 receptor agonists, therefore, decrease in BP. Compared to the older 
central-acting antihypertensives, the new selective imidazoline I1 receptor agonists have 
fewer side effects but protect against hypertensive target organ damage, including LV 
hypertrophy and kidney function.426, 427 
 
The sympatho-inhibitory effects of moxonidine are partly mediated by augmented NO 
production in the RVLM.428 Effects of the agent in brainstem regions other than the 
RVLM may also be relevant as injection of moxonidine to NTS in animals reduced 
SNA, BP, and HR.429 In addition to direct BP reducing properties the beneficial effects 
of moxonidine include improvement in the baroreflex control of renal SNA.430 When 
the baroreceptor reflex effects of selective imidazoline receptor agonist, rilmenidine was 
compared with clonidine in rabbits, many of the baroreflex effects of clonidine 
inhibition of the sympathetic component of the baroreflex was seen with rilmenidine but 
not with clonidine, which indicates a specific role of imidazoline receptors in the 
regulation of the baroreflex.431 In addition, in a rabbit model of hypertension induced by 
renal artery stenosis, chronic treatment with rilmenidine normalized BP, reduced plasma 
renin levels and renal SNA without a reduction in renal blood flow in the kidney 
supplied by the stenosed artery.432  
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Selective imidazoline receptor agonists effectively reduce sympatho-activation in 
hypertension and have proven antihypertensive effects with reasonable side effect 
profile. Current guidelines indicate that they are used in patients with hypertension in 
whom sufficient BP control cannot be achieved with first-line antihypertensive agents.20 
 
2.7.2. Beta-adrenoreceptor blockers  
 
Inhibition of beta1-adrenergic receptors produces a negative chronotropic and cardiac 
inotropic effect and slows conduction velocity and automaticity in the heart. Inhibition 
of beta2 receptors results in smooth muscle contraction (which can, for example, 
exacerbate asthma) and glycogenolysis (which can affect glycaemia control), but also 
produce vasodilation. The principle antihypertensive action of beta-blockers is likely 
largely a reduction in cardiac output and if beta2-inhibition is present by some 
vasodilation. It may also be contributed by inhibition of renin release from the kidneys. 
Overall, less selective beta-blockers (i.e., inhibit both beta1 and beta2 receptors) tend to 
have more prominent antihypertensive effects but the cost of more side effects 
compared to selective beta1-blockers.  
 
Beta-blockade was considered at one time as a first line treatment for hypertension, but 
this changed after the completion several randomized clinical trials. In the multicentre, 
prospective, controlled ASCOT trial 19,257 patients with hypertension who had at least 
three other cardiovascular risk factors were randomised either to amlodipine 5-10 mg 
adding perindopril 4-8 mg as required or atenolol 50-100 mg adding 
bendroflumethiazide 1.25-2.5 mg and potassium as required.433 The study was stopped 
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early after a median follow up of 5.5 years as the amlodipine-based regimen prevented 
more major cardiovascular events and induced less diabetes than the atenolol-based 
regimen. 
 
Consequently, a comprehensive meta-analysis of 13 randomized controlled trials, which 
involved 105,951 hypertensive patients showed that relative risk of stroke was 16% 
higher for beta-blockers (95% confidence interval 4-30%) than for other 
antihypertensive drugs.434 When compared to placebo the beta-blockers reduced the 
relative risk of stroke by 19% (7-29% for different beta-blocker), which was less than 
expected. No difference was found regarding the risk of myocardial infarction when 
beta-blockers were compared vs. either other antihypertensive agents or placebo. 
Following the publication of these data beta-blockers have been only considered as 
second line agents for the management of hypertension in patients without a history of 
myocardial infarction or systolic heart failure. Admittedly the trials have largely utilized 
older beta-blockers, such as atenolol and efficacy of modern beta-blockers, such as 
bisoprolol have not been adequately tested in specifically designed trials. In healthy 
young volunteers, a double-blind, placebo-controlled, randomized cross-over study of 
bisoprolol has demonstrated significant improvement in cardiac baroreflex sensitivity, 
but it remains to be determined how this would be translated into outcome prevention in 
hypertensive patients.435 
 
2.7.3. Selective α1-adrenergic blockers  
 
Selective α1-adrenergic blockers include prazosin, doxazosin, terazosin. These agents 
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inhibit α1-adrenergic receptors on vascular smooth muscle cells. Their antihypertensive 
effects are based on vasodilation secondary to reduction of vascular smooth muscle tone 
and peripheral resistance. The agents are not considered the first-line choice for 
treatment of hypertension following the early termination of the doxazosin arm of the 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT) study due to doxazosin being less effective than diuretics and 25% excess in 
cardiovascular disease and about 50% excess in congestive heart failure.436 
 
2.7.4. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers 
 
Angiotensin II type I receptors are expressed by sympathetic nerve terminals and cause 
the release of noradrenaline when activated by angiotensin II. Angiotensin-converting 
enzyme inhibitors and angiotensin receptor blockers have direct sympathoinhibitory 
effects.437, 438 However, the sympatholytic potency of these agents is relatively mild and 
they reduce rather than normalize muscle SNA, and these effects have been shown to 
depend on age and background plasma renin activity.282 SNA is not affected in 
hypertensive patients by long-term treatment with lisinopril.439 However, chronic 
administration of losartan for 12 weeks in hypertensive patients inhibited muscle SNA 
and increased cardiac baroreflex sensitivity.440 In a randomized, crossover trial of 12 
weeks of treatment of hypertensive patients with diabetes with losartan and telmisartan 
reduced proteinuria, partly via inhibitory effects on SNA.441 In a double-blind, placebo-
controlled, cross-over study valsartan reduced BP and reset the baroreflex set point to 
the normal BP level.442 The multicenter, prospective, randomized, open-labeled, blinded 
end point Valsartan Amlodipine Randomized Trial showed a significant decrease in 
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cardiac SNA in the valsartan group but not in the amlodipine group, which paralleled 
superiority of valsartan over amlodipine in reduction of LV mass index despite BP 
being equally well controlled in both groups.443 
 
This capacity of inhibitors of the renin-angiotensin axis to inhibit sympathetic activity 
may contribute to their overall success in the management of hypertension and their 
relative superiority compared to beta-blockers. 
 
2.7.5. Calcium channel blockers 
 
Calcium channel blockers are vasodilating drugs and include a number of agents with 
very different chemical structure and significant variability in their mode of action, 
pharmacokinetic and pharmacodynamic properties. 
 
The first generation dihydropyridine calcium-channel blocker, nifedipine markedly 
increased muscle SNA in healthy volunteers, independently of drug release formulation 
(standard or short release formulation). Nifedipine differentially activates cardiac and 
peripheral SNA depending on the pharmacokinetics of the formulations used.444, 445 In 
contrast, long-term amlodipine treatment does not appear to increase SNA (measured by 
plasma and urinary noradrenaline) in hypertensive patients.445  
 
Plasma norepinephrine concentration increases more in patients treated with amlodipine 
than with nifedipine delivered in gastrointestinal therapeutic system form. The evidence 
indicates that both these once-daily dihydropyridine calcium channel blockers 
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effectively lower BP with minimal effects on HR (i.e., <1 beat/min). There are small 
differences between the drugs in the extent to which each activates the sympathetic 
nervous system with an overall non-significant trend in favor of nifedipine 
gastrointestinal therapeutic system.446 
 
In stroke-prone spontaneously hypertensive rats amlodipine decreased BP but not SNA, 
while oxidative stress in the brainstem, hypothalamus and cortex were reduced.447 In 
patients with essential hypertension long-term treatment with amlodipine significantly 
increased HR and plasma norepinephrine particularly when administered at a high 
dose.448, 449 In contrast, increases in muscle SNA with felodipine and lercanidipine were 
mainly confined to their acute administration, despite potent BP-lowering properties and 
increase in HR and plasma noradrenaline.450  
 
The second generation dihydropyridine calcium-channel blockers have three subtypes; 
L type (such as amlodipine), L/T type (efonidipine) and L/N type (cilnidipine). 
Prolonged (6 months) treatment of hypertension with cilnidipine resulted in sympatho-
inhibition (assessed using systolic BP variability analysis) and improved cardiac 
baroreflex sensitivity.451 In another prospective, open-labeled, randomized, crossover 
study efonidipine and cilnidipine were superior to amlodipine in the reduction of 
cardiac SNA, as determined by HR variability analysis.452 Cilnidipine has been shown 
to have more favorable effects on proteinuria progression in hypertension compared to 
amlodipine.453 The antihypertensive effects of cilnidipine and ability to reduce LV 
hypertrophy in patients with neurovascular compression of the RVLM appear to be 
partly attributable to inhibition of excessive SNA.454 Also treatment with cilnidipine 
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delayed development of LV fibrosis and diastolic dysfunction and was superior in the 
reduction of LV hypertrophy in hypertensive Dahl salt-sensitive rats compared to 
amlodipine. These effects of the drug are attributed to a distinct capacity to attenuate 
abnormally high SNA.455 
 
Relative little data are available on sympathetic nervous effects of non-dihydropyridine 
calcium channel blockers, verapamil and diltiazem. Although slow release forms of 
verapamil showed a trend toward reduction in muscle SNA and plasma norepinephrine 
levels, it is difficult to make conclusions on the overall impact of this agent on the status 
of the sympathetic nervous system.456  
 
In summary, the vasodilatory effects of dihydropyridine calcium channel blockers may 
be associated with activation of the SNA. The degree of this effect vary within the 
group, and it appears less for amlodipine that for nifedipine, and less for cilnidipine than 
for amlodipine. However evidence from large randomized clinical trials on the clinical 
relevance of sympathetic nervous system related effects is generally lacking (but short-
acting nifedipine should be avoided post myocardial infarction as in can increases risk 
of death in those patients). 
 
2.7.6. Statins 
 
Statins have a number of pleiotropic effects, which appear to contribute to its clinical 
success independently of its cholesterol-lowering effects. Clinical studies suggest that 
statins have a subtle BP-reducing effect in hypertensive patients, which was associated 
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with a reduction in muscle SNA.457 Controversial results have been reported regarding 
their effect on arterial baroreflex function. Although some studies showed no such 
effect, in studies of patients with hypertension and hypercholesterolemia simvastatin- or 
atorvastatin-induced reduction in muscle SNA was associated with a significant 
increase in arterial baroreceptor sensitivity.458, 459 Mechanistic insights into these data 
comes from experiments on spontaneously hypertensive rats where statins reduced BP, 
renal SNA, and the activity of eNOS in NTS.460 In addition, atorvastatin improved 
arterial baroreflex in stroke-prone spontaneously hypertensive rats by its anti-oxidant 
effects within the RVLM.461 However, a randomized, placebo-controlled, double-blind, 
cross-over study of 13 hypertensive patients failed to find any significant effect 
atorvastatin on BP, plasma noradrenaline levels, or HR, despite a significant reduction 
in muscle SNA.462 Overall statins do not have sufficient antihypertensive power to 
justify their use for BP control, and their possible pleiotropic benefits can be utilised in 
patients who need a cholesterol-lowering therapy. 
 
2.7.7. Current management of hypertension 
 
Current National Institute for Health and Care Excellence (NICE) guidelines in the UK 
for the management of hypertension recommend initial treatment with a calcium-
channel blocker to people aged over 55 years and to people of African or Caribbean 
family origin of any age.463 In patients younger 55 years an angiotensin-converting 
enzyme inhibitor or an angiotensin-II receptor blocker. If the BP remains high, the 
combination of calcium-channel blocker with an angiotensin-converting enzyme 
inhibitor or angiotensin-II receptor blocker should be used. 
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Thiazide-like diuretics, such as indapamide or chlorthalidone, should be the next 
antihypertensive group to use if the BP does not reach the target values. If the BP is still 
above 140/90 mmHg when three agents are used in full doses, which constitutes 
resistant hypertension, adding an aldosterone antagonist (spironolactone) should be 
considered in people with potassium level under 4.5 mmol/l. If the potassium level is 
above this level a higher-dose, thiazide-like diuretic treatment should be tried. Alpha-
receptor blockers could be used if those diuretics are contraindicated or not tolerated. 
Expert advise is essential if the BP continues to be elevated despite all these 
medications, and providing there is adequate compliance with the treatment.  
 
Beta-blockers are not usually used as the first line treatment of hypertension. However 
following the guidelines above they could be considered in some younger patients, who 
cannot take angiotensin-converting enzyme inhibitors or angiotensin II receptor 
antagonists or in those with increased sympathetic activity. 
 
 
2.7.8. Lifestyle modifications 
 
Current clinical guidelines recommend modification of lifestyle as part of the 
management of all patients with hypertension.464 These recommended lifestyle 
components include restriction of dietary salt consumption, low-fat diet with high 
consumption of fruits and vegetables, maintenance of healthy weight reduction, regular 
physical activity and avoidance of alcohol excess and smoking.465, 466  
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Among those recommendations, moderate regular exercise and calorie restriction have 
the largest evidence for a beneficial effect on SNA in hypertension.467, 468 In 
hypertensive patients, regular walking, was effective in lowering BP and SNA and 
improving exercise tolerance.469 Exercise training (for 4 months) in never-treated 
hypertensive patients restored the baroreflex control of muscle SNA and HR in 
hypertensive patients and led to significant reduction in BP.470 Even though BP 
lowering effect of endurance training can be modest in some patients it is still 
associated with improvement in HR variability and baroreflex sensitivity, which is of 
particular importance for sedentary and obese patients.471, 472  
 
2.7.9. Relaxation and breathing techniques 
 
Psychosocial stress has been shown to contribute to development of hypertension.473, 474 
Heightened activation of the sympathetic nervous system is a principle mechanism of 
stress-related BP increase.473, 474 Laboratory-based stress activity (i.e. mental arithmetic) 
increases muscle SNA and BP 147 and individuals with more prominent reactivity to 
these acute stressors have a higher chance of developing hypertension in future.475, 476 A 
number of studies reported BP lowering effects in hypertensive patients by using 
different relaxation / stress reduction techniques. 477-481 The exact mechanism, leading to 
BP and stress reduction, remains not completely understood.482, 483 Partially because 
these techniques used several approaches, it is difficult to uniformly compare and 
quantify results from different methodologies.484 Systematic reviews of the efficacy of 
stress reduction approaches for hypertension have shown either negative results or 
heterogeneity of effects on BP depending on the experimental design and selection of a 
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specific technique.485-487 However, meta-analyses of stress reduction approaches 
indicate that the Transcendental Meditation program may be effective in reducing high 
BP.482-484, 488 There is evidence that long-term practice of the above meditation program 
does reduce sympathetic activity in normotensive people, as judged by reduction of 
catecholamine levels in plasma489 and urine,490 although these studies have not assessed 
muscle SNA. Manipulation of the breathing using yoga techniques leads to a BP 
reduction in hypertensive patients.491, 492 In one study that evaluated the effect after 
completion of the trial, BP lowering effect was still present at 1 year 35 and 4-year 
follow up.36 Although methodological approaches were not consistent, due to the 
different types of yoga available, resent summaries of the studies suggested consistent 
BP lowering effect among them.493  
 
Several tools have been developed to help facilitate slow breathing training. In 1974 
Leuner invented a device that guided a slow breathing rate by producing sound or light 
signals and providing feedback to the user.494 Gavish has described and patented a 
device able to detect the biorhythmic activity (breathing), based on continuous analysis 
of this activity (including the feedback monitoring, working on the principal of the 
closed-loop operation).495 The device included a circuit to produce the parameter signals 
to be translated to the user as guiding tones. This approach helped to achieve and 
maintain the desirable breathing rate during the training session.495 Later Gavish 
modified the device to detect and monitor (including the feedback monitoring) the 
breathing pattern.496 The main principle of the device was the individualised lowering of 
the breathing rate by a relatively greater prolongation of the exhalation duration and 
thus a reduction in the inhalation-to-exhalation duration ratio. The device produces two 
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distinct guiding tones, one for inhalation and another for exhalation.497 The reduction of 
the breathing rate by prolongation of the exhalation is purported to be beneficial by 
virtue of a reduction in the development of an inspiratory muscle fatigue (as the 
perfusion of the breathing muscles mostly occurs during expiration).498 This is 
particularly relevant as the inspiratory muscle fatigue results in muscle SNA 
activation27, 499 and a breath-hold per se (either on inspiration or expiration) can 
profoundly increase muscle SNA.500 To simplify slow deep breathing training the 
InterCure Inc., New York company developed the RESPeRATE device 
(www.resperate.com/MD) based on the design of the Gavish device. The device 
interactively guides the patient to reduce their breathing rate, while monitoring their 
performance (providing feedback on performance).497 The thresholds for the BP 
lowering effect was suggested as a cut-off of 65% of the actual slow breathing time 
spent in synchronization of inhalation and exhalation to the guiding tones.497 Slow deep 
breathing (e.g., assisted by the commercially available RESPeRATE device) has been 
recommended by the American Heart Association with no side-effects reported.501 
Several studies involving hypertension patients are summarized in Table 2.3. In a recent 
meta-analysis, based on 13 original studies that included 608 participants, the benefits 
of the home-based use of the device was confirmed, with a lowering of systolic and 
diastolic BP by 4 mmHg and 3 mmHg indicated, after accounting for BP changes in a 
placebo group.48 However, the physiological changes that lead to such BP lowering 
remain unclear. In hypertensive patients, acute device-guided slow deep breathing for 
10 min was shown to reduce muscle SNA.44, 56 The muscle SNA response to the long-
term slow deep breathing training was studied only in one study, performed on 
untreated hypertensive patients.44 At the baseline visit, 15 min of acute device-guided 
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slow breathing resulted in sympathoinhibition but no reduction in BP. Long-term, 8 
week training of the above group of patients failed to reduce both muscle SNA and 
ambulatory BP.44 In prospective studies the device-guided slow deep breathing 
intervention reduced BP more effectively in older patients and those with higher 
baseline BP values, thus encompassing subjects with higher vascular resistance.40, 42  
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Table 2.3. Longer-term studies examining the effect of the RESPeRATE device-guided slow deep breathing on BP 
Study  Design Overall 
duration 
Daily 
duration 
of use 
Population n  
Intervention
/ controls 
Age 
Intervention  
/ controls 
Primary 
Outcome 
Results (mmHg) 
intervention vs. control 
Altena et al. 
(2009)45 
Randomized 9 weeks 15 min HTN, no DM 15/15 60/59 Office BP  
Home BP 
QOL 
ê 4.2 (95% CI -12.4 to 3.9) 
ê 2.6 (95% CI -8.4 to 3.3) 
✖ 
Anderson et 
al. (2010)46 
Randomized 4 weeks 15 min Pre-HTN, 
mild HTN 
20/20 53/53 24hr BP 
Office BP 
✖  
ê SBP and DBP,  
Elliot et al. 
(2004)37 
Randomized 8 weeks 15 min Uncontrolled 
HTN 
79 (43 high 
use, 33 low 
use)/57 
60/59 Office SBP ê 15.0 high use vs. 7.3 low 
use  
ê 15.0 high use vs. 9.2 in 
controls 
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Grossman 
et al. 
(2001)38 
Randomized 8 weeks 10 min Uncontrolled 
HTN 
18/15 52/50 Office BP  
 
Home BP 
ê SBP (7.5 vs. 2.9) 
✖ DBP (4.0 vs. 1.5) 
✖ SBP (5.0 vs. 1.2, p=0.07) 
ê DBP (2.7 vs. +0.9) 
Logtenberg 
et al. 
(2007)47 
Randomized 8 weeks 15 min DM2 + ≥1 
anti-HTN 
15/15 63/61 BP 
 
 
 
QOL 
✖ SBP (7.5 [95% CI 12.7-2.3] 
vs. 12.2 [95% CI 17.4-7.0) 
✖ DBP (1.0 [95% CI 5.5-+3.6) 
vs. 5.5 [95% CI 9.7-1.4] 
✖ 
Meles et al. 
(2004)39 
Open label 8 weeks 15 min Mild HTN 47/26 57/49 Office BP 
 
 
Home BP 
✖ SBP 5.5 
ê DBP 3.6 (also p<0.05 
intervention vs. controls) 
ê SBP 5.4  
ê DBP 3.2 (also p<0.05 
intervention vs. controls) 
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Rosenthal et 
al. (2001)40 
Open label 8 weeks 15 min HTN 13/0 51/0 24hr BP 
Office BP 
Home BP 
ê SBP 7.2; ✖ DBP 2.3 
ê SBP 7.2; ✖ DBP 3.4 
ê SBP 5.8; ✖ DBP 3.0 
Schein et al. 
(2001)41 
 
Randomized 
 
6 moths after 
8 weeks 10 min HTN 32/29 
 
 
 
 
22/21 
58/57 Office BP ê SBP 15; ê DBP 10 
Intervention vs. controls: 
End of treatment 
✖ SBP: 95% CI 2.7-+10.6 
ê DBP: 95% CI 1.1-7.6 
6 month follow up 
ê SBP 95% CI 3.5-14.6 
ê DBP 95% CI 2.7-12.9 
Viskoper et 
al. (2003)42 
Open label  8 weeks 15 min Resistant 
HTN 
17/0 67/0 Office BP 
Home BP 
ê SBP 12.9; ê DBP 6.9 
ê SBP 6.4;ê DBP 2.6 
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Schein et al. 
(2009)43 
Randomized 8 weeks 15 min DM2 + 
Uncontrolled 
HTN 
33/33 62/63 Office BP ê SBP 10.0; ê DBP 3.6 
Intervention vs. controls: 
ê SBP 10 vs. +1.6 
✖ DBP 3.6 vs. 1.0 (p=0.08) 
Bertisch et 
al. (2011)502 
Open label 8 weeks 30 min HTN + OSA 21/0 55/0 Office BP ê SBP 9.6; ✖ DBP 2.5 
Landman et 
al. (2013)503 
Randomized 8 weeks 15 min DM2 + HTN 21/24 64/65 Office BP 
 
 
 
Home BP 
✖ SBP 2.35 (95% CI 6.50-
+11.20) 
✖ DBP 2.25 (95% CI 6.67-
+2.16) 
✖ SBP 3.02 (95% CI 13.22-
+7.17) 
✖ DBP +0.10 (95% CI 6.88-
+7.08) 
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Howorka et 
al. (2013)59 
Randomized 8 weeks 12 min DM1 or DM2 
+ HTN 
16/16 50/49 24hr BP 
 
 
 
HRV(min) 
ê SBP 2.9 
ê Pulse pressure 2.3 
Intervention vs. controls: 
ê Pulse pressure 2.3 vs.+0.2 
êLF 
Hering et al. 
(2013) 
Randomized  8 weeks 40min/we
ek 
Untreated 
HTN 
10/12 37/matched Office BP 
24hr BP 
Muscle 
SNA 
ê SBP 18.0;ê DBP 7.0 
✖ SBP; ✖ DBP 
✖ -1 burst/min 
 
BP, blood pressure; CI, confidence interval; DBP, diastolic blood pressure; DM1, diabetes mellitus type 1; DM2, diabetes mellitus type 2; HRV, 
heart rate variability; HTN, hypertension; LF, low frequency; MSNA, muscle sympathetic nerve activity; OSA, obstructive sleep apnea; QOL, 
quality of life; SBP, systolic blood pressure.  
ê Significant reduction in the parameter tested; ✖ no difference in the parameter tested. 
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Despite several trials investigating the effect of device-guided slow deep breathing on 
BP few studies assessed underlying BP-lowering effect mechanisms of the acute and 
especially long-term effect of the technique. Furthermore, controversial findings have 
been reported, likely a reflection of the intervention duration and population studied. 
Acute (10 min) slow deep breathing was shown to reduce BP, muscle SNA and improve 
cardiac baroreflex sensitivity in untreated or washout patients with hypertension.54, 56 
However, another study failed to show any acute effect of the technique on BP in 
untreated hypertension, despite reductions in muscle SNA.44 Neither BP nor muscle 
SNA changed in this study during longer-term training.44 A study of patients with both 
hypertension and diabetes showed a reduction in BP and improvements in HR 
variability parameters with slow deep breathing, but the study did not assess SNA, this 
limiting pathophysiological insight.59 
 
2.7.10. Surgical: renal denervation, carotid denervation 
 
The carotid baroreceptors have been viewed as a therapeutic target in hypertension 
when optimal BP control cannot be achieved using medications.504 In patients with 
resistant hypertension insertion of implantable arterial barostimulator, to provide 
continuous electrical stimulation of the carotid sinus, reduced BP.505-507 This 
hypotensive effect was paralleled by a reduction in muscle SNA and this confirms the 
therapeutic relevance of interruption of abnormal SNA. The procedure appears to be 
safe and well tolerated. Nevertheless, the definite proof is required from prognostic 
trials to show that “baropacing” of the carotid sinus is superior to intensified medical 
treatment.508  
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Carotid body denervation prominently reduced renal SNA and improved sympatho-
respiratory coupling in pacing-induced congestive heart failure rabbits.509 These effects 
were followed by an improvement in cardiac function and breathing stability. Carotid 
sinus nerve denervation in spontaneously hypertensive rats was effective for both 
prevention of hypertension and reduction of BP in animals with already present 
hypertension.391, 510 Carotid sinus nerve denervation in spontaneously hypertensive rats 
provided sustained inhibition of renal SNA and reduction in BP. The improvement in 
BP was shown to be related to a resetting of the renal SNA-baroreflex function and 
recovery in sensitization of the cardiac baroreflex.510 Translation of these promising 
findings to humans is warranted.511  
 
Experimental models of hypertension consistently show that renal sympathectomy 
significantly improves BP control.155 Catheter-based renal denervation has been 
suggested as an effective and safe method of BP control in resistant human 
hypertension.512 Initial reports were very promising and showed prominent and 
sustained (i.e., over 1-year) BP reduction following the procedure.146, 513-515 Renal 
denervation in humans and animal model of hypertension progressively increase cardiac 
and sympathetic baroreflex function.514 However, a recently completed trial examining 
renal denervation in severe resistant hypertension, the prospective, single-blind 
Symplicity HTN-3 trial of 535 patients randomized to undergo renal denervation or a 
sham procedure (in a 2:1 ratio)289 failed to show any benefits of the procedure. These 
results challenged utility of the procedure and it is not currently recommended for 
routine clinical practice.516 
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2.8. Summary  
 
Hypertension exerts a number of unfavorable effects on cardiac myocardium such as 
LV hypertrophy, concentric remodeling, diastolic dysfunction and ultimately increase in 
LV filling pressure (which is commonly associated with symptoms of HF). 
Susceptibility of individual patients to these changes as a result of hypertension varies 
and factors responsible for this are poorly understood.  
 
The sympathetic nervous system plays a major role in the pathogenesis of hypertension 
through its vascular, cardiac, renal, central and metabolic effects. Detrimental 
consequences of sympathetic activation include vasospasm, activation of the renin-
angiotensin-aldosterone system, promotion of oxidative stress and diastolic dysfunction 
among others. However, the reasons for the heightened sympathetic activation 
commonly observed in patients with hypertension, or indeed in healthy older 
individuals, remain unclear.  
 
Several classes of antihypertensive agents target different units of the sympathetic 
system as their primary mode of action. Some of these agents were among the very first 
antihypertensive medications and they have a very long track record in the field. 
However, these medications have some significant drawbacks, particularly due to rather 
a large number of side effects. This is perhaps not surprising given the multitude of 
sympathetic nervous system functions and the complexity of its actions in the regulation 
of different organs. Additionally, controlled clinical trials suggest relatively modest BP 
lowering effects of some of these agents. The SNA is also relevant to other 
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antihypertensive medications, particularly those with vasodilatory properties, which 
have a potential to cause undesirable activation of the sympathetic system.  
 
Overall the therapeutic agents acting through various adrenergic receptors are currently 
considered second-line choices for management of hypertension. Initially very 
promising procedures of renal denervation are now not recommended for routine use 
due to lack of longer-term efficacy. All this does not necessarily mean that the 
sympathetic system does not have future as a therapeutic target in hypertension. In fact, 
evidence supporting the role of the sympathetic system in the pathogenesis of 
hypertension and its complications is ample.  
 
Limitations of the available treatment options highlight still incomplete knowledge of 
the complex mechanisms involved in activation and regulation of the sympathetic 
system leading to sustained BP increase. The potential of respiratory control, for 
example, delivered by the RESPeRATE device for BP reduction has been recognized 
recently. However, details of the physiological mechanisms leading to the BP lowering 
effects of the approach and factors modulating sympathetic-respiratory coupling remain 
insufficiently understood. Further research is essential in this direction. 
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CHAPTER III. METHODS 
 
3.1. Methods of data acquisition 
 
3.1.1. Introduction 
 
This chapter provides a description of the study methods: 1) the instruments used to 
collect and quantify the cardiovascular and respiratory parameters in the 3 experimental 
chapters contained within this thesis and 2) the methods and techniques used to assess 
and quantify cardiovascular and respiratory parameters.  
 
3.1.2. Heart rate 
 
While subjects rested in a supine position a lead II ECG was obtained. The electrodes 
were placed on left and right anterior aspects of shoulders and on a chest in a triangular 
pattern, to detect repolarization and depolarization periods of the heart.  The quality of 
the obtained signal was assessed to ensure that the R wave peak was the most prominent 
peak on recorded ECG. HR was calculated based on the number of R waves per minute. 
 
3.1.3. Blood pressure  
 
Beat–to-beat arterial BP was recorded from the middle finger using photo-
plethysmography (Finometer Midi, Finapres Medical Systems BV, Arnhem, the 
Netherlands). The main principle used in this device is a volume clamp method 
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developed by Penaz.517 The system contained a source of infrared light and sensors 
inside the inflatable finger cuff. It detects changes in blood volume (photo-
plethysmography approach). These changes in volume were used as indicators of BP. 
The finger cuff was designed to constantly process plethysmographic data and adjust 
the pressure in a cuff in order to maintain the diameter of measured artery constant. To 
compensate for differences in position of the finger to the heart level, hydrostatic height 
correction system was used. The absolute BP values recorded using photo-
plethysmography were adjusted according to brachial artery BP measures obtained in 
triplicate using a standard automated sphygmomanometer (Omron UK, East Sussex, 
UK). This approach was used for data presented in Chapters 5 and 6.  
 
3.1.4. Muscle SNA 
 
Standard microneurography techniques were used to record efferent postganglionic 
multiunit muscle SNA.518, 519 The advantages and limitations of the techniques were 
discussed in details in Chapter 2.3.4. Among the available techniques microneurography 
clearly benefits from being a minimally invasive method for direct assessment of the 
sympathetic activity in real time. This method is suitable for repeated measurements for 
monitoring of disease progression and response to therapeutic interventions.143, 163, 164 
 The subject’s leg was supported in a relaxed position with foam cushions. In order to 
locate peroneal nerve, palpation around the fibula head was followed by provision of 
small electrical stimuli (for 0.2 ms, ranging from 2.4 mA to 12.4 mA in this study) and 
observation for small muscle contractions. The anatomical location of the nerve was 
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further confirmed by the ultrasound scanning using LOGIQ-e ultrasound machine with 
12-MHz probe (General Electric Healthcare, Tokyo, Japan) (Figure 3.1).  
 
Direct muscle SNA recordings from the peroneal nerve were obtained using unipolar 
tungsten microelectrodes. A recording microelectrode was placed into the peroneal 
nerve at a fibular head, and a reference electrode was inserted 2-3 cm distally. The raw 
signals were amplified (×100k), filtered (bandwidth 700 – 2000 Hz), rectified and 
integrated (time constant 100 ms) to obtain a mean voltage neurogram. The muscle 
SNA neurogram was confirmed by (i) pulse-synchronous bursts pattern, (ii) signal-to-
noise ratio of >3:1, (iii) excitation during an end-expiratory breath-hold or Valsalva 
manoeuvre, and (iv) lack of changes in response to an unexpected loud noise or skin 
stroking.162 After obtaining a muscle SNA signal participants rested for at least 10 min 
to confirm recording stability, following which all study measurements were obtained.  
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Figure 3.1. B-mode image of the peroneal nerve 
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3.1.5. Respiratory parameters 
 
3.1.5.1. Thoracic circumference 
 
Respiration related changes in thoracic circumference were measured using strain gauge 
pneumobelt placed securely around the upper abdomen (Pneumotrace, UFI, Morro Bay, 
CA, USA). This approach for respiration monitoring was chosen as it is unobtrusive for 
participants and avoids the need for the participants to breathe through a mouthpiece, 
which may alter breathing pattern.520, 521  
 
3.1.5.2. Respiratory volumes and end-tidal gases 
 
Participants were fitted with an oro-nasal mask and two-way valve (Hans Rudolph, 
Kansas City, KS, USA) connected to a heated pneumotachometer (Hans Rudolph, 
Kansas City, KS, USA). Prior to data collection, the pneumotachometer was calibrated 
with a known sample volume (3 litres). Using the Spirometer settings of the LabChart 
software (ADInstruments), assessments of tidal volume, respiratory frequency, and 
minute ventilation were made on a breath-by-breath basis. A sample tube connected to a 
side port on the oro-nasal mask permitted the sampling of the expired air and 
determination of the partial pressure of end-tidal carbon dioxide (PETCO2) using a side 
stream capnograph (Nonin Medical, Plymouth, MN, USA).  
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3.1.6. Echocardiography 
 
Two-dimensional echocardiography was used to assess cardiac function and structure. 
Images were acquired with a LOGIQ-e ultrasound machine with 2-MHz probe (General 
Electric Healthcare, Tokyo, Japan) in accordance with international guidelines.522-524 
Off-line software (Xcelera, Phillips Ultrasound Quantification Module, USA) was used 
for quantification of cardiac parameters. Left ventricular systolic and diastolic volumes 
and left ventricle ejection fraction were measured using the modified Simpson’s biplane 
method. To assess left ventricular diastolic function pulsed Doppler was used to detect 
transmitral inflow velocity (E and A) in the apical 4-chamber view. Early diastolic 
mitral annular velocity (e') was measured by tissue Doppler imaging with average septal 
E/ e' ratio calculated as a parameter of the diastolic function. Left atrial volume, 
interventricular septal and posterior wall thicknesses were measured. Left ventricular 
mass index as well as left atrial volume index were calculated. 
 
3.1.7. Arterial stiffness 
 
Aortic augmentation (AI) index was measured using Sphygmocor device (Sphygmocor, 
AtCor Medical, Sydney, Australia). The AI is influenced by HR and it is a standard 
practice to adjust it for a HR of 75 beats per minute, and this done in the present study. 
A high-fidelity hand-held applanation tonometer was used to record radial arterial 
waveforms non-invasively for over 10 seconds. These data were used to calculate AI, 
which is an index of wave reflection and is influenced by arterial stiffness.525 Intra-
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observer coefficient of variation (CV) for the aortic augmentation index was 12.0%. 
Inter-observer CV for the aortic augmentation index was 5.29% and 11.12% for the two 
subjects, with average CV 8.21%.  
 
3.2. Data analysis 
 
3.2.1. Introduction 
 
The raw ECG, BP, and respiratory signals underwent analogue-to-digital conversion at 
10 kHz (Powerlab and Chart v7, AD Instruments, Bella Vista, NSW, Australia) and 
were stored for offline analysis. HR was calculated on a beat-to-beat basis from the 
ECG. Beat-to-beat systolic and diastolic BP were obtained from the arterial BP 
waveform and mean arterial pressure (MAP) obtained by integration of the arterial BP 
waveform over the entire cardiac cycle. Peak inspiration was defined as the highest 
point of the pneumobelt waveform (Chapter 4) or of the tidal volume waveform 
(Chapters 5 and 6) and respiratory rate was calculated from the inspiratory peaks. Tidal 
volume and minute ventilation were calculated using the Spirometry module from 
LabChart (ADInstruments, Dunedin, New Zealand). PETCO2 level was derived from the 
relative percentage of expired CO2 waveform as the maximum value. 
 
3.2.2. Steady-state muscle SNA  
 
A custom written interactive scoring program (Spike 2, Cambridge Electronic Design, 
Cambridge, UK) was used for the muscle SNA bursts identification. Sympathetic 
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neurograms were shifted in time to account for conduction delays, calculated according 
to subject height.526 The baseline level of neurogram was set to a zero value and the 
amplitude of the highest SNA burst spontaneously occurring during the baseline period 
was assigned a value of 100 arbitrary units (AU). The amplitudes of all other bursts 
within a recording session were normalized to this.527, 528  
 
All bursts were inspected and scored as ‘burst’ or ‘no burst’. Muscle SNA was 
quantified as burst incidence (bursts·100 heart beats-1), burst frequency (bursts·min-1), 
burst amplitude (i.e., strength) and total activity (product of burst frequency and mean 
burst amplitude). The location of each burst within the respiratory cycle was 
determined, (for data presented in Chapters 4 and 5) and burst incidence, burst 
frequency, burst amplitude and total activity were calculated for each 10% time interval 
of the breath from the peak of inspiration (i.e., peak inspiration = time point 0). 
 
Inter-observer CV was determined for calculations of the burst frequency (bursts·min-1) 
and burst incidence (bursts·100 heart beats-1) with another postgraduate student from 
the same laboratory. Independent scoring was performed on 5 study participants with 
CV 7.8% for burst frequency and 8.5% for burst incidence (Table 3.1). 
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Table 3.1. Measurements of muscle SNA parameters for reproducibility analysis 
 Operator 1 Operator 2 
  Frequency Incidence Frequency Incidence 
Subject 1 17.24 31.85 23.25 43.42 
Subject 2 26.22 50.00 29.71 56.6 
Subject 3 27.58 51.82 27.68 52.37 
Subject 4 26.46 52.29 27.76 55.64 
Subject 5 29.32 57.59 31.79 63.56 
SNA, sympathetic nerve activity 
 
3.2.3. Interaction between respiration and SNA (for Chapter 4) 
 
In order to examine to examine the relationship between respiratory mediated changes 
in muscle SNA (rMSNA) and Traube–Hering wave (THW) amplitude a novel time 
domain analysis was employed using a custom written interactive analysis programme 
(Spike 2) (Figure 3.2). Respiration triggered averaging of the sympathetic neurogram 
and beat-to-beat MAP time series (obtained by the beat-to-beat integration of the 
arterial BP waveform over a cardiac cycle) was undertaken to identify temporal 
relationships between the THW amplitude and rMSNA. Regions of interest were set 
around the THW nadir, around the THW peak, and around rMSNA. The rMSNA was 
quantified as the area under the sympathetic activity curve during the inspiratory period 
plus 50% of this duration, which thus extended into the post-inspiratory period. For 
each subject, this approach was used to generate a breath-by-breath respiratory 
amplitude, THW amplitude and rMSNA time series allowing the relationships between 
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these variables to be examined. For this analysis of the association between neural 
events and the THW, sympathetic neurograms were neither time-shifted nor normalised. 
This is in line with previous studies that have examined the associations between human 
SNA and the ensuing vascular or BP response.528 
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Figure 3.2. Respiratory-triggered waveform averaging of the raw respiratory, 
blood pressure and muscle SNA signals (panel A), and sample rMSNA vs. Traube-
Hering wave amplitude (THW Amp) relationships in one older subject (panel B). 
Following respiratory-triggered averaging, regions of interest were set around the 
Traube–Hering wave (THW) nadir, around the Traube–Hering wave peak, and around 
the muscle SNA associated with respiration (rMSNA). The rMSNA was quantified as 
the area under the sympathetic activity curve during the inspiratory period plus 50% of 
this duration, which thus extended into the post-inspiratory period (panel A). For each 
subject this approach was used to generate a breath-by-breath respiratory amplitude, 
THW Amp and rMSNA time series, and the association between these variables 
examined (panel B). As the aim of this analysis was to assess the association between 
sympathetic neural events and Traube-Hering waves no time shifting of the sympathetic 
neurogram was undertaken. Note that with a shift to account for conduction delays in 
muscle SNA (1.38 s in this subjects) a sympathetic inhibition is apparent from 
approximately peak inspiration to end-inspiration. 
 
3.2.4. Arterial baroreflex sensitivity  
 
The sequence technique was used to determine spontaneous cardiac baroreflex 
sensitivity.529, 530 This approach was chosen as a good non-invasive estimate of the 
baroreflex sensitivity that can be used during the breathing manoeuvres performed by 
participants, and it is known to correlate with modified Oxford measures of resting 
cardiac baroreflex function. 530-532 Analysis of the spontaneous fluctuations of the 
systolic BP and R-R interval or HR was performed using a customized program (Spike 
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2) to identify sequences of three or more consecutive beats where systolic BP and R–R 
interval changed in the same direction (by >1 mmHg and 1 ms, respectively) and where 
systolic BP and HR changed in the opposite direction. Linear regression analysis was 
applied to identify acceptable sequences with an r2>0.85. The slope of the systolic BP–
R-R interval and the systolic BP–HR regression line represents an index of cardiac 
baroreflex sensitivity that correlates with the modified Oxford method measurements of 
resting cardiac baroreflex function.530-532 
 
Calculations of arterial baroreflex control of muscle SNA were obtained from the 
relationships between diastolic BP vs. burst incidence and total muscle SNA by 
weighted linear regression analysis.23, 124, 527 Based on 10 min recordings each diastolic 
BP value was grouped into 3 mmHg bins. Then for each diastolic BP bin, the 
percentage of cardiac cycles in which a burst occurred (burst incidence) and total burst 
amplitude divided by the number of cardiac cycles (total muscle SNA; expressed as 
AU·beat-1) were determined. 
 
3.2.5. Heart rate variability 
 
Time and frequency domain indices of HR variability were evaluated using short (5 
min) recordings by commercially available software (Kubios HRV Software, 
Biomedical Signal Analysis Group, University of Kuopio, Finland) in accordance with 
current guidelines.190  
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The time domain indices included: RMSSD, SDNN, pNN50%. Frequency analysis of 
HR variability (fast Fourier transformation) was considered at a HF range (0.15-0.4 Hz), 
a LF range (0.04–0.15 Hz) and TP between 0.0-0.4 Hz. Absolute power spectral density 
and normalized power spectral density were identified at each frequency range. 
Normalized units calculated as the proportion of each component to the total power 
minus very low frequency range. 
 
For the purposes of this thesis, the HR variability indices of interest are RMSSD, 
SDNN, pNN50% and HF, as they have been generally implied as indicators of cardiac 
parasympathetic activity.190, 191, 195, 196 The influence of parasympathetic and 
sympathetic blockade (with glycopyrrolate and propranolol, respectively) in conscious 
dogs on HR variability has been investigated by Akselrod et al.533 Parasympathetic 
blockade abolished the HF power, while the sympathetic blockade had very little effect. 
These findings confirmed that HF power is an indicator of parasympathetic activity. 
Further studies in unrestrained rats have shown significant reduction of LF power with 
propranolol, but not a complete abolition.534 Following the parasympathetic blockade 
with atropine, HF power was completely abolished, but also LF power was markedly 
reduced.534, 535 As discussed in more details in Chapter 2.3.5 interpretation of results of 
HR variability findings could be ambiguous. In hypertensive patients, an increase in LF 
and decrease in HF, RMSSD and pNN50%, as compared to normotensives, has been 
interpreted as an enhanced cardiac sympathetic activity and a reduced parasympathetic 
activity.198 
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CHAPTER IV. INFLUENCE OF AGE ON RESPIRATORY MODULATION OF 
MUSCLE SYMPATHETIC NERVE ACTIVITY, BLOOD PRESSURE AND 
BAROREFLEX FUNCTION IN HUMANS 
 
4.1. Introduction 
 
Healthy ageing is associated with elevated plasma catecholamine concentrations, 
increased noradrenaline spillover from the heart, brain, kidneys, and greater SNA 
directed to the skeletal muscle vasculature.22, 23 Such heightened SNA has been linked 
to structural and functional abnormalities of the peripheral vasculature (e.g., increased 
arterial stiffness, impaired endothelial function) in several chronic disease states24, 25 and 
in elderly individuals.265 Alongside increases in tonic muscle SNA, α-adrenergic 
receptor sensitivity and vascular responsiveness are reportedly diminished with 
increased age.536-538 The mechanistic basis for the age-related elevation in sympathetic 
neural firing remains unclear. 
 
It has been known since the earliest direct recordings that SNA shows respiratory 
modulation.539 This is generated in large part by central neural circuits26 and upon 
which is superimposed modulatory feedback signals from cardiorespiratory afferents 
that include lung-stretch receptors, baroreceptors, central and peripheral 
chemoreceptors.27 During normal breathing in young healthy individuals muscle SNA is 
inhibited during mid-inspiration, reaching a nadir when lung volume is at its highest 
(peak inspiration), and peaking when lung volume is at its lowest (end-expiration).27-30, 
33 Patients with chronic heart failure show increased muscle SNA linked to an 
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attenuation of the normal inspiratory sympathoinhibition.32 Given the increase in the 
tonic level of muscle SNA with age this may predict a reduction in the inspiratory 
inhibition of muscle SNA, however there is a paucity of information on the effect of 
aging on respiratory-sympathetic coupling. Fatouleh and Macefield418 reported a similar 
pattern of respiratory modulation of muscle SNA in young (29±2 years) and middle-
aged groups (50±3 years) using cross-correlation histograms constructed between 
sympathetic spikes and respiratory-related chest excursions. However, the respiratory 
modulation of muscle SNA was not assessed in terms of sympathetic burst occurrence 
(i.e., incidence) or strength (i.e., amplitude),122, 123, 540, 541 thus whether ageing affects the 
within-breath modulation of these distinct parameters of SNA is unclear. 
 
The respiratory modulation of vasomotor sympathetic outflow causing phasic changes 
in arteriolar smooth muscle tone generates Traube–Hering arterial BP waves (THW). 
Importantly, Simms et al. (2009) demonstrated that spontaneously hypertensive rats 
exhibited augmented respiratory–sympathetic coupling and larger THW that contributed 
more to vascular resistance than in normotensive Wistar–Kyoto control rats at all ages. 
415 However, the contribution of the sympathetic nervous system to the regulation of 
THW in humans remains controversial, perhaps as a consequence of the multiple 
mechanisms implicated and the methodological approaches previously used to 
investigate this (e.g., complete pharmacological autonomic blockade, individuals with 
brain death).542, 543 In a recent preliminary investigation employing a novel time domain 
analysis, Towie et al. (2012) revealed a significant positive correlation between 
respiratory mediated changes in muscle SNA and the following THW in a group of 
young individuals (age 21-30 years). It was suggested that this finding supported the 
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hypothesis that THW are partly a consequence of central respiratory-sympathetic 
coupling in humans.544 
 
However, it is incompletely understood whether there is an alteration in respiratory 
coupling of muscle SNA with healthy human ageing; whether this could account for the 
increased muscle SNA seen with aging; and if this sympathetic flow still gives rise to 
THW. 
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4.2. Aims and hypotheses 
 
The aim of this study was to determine the influence of age on respiratory related 
bursting of muscle SNA and on the association between the rhythmic fluctuations in 
muscle SNA and THW that occur with respiration in humans. 
 
The following hypothesis were tested: 
1. The increase muscle SNA in healthy ageing would be due to diminished inspiratory 
inhibition of muscle SNA. 
2. The sympathetic contribution to respiratory mediated fluctuations in BP (THW) would 
be attenuated in older individuals. 
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4.3. Methods  
 
4.3.1. Study subjects  
 
Ten young (22±2 years old, mean±SD) and ten older (58±6 years) males participated in 
the study, which was approved by the local ethical review committee and conducted in 
accordance with the Declaration of Helsinki (2000). All participants provided written 
informed consent before they took part in any experiments. Participants were healthy 
with no significant medical history and were not taking any prescription or over-the-
counter medications. All subjects were asked to abstain from caffeine use for at least 12 
h and from alcohol intake and strenuous physical activity at least 24 h prior to the 
participation. All study measurements were made in a temperature controlled room (20-
22ºC).  
 
4.3.2. Experimental protocol 
 
The experimental protocol consisted of 10 min of uncontrolled spontaneous breathing at 
a normal resting rate and depth. 
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4.3.3. Experimental measurements 
 
While subjects rested in a supine position the following recordings were simultaneously 
obtained and stored: muscle SNA, beat-to-beat arterial BP, electrocardiogram, 
respiratory rate, as described in section 3.1 (Figure 4.1).  
 
Figure 4.1. A raw trace of an original recording 
ABP, arterial blood pressure; ECG, electrocardiogram; SNA, sympathetic nerve 
activity. 
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4.3.4. Experimental data analyses 
 
The analyses of HR, BP, steady-state muscle SNA, respiration related muscle SNA, 
arterial baroreflex sensitivity, HR variability were performed as described in section 
3.2. Briefly HR variability was calculated from the ECG signal, as described in section 
3.2.5. Calculations of the BP were obtained from the arterial BP waveform as described 
in section 3.2.1. Respiratory rate was calculated form thoracic excursion as described in 
section 3.2.1. The raw muscle SNA signal (Figure 4.1.) was used to calculate steady-
state muscle SNA as burst incidence (bursts·100 heart beats-1), burst frequency 
(bursts·min-1), burst amplitude (i.e., strength) and total activity (product of burst 
frequency and mean burst amplitude). The location of each burst within the respiratory 
cycle was also determined, and burst incidence, burst frequency, burst amplitude and 
total activity were calculated for each 10% time interval of the breath from the peak of 
inspiration (i.e., peak inspiration = time point 0) The same raw muscle SNA, as well as 
arterial BP, and thoracic excursion waveforms were used for calculation of interaction 
between respiration and SNA as described in section 3.2.3.  
 
4.4. Statistical analysis 
 
Statistical analysis was performed using Statistical Package for the Social Sciences 
(SPSS) software, version 19.0 for Windows (IBM Inc, Chicago, IL). Data were tested 
for normality by Kolmogorov-Smirnov test. Baseline subject characteristics were 
compared using an independent sample t-test. Mixed between-within subjects ANOVA 
analysis, adjusted using the Greenhouse-Geiser correction, was used to examine the 
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main effects of respiratory phase, age group and their interaction. Spearman correlation 
analysis was used to evaluate relationships between breath-by-breath values of 
respiratory waveform amplitude (e.g., index of breath depth), rMSNA and THW 
amplitude (Chapter 3, Figure 3.2, panel A). Chi-square analysis was employed for 
comparisons of categorical data. Data are expressed as mean ± SD, or median 
(interquartile range) in text and tables and as median ± SE in figures. A P value of 
<0.05 was considered statistically significant. 
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4.5. Results 
 
4.5.1. Subject characteristics 
 
The mean age difference between young and older groups was 36 years (Table 4.1). 
Young and older participants were matched for body mass index (BMI 25 ± 3.5 vs. 26 ± 
4.0 kg·m2, respectively, P=0.82). MAP was significantly higher in the older group (95 ± 
8.9 mm Hg) than in the young group (86 ± 8.2 mm Hg, P=0.04), whereas HR (60 ± 7.9 
beats·min-1 in the young group vs. 62 ± 17.2 beats·min-1 in the older group, P=0.81) and 
respiratory rate (15.3 ± 1.8 breaths·min-1 in the young group vs. 13.4 ± 2.4 breaths·min-1 
in the older group, P=0.06) were similar. THW amplitude was also similar between 
groups (2.0 ± 0.9 mm Hg in the young group vs. 2.7 ± 1.3 mm Hg in the older group, 
P=0.19), but as anticipated muscle SNA burst incidence (22.7 ± 9.2 vs. 42.2 ± 13.7 
bursts·100 heart beats-1, P=0.002) and burst frequency (13.5 ± 6.0 vs. 25.0 ± 7.6 
bursts·min-1, P=0.001) were higher in the older group. Spontaneous cardiac baroreflex 
sensitivity was lower in the older group compared with the younger group (P<0.001), 
while arterial baroreflex control of muscle SNA was similar between groups (Figure 
4.2.).  
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Table 4.1. Subject characteristics 
 Young Older P value 
Age, years 22±2 58±6 <0.001 
Weight, kg 79±11 81±18 0.75 
Height, cm 177±5 177±9 0.97 
SBP, mm Hg 123±14.0 136±14.3 0.046 
DBP, mm Hg 68±5.6 74±6.3 0.04 
Data presented as mean±SD. DBP, diastolic blood pressure; SBP, systolic blood 
pressure. 
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Figure 4.2. Spontaneous measures of cardiac baroreflex sensitivity (upper panels) 
and arterial baroreflex control of muscle sympathetic nerve activity (lower panels) 
in young and older groups. 
Data presented as mean±SE; * represents P<0.05 vs. young; AU, arbitrary units; BP, 
blood pressure; HR, heart rate; MSNA, muscle sympathetic nerve activity.  
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4.5.2. Respiratory-sympathetic coupling 
 
The influence of respiration on muscle SNA parameters in young and older participants 
is summarised in Figures 4.3 and 4.4. All parameters of muscle SNA examined (burst 
incidence, burst frequency, burst amplitude and total activity) were significantly higher 
in the older group in all respiratory phases (P<0.05, ANOVA main effect of age). 
Muscle SNA was modulated by respiration, such that muscle SNA burst incidence, 
burst frequency, burst amplitude and total activity were lowest around the mid-
inspiratory to post-inspiratory period and highest during mid-to-late expiration (P<0.05, 
ANOVA main effect of respiratory phase) (Figure 4.4). Importantly, the magnitude of 
the respiratory modulation of all parameters of muscle SNA was similar in both groups 
(i.e., no significant statistical interactions were observed between age group and 
respiratory phase [ANOVA]). More specifically, muscle SNA burst incidence, burst 
frequency, burst amplitude and total activity were significantly higher in the older group 
compared to the younger group during both the mid-to-late expiratory period and the 
inspiratory to post-inspiratory period (Figure 4.4). However, a similar degree of 
inspiratory attenuation of muscle SNA was observed in both groups (i.e., a significant 
main effect of respiratory phase was observed, but a significant interaction between age 
and phase was not), such that muscle SNA was significantly lower during the 
inspiratory to post-inspiratory period compared to the mid-to-late expiratory period 
(Figure 4.4). 
 
 119 
 
Figure 4.3. Respiratory modulation of muscle sympathetic nerve activity burst 
incidence (panel A), frequency (panel B), amplitude (panel C) and total activity 
(panel D) in young and older groups 
Peak of inspiration at 0 mid-to-late expiration was denoted as 30-79% of the breath, 
while inspiratory to post-inspiratory period was taken as the remaining period of the 
respiratory cycle. Data presented as mean±SE; AU, arbitrary units. 
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Figure 4.4. Respiratory modulation of muscle sympathetic nerve activity burst 
incidence (panel A), frequency (panel B), amplitude (panel C) and total activity 
(panel D) during the inspiratory to post-inspiratory period and mid-to-late 
expiration in the study groups 
Note that sympathetic neurograms were shifted in time to account for conduction delays 
calculated according to subject height. Mid-to-late expiration was taken as 30-79% of 
the breath and the inspiratory to post-inspiratory period taken as 0-29% and 80-100% of 
breath as presented in Figure 4.3. Data presented as mean±SE; AU, arbitrary units. 
!
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RMSSD, SDNN, pNN50%, HF, LF and TP were significantly lower in older group 
compared to the younger group, while LF/HF was higher in the older group (Table 4.2). 
 
Table 4.2. Time and frequency domain measures of HR variability in young and 
older subjects 
 Young Older P value 
RMSSD (ms) 49.3 (37.2-74.4) 20.2 (16.8-36.3) 0.004 
SDNN (ms) 64.2±18.7 42.6±16.1 0.013 
pNN50 (%) 29.2 (16.7-48.8) 2.2 (1.4-10.9) 0.003 
HF (ms2) 981 (633-1593) 152 (112-234) 0.002 
LF (ms2) 869 (475-1817) 407 (211-681) 0.02 
TP (ms2) 3288 (2624-5848) 1218 (857-3381) 0.02 
HF (n.u.) 50.1±12.4 34.7±19.5 0.05 
LF (n.u.) 49.9 ± 2.4 65.3±19.5 0.05 
LF/HF 1.1 (0.6-1.4) 2.2 (1.5-3.8) 0.02 
Data presented as median (interquartile range) or mean±SD; RMSSD, square root of the 
mean of the sum of successive differences in R-R interval; SDNN, standard deviation of 
normal to normal R-R interval; pNN50%, proportion of successive R-R interval which 
vary by >50 ms; TP, total power (0.0-0.4 Hz); HF, high-frequency power (0.15-0.4 Hz); 
LF, low-frequency power (0.04-0.15 Hz).  
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4.5.3. Respiratory related muscle SNA-BP coupling 
 
The proportion of participants in whom significant correlations between parameters of 
rMSNA-BP coupling (THW amplitude, rMSNA, respiratory waveform amplitude [i.e., 
breath depth]) is summarised in Table 4.3. rMSNA positively and significantly 
predicted the magnitude of the following THW (lag 0) in 100% of young (Chapter 3, 
Figure 3.2, panel B) and 80% of older subjects (P=0.14 young vs. older groups). This 
positive correlation was not observed with the magnitude of the THW amplitude 
associated with the next breath (lag +1), indeed this showed a negative correlation in 
80% of young and 70% of older subjects (P=0.606 young vs. older groups). In some 
individuals (30% of young and 50% of older subjects, P=0.36) a significant correlation 
was noted between THW amplitude and the following rMSNA, however in the 
majority, this relationship was positive (counter to the expected relationship). This test 
of reverse causation (i.e., whether the rMSNA related to the magnitude of the preceding 
THW through the engagement of the arterial baroreflex) was thus not proven and was 
less common than the proportion of individuals in which a correlation between rMSNA 
and the following THW was observed. In 60% of the young group and 50% of the older 
group, the respiration waveform amplitude was significantly and positively correlated 
with the following THW amplitude, which was not different between groups (P=0.65 
young vs. older groups). 
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Table 4.3. Proportion of participants in whom significant correlations between 
parameters of respiratory related muscle SNA-BP coupling were observed 
 Young (n=10) Older (n=10) P value 
Respiratory amp vs. THWamp 
Direction of correlation, r 
60% positive  
0.28± 0.07 
50% positive 
0.22±0.05 
0.65 
rMSNA vs. THWamp 
Direction of correlation, r 
100% positive 
0.45± 0.07 
80% positive  
0.48± 0.19 
0.14 
rMSNA vs. THWamp (lag +1) 
Direction of correlation, r 
80% negative  
-0.31± 0.09 
70% negative  
-0.34± 0.09 
0.61 
Previous THWamp vs. rMSNA 
Directions of correlation, r 
30%  
1 negative -0.19 
2 positive 
0.20±0.02 
50%  
1 negative -0.18 
4 positive 0.20± 0.04 
0.36 
Respiratory amp vs. rMSNA 
Directions of correlation, r 
50% positive  
0.34± 0.11 
30% 
1 positive 0.60 
2 negative -0.24± 0.04 
0.36 
Data presented as mean±SD; Respiratory amp, amplitude of the respiratory waveform 
excursion (e.g. index of breath depth); THWamp, amplitude of the Traube-Hering 
wave; rMSNA, respiratory linked MSNA; r, correlation coefficient.  
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4.6. Discussion 
 
The major novel findings of this investigation are twofold. First, in contrast to the initial 
hypothesis, the strength of the respiratory modulation of the muscle SNA parameters 
(e.g., burst incidence, frequency, amplitude and total activity) was preserved in healthy 
older individuals. Second, a significant association between the rMSNA and THW 
amplitude was identified and that this was similar in healthy young and older groups. 
Collectively, these findings suggest that a potential attenuation of inspiratory-linked 
inhibition of muscle SNA does not appear to explain the elevated resting muscle SNA 
in older individuals, and that central respiratory-sympathetic coupling is a component of 
the THW in both young and older humans.  
 
A respiratory modulation of SNA is evident in recordings from rats415, cats545 and 
humans27-30, 33, 546, with the exact pattern of respiratory modulation of SNA being 
species and target organ specific. In adult rats muscle vasoconstrictor-type sympathetic 
neurones are typically inhibited during early-inspiration, with a peak of activity 
observed during the mid-inspiratory to post-inspiratory phase (i.e., first part of 
expiratory interval) and sometimes a smaller peak in late expiration.415 Importantly, this 
pattern of respiratory-sympathetic coupling is altered in several rat models of 
hypertension, such that sympathetic activity becomes particularly enhanced during 
inspiration, and appears to be a causative factor in the increased vascular resistance, BP 
and potentially end organ damage in these animals.415, 424, 547, 548 Increased sympathetic 
activity in patients with chronic heart failure has also been linked to alterations in 
respiratory-sympathetic coupling such that the muscle SNA is highest in those patients 
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in whom the normal inspiratory-linked inhibition of muscle SNA is most diminished.32 
An attenuation of the direct inhibitory effect of pulmonary stretch receptors on 
sympathetic activity in response to lung inflation could potentially explain this 
observation,549, 550 although an enhanced central-respiratory coupling that elevates 
muscle SNA during inspiration remains a possibility. Given the well-established 
increase in SNA in older individuals22 it was expected to observe a reduced inspiratory 
inhibition of muscle SNA in older compared with young participants. However, a clear 
inspiratory attenuation of muscle SNA was evident and no statistical interaction 
between age and respiratory cycle phase was observed. This indicates that a diminished 
inspiratory-linked inhibition of muscle SNA in the older group does not contribute to 
the elevated muscle SNA in the older individuals. Nevertheless, it is important to note 
that all indices of muscle SNA studied were significantly higher in the older group 
compared to the younger group at all respiratory phases examined, which may represent 
an enhancement of respiratory drive to muscle SNA across respiratory cycle phase, 
although the temporal pattern of the modulation is similar. Given the similar arterial 
baroreflex regulation of muscle SNA in young and older individuals observed in the 
present study and reported before551 this also appears to be an unlikely explanation. 
However, impaired cardiopulmonary baroreflex buffering of muscle SNA,552 elevated 
brain noradrenaline activity553 and or enhanced peripheral afferent drive from, for 
example, the heart,554 kidney555 or carotid body510 remain as potential mechanisms for 
the elevated muscle SNA observed in the older group.  
 
Using cross-correlation histograms between the sympathetic spikes and respiratory-
related chest excursion signals Fatouleh and Macefield418 reported a similar respiratory 
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modulation of muscle SNA in groups of young (29 ± 2 years) and middle-aged 
individuals (~20 years older), although no respiratory mediated fluctuations in BP were 
detected. The findings of the present study partly support these observations and extend 
them by determining whether sympathetic burst occurrence (i.e., incidence) and strength 
(i.e., amplitude) are differentially modulated within a breath. Both animal122, 123 and 
human 124 investigations have identified that the arterial baroreflex differentially 
modulates sympathetic burst incidence and amplitude. Previous work examining 
respiratory modulation of muscle SNA bursts in humans has focused on the evaluation 
of muscle SNA in terms of total activity.27-31, 33 In this work it has been observed that all 
indices of muscle SNA parameters examined (e.g., burst incidence, burst frequency, 
amplitude and total activity) were significantly modulated by respiration and, despite an 
age-related elevation in all parameters, no significant interactions between age and 
respiratory phase were observed. 
 
The study utilises a novel methodological approach to examine the relationships 
between respiratory mediated changes in muscle SNA and arterial BP.544 Whilst animal 
experiments support the contention that respiratory modulation of vasomotor 
sympathetic outflow causes phasic changes in arteriolar smooth muscle tone thus 
generating THW,415 the results of human work are more equivocal.542, 543 In several 
recent studies the ability of spontaneously occurring muscle SNA bursts to evoke a 
beat-to-beat change in peripheral vascular resistance and BP has been carefully 
described.528, 536 In accordance with these reports there was significant association 
between the rMSNA and the THW amplitude of the following breath in all of the young 
individuals and the large majority of older individuals studied. This relationship was 
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evident in a similar proportion of young and older individuals. This was somewhat 
surprising given the reported age-related reduction in a-adrenergic responsiveness,537, 538 
and may be related to the reported down regulation of uptake mechanisms and/or down 
regulation of degrading enzymes for noradrenaline,538 or indeed it may be the case that 
despite a reduction in a-adrenergic responsiveness there is a sufficient safety margin for 
transmission at the neurovascular junction to maintain effective sympathetic signalling. 
Notably, the changes in rMSNA were not robustly associated with the previous THW 
amplitude, supporting the contention that respiratory modulation of muscle SNA is 
independent of fluctuations in BP.29, 31 
 
These data support the contention that respiratory modulation of vasomotor sympathetic 
outflow causes phasic changes in arteriolar smooth muscle tone thus generating THW. 
However, it is important to appreciate that a number of complex feedforward and 
feedback mechanisms have also been implicated.543, 556 Indeed, Tan and Taylor556 
demonstrated that respiratory fluctuations in heart period cause arterial BP fluctuations 
especially in young healthy individuals, rather than buffering such pressure fluctuations. 
In the present investigation a clear reduction in the respiratory linked fluctuations of 
heart period was noted in the older group, however as in a previous investigation557 
respiratory-linked fluctuations in BP were not significantly different in the young and 
older groups. Nevertheless, further studies are required to determine how age changes 
the relative contribution of the many mechanisms implicated in the generation of THW. 
 
In the present study muscle SNA was examined due to its well-established importance 
in BP regulation. The inability to record directly from the sympathetic nerves supplying 
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the renal or splanchnic vascular beds in humans means that the potential contribution 
from these regions to THW amplitude was not ascertained. Furthermore, a definitive 
explanation for the age-related elevation in BP remains elusive. Aside from adrenergic 
mechanisms, a number of other factors remain as possible contributors including 
increased arterial stiffness,558 up-regulation of endothelin-1 mediated 
vasoconstriction,559 reductions in endothelial nitric oxide bioavailability560 and 
alterations in renin-angiotensin-aldosterone pathways.561 Of note, the higher BP with a 
concomitant preservation in the sensitivity of arterial baroreflex control of muscle SNA 
observed in the older group, may be explained by the resetting (or shift of the set-point) 
around which muscle SNA is regulated. However, a limitation of the method employed 
to assess arterial baroreflex function in the present study was that a complete assessment 
of the full stimulus–response relationship is not provided and for this a more direct 
method is required (e.g., modified Oxford technique). Furthermore, while the 
‘spontaneous’ index of arterial baroreflex function used has been considered to provide 
a useful indicator of sensitivity around the prevailing BP (i.e., operating point of the full 
baroreflex function curve),562 they are poorly associated with sensitivity measures 
derived using the modified Oxford technique.563 
 
As in many human studies examining respiratory modulation of SNA, respiration was 
assessed using a strain-guage pneumobelt.520, 521 The advantage of this approach is that 
it is unobtrusive and avoids participants having to breathe through a mouthpiece, which 
almost inevitably tends to alter breathing pattern.520, 521 The potential disadvantage of 
this approach is that the time-delay between the occurrence of respiratory related events 
within the central nervous system and changes in thoracic circumference (as well as 
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delays between respiratory central pattern generators and muscle SNA) is not accounted 
for, and I have assumed that this is a constant between young and older groups. It 
should also be noted that as in several other cross-sectional studies of respiratory 
sympathetic coupling418, 564 respiratory rate and depth were not controlled. However, 
importantly, it has been reported that muscle SNA is no different during uncontrolled 
spontaneous breathing and controlled breathing at 12 breaths per minute.28 Given that 
the absolute amplitude of a sympathetic burst is related to the proximity of the recording 
microelectrode to the sympathetic fibres, as is conventional in human sympathetic 
microneurography studies burst amplitude have been expressed in normalized units.415, 
416 
 
4.7. Conclusion 
 
In conclusion, the study suggests that despite an age-related elevation in muscle SNA 
the strength of the respiratory modulation of muscle SNA is similar in young and older 
individuals. Indeed, the normal inspiratory-linked inhibition of muscle SNA is 
preserved in older individuals. This suggests that the elevation in muscle SNA found in 
older individuals is unrelated to a diminished respiratory-sympathetic coupling. In 
addition, rMSNA changes appear to be a significant component of THW amplitude in 
both young and older groups. 
 
Contribution  
For this experimental chapter, I processed the raw data for extraction, and undertook the 
data analysis, statistical analysis, data interpretation, and writing of the thesis chapter. 
 130 
CHAPTER V. INFLUENCE OF DEVICE-GUIDED SLOW DEEP BREATHING 
ON RESPIRATORY AND ARTERIAL BAROREFLEX CONTROL OF 
MUSCLE SYMPATHETIC NERVE ACTIVITY IN HUMANS 
 
5.1. Introduction 
 
Interest in the potential BP lowering effects achieved by the volitional control of 
breathing has a long history.35, 36 Recent trials of devices that guide slow deep breathing 
have reported a hypotensive effect from their chronic (e.g., 10-15 min/day for 8 weeks) 
37-43 or acute (10 min) use,56, 58 although such findings have not been uniform.44-47 The 
mechanism by which slow deep breathing may lower BP is complex and incompletely 
understood,48 but in light of studies reporting coincident reductions in total peripheral 
resistance,56 the manipulation of autonomic activity to the peripheral vasculature likely 
plays a key role. 
 
In a cross sectional study a positive association between spontaneous breathing rate and 
vasoconstrictor SNA to the skeletal muscle vasculature was identified in young group of 
healthy men.130 Moreover, acute device-guided slow deep breathing has been reported 
to reduce muscle SNA in treated mild hypertensives,56 in untreated hypertensives,44 and 
in patients with chronic heart failure.565 Although such observations were not confirmed 
in a mixed group of participants, half of whom were healthy and half had metabolic 
syndrome.518 To date there has been no assessment of muscle SNA in young healthy 
participants performed in studies investigating acute effect of slow deep breathing on 
cardiovascular parameters.49, 50, 57 
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There are multiple mechanisms whereby slow deep breathing might be expected to 
evoke a sympatho-inhibitory effect. These include the pulmonary-stretch inflation reflex 
(Hering-Breuer), the peripheral chemoreflex and baroreflex mechanisms. It has long 
been established that SNA undergoes respiratory modulation in humans.539 In young 
healthy individuals, during normal breathing sympathetic outflow to the skeletal muscle 
vasculature reaches a nadir at peak inspiration and shows maximal activity during 
expiration.27-33 The interaction of central cardiovascular-respiratory circuits along with 
modulatory feedback signals from cardiorespiratory sensory afferents account for these 
cyclical sympathetic and cardiac parasympathetic flow fluctuations.26-33 The sympatho-
inhibitory effects of pulmonary-stretch inflation reflex are the primary mechanism of 
within-breath variation of muscle SNA in humans at higher lung tidal volumes.29, 31 
Spontaneous shallow breathing (decreased tidal volume) has been related to 
sympathetic hyperactivity in patients with heart failure, likely on account of a reduced 
inhibition of sympathetic activity by pulmonary stretch receptors.32, 34 It is presently 
unclear whether slow deep breathing in young health individuals enhances the 
inspiratory inhibition of muscle SNA and thus lowers BP. 
 
The acute effect of device-guided slow deep breathing on cardiac parasympathetic 
activity mediated HR variability has to date been examined in a single study.58 In a 
group of healthy middle age participants (with borderline elevated BP) slow deep 
breathing evoked a significant increase in low-frequency power spectral density, but no 
effect on high-frequency power spectral density.58 It has been reported that slow deep 
breathing increases cardiovagal baroreflex sensitivity in young healthy individuals,49, 50 
obese children,51 chronic heart failure patients52, 53 and hypertensive patients.54 This 
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improvement in cardiovagal baroreflex sensitivity was attributed to an increase in tidal 
volume, a reduction in sympathetic overactivity and a restoration of autonomic 
cardiovascular balance.53, 54 However, to date it remains unknown whether the slow 
deep breathing would affect arterial baroreflex control of muscle SNA. This is 
important to establish because cardiovagal baroreflex sensitivity and arterial baroreflex 
control of muscle SNA are differentially controlled and do not always change in 
parallel.55 To date no studies evaluated the acute effect of slow deep breathing on 
muscle SNA in young healthy subjects without cardiovascular risk factors. 
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5.2. Aims and hypotheses 
 
The aim of this study was to investigate whether slow deep breathing reduces BP and 
muscle SNA in young healthy individuals, and to investigate the underlying autonomic 
neural control mechanisms. To achieve this, microneurographic recordings of muscle 
SNA were obtained in young healthy men during spontaneous breathing and acute 
device-guided slow deep breathing. Offline calculations were made of arterial 
baroreflex control of muscle SNA, and indices of cardiac parasympathetic regulation 
derived using HR variability analyses. 
 
The following hypotheses were tested: 
1. Slow deep breathing will reduce muscle SNA and BP in young healthy 
individuals.  
2. Slow deep breathing will enhance the inspiratory inhibition of muscle SNA. 
3. Slow deep breathing will enhance HR variability and increase the sensitivity of 
arterial baroreflex control of muscle SNA and HR. 
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5.3. Methods  
 
5.3.1. Study participants 
 
Ten young males (27±5 years old, body mass index 24±2 kg/m2, mean±SD) were 
recruited into the study. All participants were healthy, non-smokers and were not taking 
any prescription or over-the-counter medications. All participants were asked to abstain 
from caffeine for at least 12 hours and from alcohol and strenuous physical activity for 
at least 24 hours prior to the study. All study measurements were made in a temperature 
controlled room (20-22ºC). Whilst participants were seated office BP were measured 
from the right arm, prior to any experimental measurements were performed. 
 
The study was approved by local research ethics committee (National Research and 
Ethics Committee West Midlands-Edgbaston, 11/WM/0368) and conducted in 
accordance with the Declaration of Helsinki (2008) with written informed consent 
provided by all participants. 
 
5.3.2. Experimental protocol 
 
The experimental protocol consisted of 10 min of uncontrolled spontaneous breathing 
followed by 10 min of slow deep breathing guided by the RESPeRATE device 
(InterCure [UK] Limited, London, UK), which generates melodic tones to assist the 
individual in slowing their respiratory rate below 10 breaths per minute or less.  
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5.3.3. Experimental measurements 
 
5.3.3.1. Blood sampling 
Fasting venous blood samples were taken prior to any other tests after 15-20 min rest in 
the supine position. 
 
5.3.3.2. Cardiovascular measures 
While participants rested in a supine position muscle SNA, beat-to-beat arterial BP, 
electrocardiogram, respiratory parameters, PETCO2, echocardiography and arterial 
stiffness were obtained and stored as described in section 3.1.  
 
5.3.4. Experimental data analyses  
 
The analyses of HR, BP, steady-state muscle SNA, arterial baroreflex sensitivity, HR 
variability were performed as described in section 3.2.  
 
5.4. Statistical analysis 
 
Statistical analysis was performed using Statistical Package for the Social Sciences 
(SPSS) software, version 21.0 for Windows (IBM Inc, Chicago, IL). Data were tested 
for normality by Kolmogorov-Smirnov test. Effect of device-guided slow deep 
breathing on cardiorespiratory and autonomic parameters was assessed using paired 
sample t-test for parametric data and Wilcoxon test for non-parametric data. Mixed 
between-within subject ANOVA analysis, adjusted using the Greenhouse-Geiser 
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correction, was used to examine the main effects of respiratory cycle phase, condition 
(spontaneous breathing/slow deep breathing) and their interaction with respiratory 
modulation of muscle SNA. Data are expressed as mean ± SD, or median (interquartile 
range) in text and tables and as median ± SE in figures. A P value of <0.05 was 
considered statistically significant.   
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5.5. Results  
 
5.5.1. Subject characteristics 
 
Demographic characteristics of the study participants are summarised in Table 5.1. 
Blood biochemistry and arterial stiffness were within the normal range for this age 
group. Any underlining abnormalities in cardiac structure or left ventricular systolic and 
diastolic function were excluded by echocardiography (Table 5.2). 
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Table 5.1. Demographic and clinical characteristics of the study groups 
Age (years) 27±5.4 
Weight (kg) 78±8.1 
Height (cm) 180±3.2 
Body mass index (kg/m2) 24±2.0 
Aortic augmentation index HR@75 -4.1±10.1 
Total cholesterol (mmol/l) 4.1±0.5 
HDL cholesterol (mmol/l) 1.3±0.2 
Triglycerides (mmol/l) 0.9±0.4 
Glucose (mmol/l) 4.1±0.7 
Creatinine (µmol/l) 78.5±8.8 
Estimated glomerular filtration rate 
(mL/min/1.73 m2) 
89.2±2.5 
Haemoglobin (g/l) 145.1±8.7 
Lymphocytes (x103 per µl) 1.70±0.72 
Monocytes (x103 per µl) 0.60±0.19 
Data presented as mean±SD. HDL, high-density lipoprotein 
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Table 5.2. Echocardiographic characteristics of the study group 
Left ventricular mass index (g/m2) 68.2±8.8 
Left ventricular ejection fraction (%) 61.3±1.8 
Systolic annular septal velocity 
(cm/sec) 
7.1±0.8 
Systolic annular lateral velocity 
(cm/sec) 
9.4±2.1 
Cardiac output (L/min) 4.0±0.6 
Mitral valve inflow (E/A) ratio 2.1±0.6 
E/e’ septal ratio 6.5±1.6 
Lateral E/e’ ratio 4.7±1.0 
Left atrial volume index (ml/m2) 18.1±4.5 
Data presented as mean±SD 
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5.5.2. Acute device-guided slow deep breathing 
 
5.5.2.1. Cardiorespiratory parameters and steady–state muscle SNA 
 
Device-guided slow deep breathing resulted in a 2-fold decrease in respiratory rate 
(P<0.001) and ≈2-fold compensatory increase in tidal volume, such that minute volume 
and PETCO2 were unchanged (Table 5.3). Muscle SNA was reduced with slow deep 
breathing (burst incidence, 23 (19-34) vs. 20 (17-29) bursts·100 heart beats-1, P=0.03; 
burst frequency, 14 (12-19) vs. 13.5 (9-17) bursts-1, P=0.04; total activity, 772 (521-
858) vs. 598 (492-746) AU, P=0.04) with no effect on burst amplitude, 49±7 vs. 46±10 
AU, P=0.25 (Figure 5.1, Figure 5.2). However, systolic BP, diastolic BP, mean BP, 
pulse pressure and HR were not significantly changed with device-guided slow deep 
breathing. 
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Table 5.3. Influence of device-guided slow deep breathing on cardiorespiratory 
parameters 
 
Spontaneous 
breathing 
Slow deep 
breathing 
P value 
Respiratory rate (breaths/min) 12.4±0.8 6.2±0.7 0.001 
Tidal volume (L) 0.8±0.2 1.4±0.3 0.001 
Minute ventilation (L/min) 8.9±1.6 8.2±1.7 0.20 
PETCO2 (mmHg) 40.7±3.1 40.3±3.2 0.63 
Systolic BP (mmHg) 125±9.3 124±9.9 0.62 
Diastolic BP (mmHg) 88±6.3 86±7.3 0.38 
Mean BP (mmHg) 69±6.7 68±8.2 0.29 
Pulse pressure (mmHg) 53±10.0 56±8.5 0.28 
Heart rate (beats/min) 61±3.0 62±3.2 0.61 
R-R interval (s) 1.013±0.176 1.005±0.179 0.8 
Data presented as mean±SD; BP, blood pressure; PETCO2, partial pressure of end-tidal 
carbon dioxide.  
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Figure 5.1. Influence of acute device-guided slow deep breathing (SDB, 10 min) on 
muscle SNA burst incidence (panel A), frequency (panel B), total activity (panel C) 
and amplitude (panel D)  
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Figure 5.2. Individual influences of acute device-guided slow deep breathing (SDB, 
10min) on muscle SNA burst incidence (panel A), frequency (panel B), total 
activity (panel C) and amplitude (panel D) 
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5.5.2.2. Baroreflex sensitivity and HR variability 
 
Device-guided slow deep breathing did not significantly alter either cardiac baroreflex 
sensitivity (systolic BP–RR interval, 13.6±3.4 vs. 14.7±2.1, P=0.21) or arterial 
baroreflex control of muscle SNA (burst incidence gain, -3.96 (-4.86 – -2.55) vs. -3.52 
(-4.69 – -2.64), P=0.88; total muscle SNA gain, -17.2 (-26.4 – -11.1) vs. -14.4 (-17.9 – -
9.01), P=0.39; (Figure 5.3). Time domain indices of HR variability (RMSSD, SDNN 
and pNN50%) were not changed with device-guided slow deep breathing (Table 5.4, 
Figure 5.4). However, device-guided slow deep breathing significantly decreased HF 
power spectral density, while LF power spectral density and LF:HF ratio were 
significantly increased and total power remained unchanged.   
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Figure 5.3. Influence of acute device-guided slow deep breathing (SDB, 10 min) on 
indices of spontaneous cardiac and sympathetic baroreflex sensitivity 
Data presented as mean±SE; BP, blood pressure; MSNA, muscle sympathetic nerve 
activity.    
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Table 5.4. Influence of device-guided slow deep breathing on heart rate variability 
parameters 
 Spontaneous breathing Slow deep breathing P value 
RMSSD (ms) 54.4 (36.0-77.5) 46.8 (33.8-66.1) 0.96 
SDNN (ms) 67.8±22.5 76.7±20.8 0.21 
pNN50 (%) 34.5 (14.8-51.4) 23.8 (12.0-46.2) 0.29 
HF (ms2) 1098 (708-2426) 331 (204-939) 0.005 
LF (ms2) 1092 (562-1993) 3724 (2344-5741) 0.01 
TP (ms2) 3479 (1839-5715) 4581 (3182-7370) 0.11 
HF (n.u.) 58.4 (42.0-66.0) 7.9 (6.7-15.4) 0.005 
LF (n.u.) 46.3±15.0 88.7±8.0 0.001 
LF/HF 0.7 (0.5-1.4) 11.6 (5.5-13.9) 0.005 
Data presented as median (interquartile range) or mean±SD; RMSSD, square root of the 
mean of the sum of successive differences in R-R interval; SDNN, standard deviation of 
normal to normal R-R interval; pNN50%, proportion of successive R-R interval which 
vary by >50 ms; TP, total power (0.0-0.4 Hz); HF, high-frequency power (0.15-0.4 Hz); 
LF, low-frequency power (0.04-0.15 Hz).  
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Figure 5.4. Individual influences of acute device-guided slow deep breathing (SDB, 
10min) on heart rate variability parameters, low-frequency (LF) (panel A), high-
frequency (HF) (panel B), total power (panel C) and LF/HF ratio (panel D) 
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5.5.2.3. Effects on respiration related muscle SNA  
 
Figure 5.5 provides an original record from a representative subject illustrating the 
effect of device-guided slow deep breathing on the measured cardiorespiratory and 
autonomic parameters. With the decreased respiratory frequency and increased tidal 
volume a more pronounced inhibition in muscle SNA during the inspiratory to post-
inspiratory period was observable. Figure 5.6 shows distribution of muscle SNA over 
the breathing cycle (the inspiratory peak was marked as 0). Mixed between-within 
subject ANOVA analysis revealed a significant interaction between respiratory cycle 
phase and the study condition (spontaneous breathing vs. slow deep breathing) for 
parameters of muscle SNA (burst incidence, burst frequency, total activity) (P<0.001). 
More specifically, device-guided slow deep breathing enhanced the inhibition of the 
muscle SNA (incidence, frequency and total activity) during inspiration, whereas during 
expiration muscle SNA was elevated. In contrast, muscle SNA burst amplitude was not 
significantly different at any phase of the respiratory cycle during either the 
spontaneous breathing or slow deep breathing conditions. 
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Figure 5.5. Original record showing cardiorespiratory responses to slow deep 
breathing (see more details in text) 
ABP, arterial blood pressure; ECG, electrocardiogram; SNA, sympathetic nerve 
activity. 
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Figure 5.6. Influences of acute device-guided slow deep breathing (SDB, 10 min) on 
respiratory modulation of muscle SNA burst incidence (panel A), frequency (panel 
B), amplitude (panel C) and total activity (panel D) 
Data presented as mean±SE; peak of inspiration at 0 mid-to-late expiration was denoted 
as 30-79% of the breath, while inspiratory to post-inspiratory period was taken as the 
remaining period of the respiratory cycle.  
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 5.6. Discussion  
 
The main finding of the present study is that acute device-guided slow deep breathing 
reduces muscle SNA (burst incidence, burst frequency and total activity) but not BP, 
arterial baroreflex control of muscle SNA or cardiovagal baroreflex regulation in young 
healthy males. These observations indicate that device-guided slow deep breathing 
reductions in central sympathetic outflow are not accompanied by an increase in 
baroreflex sensitivity (cardiac or muscle SNA), but may be attributable to enhanced 
sympatho-inhibitory effects of lung inflation reflex and/or changes in central 
respiratory-sympathetic coupling. 
 
No changes in BP were seen in healthy volunteers in this study. This is in agreement 
with previous observations that young healthy individuals with normal BP pressure are 
unlikely to exhibit reductions in BP in response to the slow deep breathing, potentially 
due to the fact that their vascular resistance is not elevated.49, 50, 57 In contrast, the 
majority of studies on hypertensive patients show an acute reduction in BP with slow 
deep breathing.54, 56 In prospective studies, device-guided slow deep breathing training 
reduced BP more effectively in older patients and in those with higher baseline BP 
values, two populations known to typically exhibit a higher vascular resistance.40, 42 
 
This study evaluated for the first time the acute effect of the RESPeRATE device on 
directly recorded muscle SNA in a young healthy cohort, showing a small but 
statistically significant reduction in skeletal muscle SNA. A slower spontaneous 
breathing rate has previously been associated with lower levels of sympathetic 
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activation. For instance, Narkiewicz at al. reported that respiratory rate in a group of 
healthy males was the only independent predictor of muscle SNA, and that individuals 
with slower spontaneous respiratory rates have reduced chemoreflex responses to 
hypoxia and hypercapnia.130 Furthermore, acute slow deep breathing reduces 
chemoreflex sensitivity within an individual.50, 58, 566 This study results are consistent 
with these findings as the device-guided slow deep breathing mediated reduction in 
respiratory rate led to a reduction in muscle SNA. The majority of studies of 
hypertensive patients show acute reduction in muscle SNA and improvement in cardiac 
baroreflex sensitivity in response to the slow deep breathing intervention.54, 56 Previous 
data from Hering at al. from untreated relatively young (mean age 37 years) 
hypertensive patients showed no acute reduction in BP or HR but significant reduction 
in muscle SNA following the acute use of this device.44 The present study extends these 
findings by determining whether acute device-guided slow deep breathing modulates 
arterial baroreflex regulation of heart and muscle SNA. It is important to emphasise that 
both arms of the baroreflex do not always change in parallel, and both functions need to 
be assessed in order to comprehensively evaluate baroreflex function.55, 567 In contrast to 
the original hypothesis, no significant increase in the arterial baroreflex control of 
muscle SNA measured by both incidence gain and total muscle SNA gain was 
observed. Similarly, device-guided slow deep breathing did not change cardiac 
baroreflex sensitivity. Reports examining the acute cardiac baroreflex sensitivity 
responses to slow deep breathing in young healthy subjects have not been uniform, with 
studies showing increases49, 50 or no effect on sensitivity.57 This study on carefully 
selected healthy volunteers free from any cardiovascular system pathologies does not 
show any improvement in cardiac baroreflex sensitivity. 
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At a higher lung tidal volume the pulmonary-stretch inflation reflex is the main 
sympatho-inhibitory mechanism, however afferent feedback from arterial baroreflexes, 
chemoreflexes and central respiratory motor output also play a modulatory role.26-33, 539, 
549, 568-572 The original record provided (Figure 5.5) shows clearly that the pattern of the 
within-breath inhibition during the inspiratory to post-inspiratory period was more 
pronounced during the device-guided slow deep breathing. Group analysis shows the 
within breath modulation of muscle SNA burst incidence, burst frequency and total 
activity during the spontaneous breathing and slow deep breathing. 
 
In this study, acute device-guided slow deep breathing (mean frequency 0.1Hz) led to a 
significant increase in LF (0.04-0.15 Hz) power spectral density, LF/HF ratio and 
reduction of HF (0.15-0.4 Hz) power spectral density of HR variability. This result is 
consistent with the data from previous studies, showing the effect of slowing of 
breathing rate (non-device guided).573 This effect was specifically attributed to the 
significant increase in LF power spectral density, LF/HF ratio in young healthy men and 
women participants. The acute effect of the RESPeRATE device has not been studied 
before in a young healthy cohort and only a single study tested this in a healthy older 
group with borderline elevated BP.58 That latter study found an increase in LF power 
spectral density, which is consistent with this study, but no effect on the HF power 
(time domain indices were not reported). An increase in LF power spectral density have 
been also noted during yoga and meditation. Furthermore, this increase in LF power 
spectral density was correlated with changes in frequency of respiratory sinus 
arrhythmia and increased coherence in cardiopulmonary coupling (i.e., between HR and 
breathing rate).574, 575 Respiratory sinus arrhythmia depends principally on 
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parasympathetic tone.569, 576 Thus in the settings of reduced breathing rate, an increase 
in the power in LF band corresponds to increase in the parasympathetic tone. Bernardi 
et al. pointed out that when the HR variability is assessed by frequency analysis and the 
breathing pattern is altered, the mechanistic implication of the finding should be 
interpreted with care.577 As specified before in Chapter 2.3.5 traditional indicators of 
increased cardiac parasympathetic tone is reduced LF power spectral density and 
increased HF power alone with higher time domain parameters (RMSSD, SDNN, 
pNN50%).190 21 Admittedly interpretation of results of HR variability findings could be 
ambiguous, partly due to the on-going dispute on physiological meaning of changes in 
LF and HF.578, 579 
 
5.7. Limitations  
 
The relatively small sample size is a potential limitation of the present study however 
this did not prevent detection of a significant reduction in muscle SNA in response to 
acute device-guided slow deep breathing with RESPeRATE device. 
 
5.8. Conclusion 
 
The study findings indicate that although slow deep breathing does not affect BP or 
arterial baroreflex control of muscle SNA in young healthy individuals it does reduce 
muscle SNA burst incidence, frequency and total activity. The reduction in muscle SNA 
with device-guided slow deep breathing in young healthy participants appear not to be 
mediated by a change in baroreflex sensitivity, but may reflect an increase in lung 
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inflation afferent input and/or a reduction in central respiratory-sympathetic coupling. 
Undoubtedly, complexity of regulatory mechanisms implicated in the processes studies 
leaves a possibility for alternative contributing factors, and certainly further research is 
essential to understand intimate details of the phenomenon examined in this study. 
 
Contribution  
For this experimental chapter, I contributed to the study design. I undertook 
identification of the study participants, their screening, recruitment, consent, 
examination, data acquisition (except for the microneurography, where positioning of 
the electrodes into the peroneal nerve was performed by Dr J. Fisher). I performed data 
analysis, data interpretation and wrote the thesis chapter. 
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CHAPTER VI. THE INFLUENCE OF HOME-BASED, SLOW DEEP 
BREATHING TRAINING ON CENTRAL SYMPATHETIC OUTFLOW AND 
BAROREFLEX SENSITIVITY IN ESSENTIAL HYPERTENSION 
 
6.1. Introduction 
 
Hypertension is a key cardiovascular risk factor and affects around 1 billion people 
worldwide, as emphasized in section 2.2.1.1-4 More than half fail to achieve optimal BP 
control.1, 5 This has major clinical and social consequences because with each 2 mmHg 
increase in systolic BP there is a 7% and 10% increase in mortality from coronary 
disease and stroke, respectively.6 In parallel with pharmacological management, non-
pharmacological approaches can help to achieve desirable BP control. The potential for 
BP lowering by the volitional control of breathing has long been purported35, 36 and 
recently home-based device-guided slow deep breathing training (e.g., RESPeRATE© 
device) has been recommended by the American Heart Association.48 In a recent meta-
analysis based on 13 original studies, such home-based slow deep breathing training 
was concluded to reduce systolic and diastolic BP by 4 and 3 mmHg respectively, after 
accounting for BP in placebo group.48 However, the physiological mechanisms leading 
to the BP lowering effects of device-guided slow deep breathing, and the potential for 
associated effects on neural regulation, cardiovascular structure and function remain 
unclear. 
 
The respiratory-related modulation of the SNA has been recognized since the earliest 
direct recordings and is substantively generated by central neuronal circuits and the 
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modulatory influence of feedback signals from cardiorespiratory sensory afferents (e.g., 
lung-stretch receptors, baroreceptors, peripheral chemoreceptors).26-33 Activation of 
baroreflex afferents by BP changes stimulates central neuronal circuits and modulates 
efferent parasympathetic and sympathetic activities to the sinus node, resulting in 
characteristic fluctuations in HR.28, 31, 549, 568-572 Increased SNA and reduced 
parasympathetic tone is believed to be a strong contributor to development of 
hypertension.9, 12, 28, 140, 214, 216-222, 568, 569 Excessive sympathetic outflow in hypertension 
leads to development of LV hypertrophy14-16 and presence of LV hypertrophy in 
hypertensive patients was linked to reduced HR variability.17 Furthermore high muscle 
SNA is associated with LV diastolic dysfunction independently of BP levels18, 19 
Hypertensive patients have increased arterial stiffness.238, 580, 581 It has been shown that 
heightened SNA directly affects vascular smooth muscle cell proliferation and 
hypertrophy independently from BP levels thus contributing to target organ damage in 
these patients.229, 232, 238 Emerging evidence suggests that device-guided slow deep 
breathing may favorably modify the profile of autonomic cardiovascular control, but it 
is not known whether it could diminish the target organ damage.  
 
In a study of middle age community volunteers, 15 min slow deep breathing produced a 
significant reduction in systolic BP, PETCO2 and increase in low-frequency HR 
variability. However, HF power spectral density of HR variability was not altered and 
muscle SNA was not studied.58 Slow deep breathing for 10 min in hypertensive patients 
is reported to reduce BP,54, 56 increase cardiac baroreflex sensitivity54 and reduce muscle 
SNA.44, 56 There has been only one investigation of the muscle SNA response to the 
long-term slow deep breathing training, performed on untreated hypertensive patients.44 
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At the baseline visit, 15 min of acute device-guided slow breathing resulted in 
sympathoinhibition but no reduction in BP. Long-term follow up for 8 weeks of the 
above group of patients44 failed to show a reduction in BP or muscle SNA. In patients 
with hypertension and diabetes, 8 weeks of home-based device-guided slow deep 
breathing training reduced BP and increased LF power spectral density HR variability, 
with no effect on HF and total power. However, the study did not assess SNA, thus 
limiting the pathophysiological insights provided.59  
 
Despite several trials investigating the effect of device-guided slow deep breathing on 
BP few studies have assessed the mechanisms of the acute and especially long-term 
effects of the technique. Indeed, the acute and longer-term effects of slow deep 
breathing on arterial baroreflex have not been considered. Of note, arterial baroreflex 
control of muscle SNA is modulated by different mechanisms than cardiac baroreflex 
and they do not correlate.55 The acute effect of device-guided slow deep breathing on 
HR variability in hypertensive patients has not been studied, and neither has the effect 
of longer term slow deep breathing training on HR variability been evaluated in a 
hypertensive cohort without diabetes. Furthermore, controversial findings have been 
reported regarding the BP and muscle SNA responses to longer-term slow deep 
breathing training, likely reflecting duration of the intervention and populations studied. 
Finally, the effects of home-based device-guided slow deep breathing training on 
cardiovascular function and structure have not been evaluated.  
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6.2. Aims and hypotheses 
 
The aim of this study was to comprehensively evaluate the acute and long-term training 
effects of device-guided slow deep breathing on autonomic regulation in hypertension 
and effects on target organ damage (e.g. heart, vessels, kidney). To achieve this, 
cardiorespiratory parameters, muscle SNA, HR variability and arterial baroreflex 
function were measured at rest and in response to acute slow deep breathing (10 min), 
both before and after home-based long-term device-guided slow deep breathing training 
(8 weeks). The influence of this training regime on cardiac (echocardiography), vascular 
(arterial stiffness) and kidney function was also determined.  
 
The following hypotheses were tested: 
1. BP will be reduced in response to acute and longer-term device-guided slow 
deep breathing training in patients with hypertension. 
2.  BP reductions will be accompanied by a reduction in muscle SNA, and 
enhanced HR variability and arterial baroreflex control of the heart and muscle 
SNA. 
3. Home-based device-guided slow deep breathing training in patients with 
hypertension will improve cardiac and vascular function.  
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6.3. Methods  
 
6.3.1. Study design  
 
Ethical approval was granted by local research ethics committee (National Research and 
Ethics Committee West Midlands-Edgbaston, 11/WM/0368) and conducted in 
accordance with the Declaration of Helsinki (2008). Prior to any study measurements all 
participants provided written informed consent for participation. 
 
The study contained both cross-sectional and longitudinal components. In the cross-
sectional study patients with essential hypertension were compared with matched 
healthy control participants. In the longitudinal study hypertensive patients underwent 
home-based training with the RESPeRATE device. This involved patients spending at 
least 10 min breathing at ≤10 breath/min (‘therapeutic zone’) on a minimum of 4 days 
per week for 8 consecutive weeks.41 To ensure adherence, weekly telephone calls were 
made to participants and usage data from the last 30 days of the training was stored in 
the microprocessor of the RESPeRATE device for quantification of adherence to 
intervention and average synchronization of the breath (i.e., how well duration of 
inhalation and exhalation synchronized with guiding tones). 
 
In total 21 hypertensive patients were recruited, however 1 experienced multiple cardiac 
rhythm ectopics meaning that their data was not suitable for analysis. Therefore, in the 
cross-sectional comparison 20 hypertensive patients were compared with 19 matched 
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controls. In the longitudinal study 19 from 20 completed follow up and were included in 
the analysis.  
 
6.3.2. Study participants  
 
In the cross-sectional study twenty patients with essential hypertension were compared 
with 19 age (mean±SD, 54±12 vs. 54±15 years old, respectively, P=0.9), sex (13 vs. 12 
males, P=0.5) and body mass index (28±3 kg/m2 vs. 26±3 kg/m2, P=0.07) matched 
normotensive healthy controls. All hypertensive patients were clinically stable and 
treated (≥3 months, median time since diagnosis 48 months, range 12-169 months). 
Control participants were not taking prescription or over-the-counter medications and 
deemed healthy by careful medical history, clinical examination, baseline blood tests, 
ECG and transthoracic echocardiography. Participants were free from coronary artery 
disease, significant valvular heart disease; recent (<6 months) primary angioplasty, 
stroke; atrial fibrillation; active infections and/or a history of inflammatory or 
connective tissue disorders; chronic and systemic illnesses (e.g. respiratory diseases, 
renal or liver failure, diabetes mellitus, malignancy); were not on hormone replacement 
therapy and were not pregnant. 
 
All study participants were asked to abstain from caffeine use for at least 12 hours and 
from alcohol intake and strenuous physical activity for at least 24 hours prior to the 
study tests. All participants were non-smokers. Hypertensive subjects refrained from 
taking their medications on the study day. All study measurements were performed in 
the morning, in a quiet and temperature controlled room (20-22ºC). Office BP 
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measurements were performed prior to any testing from the right arm whilst participants 
were seated. 
 
 
6.3.3. Experimental protocol 
The experimental protocol consisted of 10 min of uncontrolled spontaneous breathing 
followed by 10 min of slow deep breathing guided by the RESPeRATE device 
(InterCure (UK) Limited, London, UK), which uses melodic tones to slow the 
respiratory rate below 10 breaths per minute. All measurements were obtained while 
participants were in a supine position. The same protocol was repeated in hypertensive 
patients who completed their 8 weeks follow up training. 
 
6.3.4. Experimental measurements  
 
6.3.4.1. Blood sampling 
Baseline venous blood sampling was performed prior to any other tests after 15-20 
minute rest in the supine position. The samples were used for clinical biochemistry and 
full blood counts analysis. 
 
6.3.4.1. Cardiovascular measures 
HR, beat-to-beat arterial BP, muscle SNA, respiratory parameters, PETCO2, 
echocardiography and arterial stiffness were obtained and stored as described in section 
3.1. 
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6.3.5. Experimental data analyses  
 
The analyses of HR, BP, steady-state muscle SNA, arterial baroreflex sensitivity, HR 
variability were performed as described in section 3.2. 
 
6.4. Statistical analysis and power calculation 
 
Statistical analysis was performed using Statistical Package for the Social Sciences 
(SPSS) software, version 21.0 (IBM Inc, Chicago, IL). Data were tested for normality 
by Kolmogorov-Smirnov test. Data are expressed as mean ± SD, or median 
(interquartile range) in text and tables. Chi-square analysis used for comparisons of 
categorical data. In the cross-sectional analysis the groups were compared using 
unpaired sample t-test for parametric data and Mann-Whitney test for non-parametric 
data. Comparisons of the acute effects of slow deep breathing were made using 
calculated differences (deltas) between values before and after the test in each group.  
 
In the longitudinal study, the effect of device-guided slow deep breathing on study 
parameters was assessed using paired sample t-tests for parametric data and Wilcoxon 
tests for non-parametric data. The analysis also included comparison of the acute effects 
of slow deep breathing at the beginning and the end of the study. The acute effects were 
quantified as differences (deltas) between values after and before the test performed at 
each time point of the study. 
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In the longitudinal study Spearman correlation analysis was used to assess associations 
between number of successful training sessions over the last 30 days of follow up 
period and diastolic BP at follow up visit. A P value of ≤0.05 (two tailed) was 
considered statistically significant. 
 
On the basis of the data of Schein et al.,43 demonstrating the BP lowering effects of 
device-guided slow deep breathing in patients with hypertension, a sample size of 20 
will allow the minimal detectable difference in systolic BP pre and post training of 8% 
(with P=0.05, power = 80% and assuming that the patients have a similar systolic BP of 
156.6 ± 14.0 mmHg).  
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6.5. Results  
 
6.5.1. Cross-sectional study of healthy controls and patients with hypertension 
 
6.5.1.1. Subject characteristics  
 
Patients with hypertension were closely matched by age, sex and body mass index to the 
healthy control participants (Table 6.1). Three patients did not receive antihypertensive 
treatment and 17 were treated with medications. Medication use (60% calcium channel 
blockers, 45% angiotensin-converting-enzyme inhibitor or angiotensin receptor 
blockers, 40% thiazide diuretics, 20% beta-blockers and 25% statins) was stable for at 
least 3 months before the study. As expected hypertensive group had significantly 
higher office BP compared with healthy group (P<0.001). There was no difference in 
parameters of clinical biochemistry (Table 6.2) or AI corrected for HR of 75 bpm 
(Table 6.3) between the study groups. Echocardiography ruled out any abnormalities in 
cardiac structure and left ventricular systolic and diastolic function in healthy controls 
(Table 6.3). Compared to healthy controls hypertensive patients had a significantly 
higher left ventricle mass index and E/e’ septal ratio, while all other parameters 
examined were not different. 
 
Cardiorespiratory parameters for the two groups are provided in Table 6.4. Muscle SNA 
burst frequency was higher in the hypertensive group (31.3 ± 7.7 vs. 24.0 ± 7.9 
bursts/min in healthy controls, P=0.04) with no significant difference in the burst 
incidence found. Reductions in spontaneous cardiac baroreflex sensitivity and arterial 
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baroreflex control of muscle SNA were observed in the hypertensive group (P≤0.05). 
Parameters of HR variability (SDNN, LF and TP) were higher in healthy controls 
(P≤0.05) value (Table 6.5). 
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Table 6.1. Baseline characteristics in healthy controls and patients with 
hypertension 
 Healthy Controls Hypertensive Patients P value 
Age (years) 53.7±14.8 54.4±12.4 0.88 
Males (n, %) 13 (72) 12 (60) 0.51 
Weight (kg) 78±10.5 81±13.3 0.45 
Height (cm) 173±10.4 170±8.2 0.35 
BMI (kg/m2) 25.9±2.7 27.6±2.8 0.07 
Office systolic BP 
(mmHg) 
122±9.7 147±17.7 <0.001 
Office diastolic BP 
(mmHg) 
71±6.4 85±9.8 <0.001 
Data presented as mean±SD. BMI, body mass index; BP, blood pressure. 
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Table 6.2. Blood biochemistry at rest in healthy controls and patients with 
hypertension 
 Healthy Controls Hypertensive Patients P value 
Total cholesterol 
(mmol/l)  
4.9±1.0 5.3±1.1 0.64 
HDL (mmol/l)  1.4±0.3 1.3±0.4 0.19 
Triglycerides 
(mmol/l) 
4.6 (4.1-5.8) 5.2 (4.8-6.3) 0.32 
Glucose (mmol/l)  4.9±0.8 5.0±0.4 0.65 
Creatinine 
(µmol/l) 
83.3±21.6 84.4±22.7 0.49 
Estimated 
glomerular 
filtration rate 
(mL/min/1.73 m2) 
76.2±13.2 75.4±14.1 0.60 
Lymphocytes  
(x103 per µl) 
1.8±0.6 1.9±0.6 0.37 
Monocytes  
(x103 per µl)  
0.48 (0.33-0.59) 0.56 (0.37-0.63) 0.44 
Data presented as mean±SD or median (interquartile range). HDL, high-density 
lipoprotein.  
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Table 6.3. Echocardiography parameters and arterial stiffness at rest in healthy 
controls and patients with hypertension 
 Healthy Controls Hypertensive Patients P value 
Left ventricular mass 
index (g/m2) 
66.3±8.6 82.3±20.1 0.004 
Left ventricular 
ejection fraction (%) 
60.9±3.3 61.6±2.9 0.53 
Systolic annular septal 
velocity (cm/s) 
6.3±0.8 6.9±1.6 0.22 
Systolic annular 
lateral velocity (cm/s) 
7.8±1.4 7.2±2.4 0.42 
Stroke volume (ml) 65.8±11.6 62.2±12.5 0.38 
Cardiac output 
(L/min) 
3.7±0.4 3.9±1.0 0.37 
Mitral valve inflow 
(E/A) ratio 
1.4±0.4 1.1±0.4 0.02 
E/e’ septal ratio 7.8±2.0 10.8±3.2 0.002 
Left atrial volume index 
(ml/m2) 
16.9±4.2 18.0±4.4 0.48 
Aortic Augmentation 
Index HR@75 
18.0 (1.0-27.0) 26.5 (12.3-29.8) 0.14 
Data presented as mean±SD or median (interquartile range). HR, heart rate. 
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Table 6.4. Baseline cardiorespiratory parameters in healthy controls and patients 
with hypertension 
 Healthy Controls Hypertensive Patients P value 
Respiratory frequency 
(b/min) 
11.6±2.6 12.3±3.5 0.49 
Tidal volume (L) 0.6 (0.5-0.7) 0.4 (0.4-0.9) 0.19 
Minute ventilation 
(L/min) 
6.6±1.6 5.9±1.9 0.23 
PETCO2 (mmHg) 41.0±2.5 39.9±2.3 0.16 
Heart rate (beats/min) 57±8.6 61±9.1 0.14 
R-R interval (s) 1.09±0.17 1.01±0.15 0.13 
Burst incidence 
(bursts/100hb-1)  
42.5±14.9 53.1±17.8 0.14 
Burst frequency 
(bursts/min)  
24.0±7.9 31.3±7.7 0.04 
Total activity (AU)  1309.1±515.9 1658.4±436.6 0.09 
Burst incidence gain 
(bursts/100hb/mmHg) 
-4.6 (-6.4– -3.8) - 2.8 (-5.0 – -2.2) 0.03 
 Total muscle SNA gain 
(AU/beats/mmHg) 
-28.1 (-40.5 – -18.1) - 13.2 (-27.8 – -1.8) 0.05 
Systolic BP-RRI gain 
(ms/mmHg) 
12.3 (10.7-16.6) 9.4 (6.9-14.8) 0.03 
Data presented as mean±SD or median (interquartile range). BP, blood pressure; 
PETCO2, partial pressure of end-tidal carbon dioxide; SNA, sympathetic nerve activity.  
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Table 6.5. Baseline HR variability indices in healthy controls and patients with 
hypertension 
 Healthy Controls Hypertensive Patients P value 
RMSSD (ms) 40.6 (28.6-51.2) 30.0 (26.2 –38.2) 0.07 
SDNN (ms) 53.7 (50.8-63.2) 42.2 (35.6-63.0) 0.04 
pNN50 (%) 18.6 (6.4-34.5) 7.4 (1.6–18.4) 0.06 
HF (ms2) 602.2 (228.2-1058.1) 330.8 (130.1-612.7) 0.22 
LF (ms2) 944.4 (622.5-1398.1) 335.0 (230.1–1058.6) 0.009 
TP (ms2) 
2704.0 (2183.4-
3883.6) 
1692.4 (1039.1-
2743.9) 
0.02 
HF (n.u.) 43.2 (22.1-60.1) 45.2 (24.3-65.2) 0.41 
LF (n.u.) 56.8 (39.9-77.9) 54.8 (34.8-74.7) 0.41 
LF/HF 1.3 (0.7-4.0) 1.2 (0.5-3.2) 0.41 
Data presented as median (interquartile range). RMSSD, square root of the mean of the 
sum of successive differences in R-R interval; SDNN, standard deviation of normal to 
normal R-R interval; pNN50%, proportion of successive R-R interval which vary by 
>50 ms; TP, total power (0.0-0.4 Hz); HF, high-frequency power (0.15-0.4 Hz); LF, 
low-frequency power (0.04-0.15 Hz).  
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6.5.1.2. Effect of acute device-guided slow deep breathing on cardiorespiratory 
parameters in healthy controls and patients with hypertension 
 
The magnitude of the device-guided slow deep breathing evoked change in respiratory 
parameters was not significantly different between the two groups (Table 6.6). Acute 
device-guided slow deep breathing led to a significantly greater reduction in systolic, 
diastolic and mean BP in the hypertensive group (P=0.05 for systolic BP, P=0.02 for 
diastolic BP, and P=0.01 for mean BP). The change in muscle SNA and baroreflex 
sensitivity was not different between two groups. The HR variability responses to the 
acute slow deep breathing was more pronounced in the healthy group, in particularly 
there was a significant difference in change in TP of HR variability (2520 (723–3980) 
ms2 in the healthy group vs. to 334 (-508–946) ms2 in the hypertensive group (P=0.002) 
as well as LF power P=0.003, RMSSD, P=0.004, SDNN, P=0.006, in a favor to the 
healthy group (Table 6.7). HF power and LF/HF were unchanged  
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Table 6.6. Acute effects of device-guided slow deep breathing on cardiorespiratory 
parameters in healthy controls and patients with hypertension 
 Healthy Controls Hypertensive Patients P value 
Δ Respiratory frequency 
(b/min) 
-5.4 (-7.5 – -2.6) -6.2 (-8.2 – -3.3) 0.39 
Δ Tidal volume (L) 0.4 (0.2 – 0.7) 0.4 (0.1 – 0.8) 0.87 
Δ Minute ventilation 
(L/min) 
-0.5 (-1.2 – 1.3) 0.3 (-1.6 – 1.9) 0.73 
Δ PETCO2 (mmHg) -1.1 (-4.2 – 0.3) 0.1 (-3.9 – 2.1) 0.33 
Δ Supine systolic BP 
(mmHg) 
-1.0 (-4.3 – 2.0) -4.5 (-7.8 – -2.3) 0.05 
Δ Supine diastolic BP 
(mmHg) 
-0.5 (-1.3 – 2.0) -2.0 (-4.5 – -0.3) 0.02 
Δ Supine mean BP 
(mmHg) 
0.0 (-2.0 – 1.0) -3.0 (-4.8 – -1.3) 0.01 
Δ Supine PP (mmHg) -0.5 (-3.5 – 1.0) -2.0 (-7.0 – 0.0) 0.15 
Δ Heart rate (beats/min) 1.1 (-0.5 – 3.4) 2.2 (0.6 – 3.9) 0.41 
Δ Burst incidence 
(bursts/100hb-1) 
-4.5 (-5.3 – -0.9) -3.7 (-7.7 – 2.5) 0.67 
Δ Burst frequency 
(bursts/min)  
-0.6 (-3.3 – -0.2) -1.9 (-3.8 – 0.8) 1.0 
Δ Total activity (AU)  
-43.7 (-135.2 – 
41.7) 
3.3 (-186.0 – 428.9) 0.36 
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Δ Burst incidence gain 
(bursts/100hb/mmHg) 
0.04 (-1.1 – 2.0) 0.9 (-0.4 – 1.8) 0.45 
 Δ Total muscle SNA gain 
(AU/beats/mmHg) 
2.3 (-6.1 – 11.2) -1.7 (-4.3 – 7.1) 0.92 
Δ Systolic BP-RRI gain 
(ms/mmHg) 
-1.3 (-3.1 – 1.60 -1.5 (-3.0 – 0.4) 0.80 
Data presented as median (interquartile range). BP, blood pressure; PETCO2, partial 
pressure of end-tidal carbon dioxide; SNA, sympathetic nerve activity. 
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Table 6.7. Acute effects of device-guided slow deep breathing on indices of HR 
variability in healthy controls and patients with hypertension 
 Healthy Controls Hypertensive Patients P value 
Δ RMSSD (ms) 10.5 (- 3.0– 15.7) - 4.8 (- 8.7– 0.5) 0.004 
Δ SDNN (ms) 20.3 (3.9– 27.8) 1.5 (- 4.0– 9.1) 0.006 
Δ pNN50 (%) 2.9 (- 6.3– 11.3) - 2.3 (- 5.9– -0.03) 0.07 
Δ HF (ms2) - 133.2 (- 558.0– 93.6) - 146.9 (- 434.6– -54.2) 0.73 
Δ LF (ms2) 1914.8(1077.1–4060.4) 277.5 (57.1–1177.9) 0.003 
Δ TP (ms2) 2519.8 (723.4– 3979.7) 333.6 (- 508.0– 946.3) 0.002 
Δ HF (n.u.) - 26.3 (- 42.4– -6.1) - 26.3 (- 49.1– -13.4) 0.78 
Δ LF (n.u.) 26.3 (6.1– 42.4) 24.7 (13.4– 49.1) 0.80 
Δ LF/HF 8.7 (3.7– 10.2) 5.4 (1.0– 24.1) 0.73 
Data presented as median (interquartile range). RMSSD, square root of the mean of the 
sum of successive differences in R-R interval; SDNN, standard deviation of normal to 
normal R-R interval; pNN50%, proportion of successive R-R interval which vary by 
>50 ms; TP, total power (0.0-0.4 Hz); HF, high-frequency power (0.15-0.4 Hz); LF, 
low-frequency power (0.04-0.15 Hz) 
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6.5.2. Longitudinal study of patients with hypertension before (first visit) and after 
(follow up visit) home-based device-guided slow deep breathing 
 
6.5.2.1. Compliance with the intervention 
 
During the last 30 days of device use patients performed 22±6 successful sessions 
(interquartile range 20-26), spent 49±15 min per week (interquartile range 42-57) in 
‘therapeutic zone’ (breathing rate reduced to ≤10 breath/min). Average synchronization 
of the breath was 78±18% (interquartile range 69-85%). There was inverse relationship 
between the change in office diastolic BP and number of successful device-guided 
sessions over the last 30 days of intervention (r=-0.54, P=0.02) (Figure 6.1). 
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Figure 6.1. The association between adherence to the home-based device-guided 
slow deep breathing training and long-term changes in diastolic blood pressure. 
BP, blood pressure 
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6.5.2.2. Effect of home-based device-guided slow deep breathing on steady state 
cardiorespiratory parameters at baseline 
 
After 8 weeks of home-based slow deep breathing training, office systolic BP was 
significantly reduced from 147±18.1mmHg at the first visit to 133±17.0 mmHg at the 
follow up visit (P=0.001). Office diastolic BP was also significantly reduced over the 
same time period (84±9.5 vs. 79±12.3 mmHg, P=0.008). There was no change in 
weight (81±13.7 vs. 81±14.2 kg, P=0.52) or BMI (28±2.8 vs. 28±3.08 kg/ m2, P=0.55) 
between the two visits. No significant changes were observed in either the clinical 
biochemistry or the echocardiography measurements (Tables 6.8 and 6.9). There was no 
change in respiratory parameters over the 8 weeks of training (Table 6.10). Muscle SNA 
burst frequency and burst incidence were significantly reduced at the follow up 
(33.8±8.2 to 28.3±7.1 bursts/min, P=0.03 and 59.0±19.5 to 48.6±14.4 bursts/100hb-1, 
P=0.05, respectively; Figure 6.2). There were no changes in cardiac and sympathetic 
baroreflex control. RMSSD, SDNN, pNN50%, HF were modestly but significantly 
reduced following home-based slow deep breathing training, whereas TP, LF and 
LF/HF were unchanged (Table 6.11).  
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Table 6.8. Baseline blood biochemistry in patients with hypertension before (first 
visit) and after (follow up visit) home-based device-guided slow deep breathing 
 First visit Follow up visit P value 
Total cholesterol 
(mmol/l) 
5.3±1.1 
 
5.2±1.2 
 
0.45 
HDL (mmol/l) 1.3±0.45 1.4±0.50 0.19 
Triglycerides 
(mmol/l) 
1.5±0.9 1.3±0.6 0.33 
Glucose (mmol/l) 4.9±0.4 4.7±0.9 0.65 
Creatinine (µmol/l) 86.0±23.2 77.0±14.8 0.49 
Estimated 
glomerular filtration 
rate (mL/min/1.73 
m2) 
75.4±13.7 82.2±7.2 0.60 
Lymphocytes  
(x103 per µl) 
1.8±0.6 1.3±0.3 0.37 
Monocytes  
(x103 per µl) 
0.58 (0.38-0.64) 0.49 (0.37-0.57) 0.31 
Data presented as mean±SD or median (interquartile range). HDL, high-density 
lipoprotein. 
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Table 6.9. Baseline echocardiography parameters and arterial stiffness in patients 
with hypertension before (first visit) and after (follow up visit) home-based device-
guided slow deep breathing. 
 First visit Follow up visit P value 
Left ventricular mass index 
(g/m2) 
82.3±20.1 84.4±19.7 0.23 
Left ventricular ejection 
fraction (%) 
61.8±2.9 60.6±3.5 0.07 
Systolic annular septal velocity 
(cm/s) 
6.9±1.6 6.6±1.3 0.32 
Systolic annular lateral 
velocity (cm/s) 
7.4±2.4 7.3±2.3 0.97 
Stroke volume (ml) 62.2±12.5 61.7±11.8 0.77 
Cardiac output (L/min) 3.9±1.0 4.0±1.0 0.35 
Mitral valve inflow (E/A) ratio 1.1±0.4 1.1±0.3 0.61 
E/e’ septal ratio 10.3±2.9 10.7±2.9 0.46 
Left atrial volume index (ml/m2) 16.8±3.5 18.2±3.4 0.06 
Aortic Augmentation Index 
HR@75 
23.7±11.5 24.0±8.5 0.9 
Data presented as mean±SD. HR, heart rate. 
  
 181 
Table 6.10. Baseline cardiorespiratory parameters in patients with hypertension 
before (first visit) and after (follow up visit) home-based device-guided slow deep 
breathing. 
 First visit Follow up visit P value 
Respiratory frequency 
(b/min) 
12.2±3.6 11.3±3.4 0.22 
Tidal volume (L) 0.47 (0.3-0.9) 0.56 (0.4-0.8) 0.74 
Minute ventilation (L/min) 6.0±1.9 6.2±1.8 0.67 
PETCO2 (mmHg) 39.7±2.3 40.5±2.2 0.23 
Heart rate (beats/min) 61±9.4 61±7.1 0.83 
R-R interval (s) 1.01±0.15 1.00±0.12 0.84 
Burst incidence  
(bursts/100hb-1) 
59.0±19.5 48.6±14.4 0.05 
Burst frequency (bursts/min)  33.8±8.2 28.3±7.1 0.03 
Burst incidence gain 
(bursts/100hb/mmHg) 
-2.9 (-5.1 – -1.3) -2.4 (-7.0 – -1.1) 0.58 
Total muscle SNA gain 
(AU/beats/mmHg) 
-11.8 (-25.0 – -0.4) -7.1 (-16.0– -1.7) 0.87 
Systolic BP-RRI gain 
(ms/mmHg) 
9.4 (6.9-14.8) 9.5 (5.8-14.2) 0.71 
Data presented as mean±SD or median (interquartile range). BP, blood pressure; 
PETCO2, partial pressure of end-tidal carbon dioxide; SNA, sympathetic nerve activity.  
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Figure 6.2. Original record showing cardiorespiratory responses to long-term slow 
deep breathing training (see more details in text). 
ABP, arterial blood pressure; ECG, electrocardiogram; SNA, sympathetic nerve 
activity. 
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Table 6.11. Baseline HR variability indices in patients with hypertension before 
(first visit) and after (follow up visit) home-based device-guided slow deep 
breathing 
 First visit Follow up visit P value 
RMSSD (ms) 30.0 (26.2 –38.2) 26.1 (19.3 – 37.6) 0.04 
SDNN (ms) 42.2(35.6-63.0) 42.1 (33.0-50.2) 0.02 
pNN50 (%) 7.4(1.6–18.4) 5.8 (0.8-11.7) 0.01 
HF (ms2) 330.8 (130.1-612.7) 251.1 (128.5-430.4) 0.04 
LF (ms2) 335.0 (230.1–1058.6) 385.6 (200.9-1165.8) 0.91 
TP (ms2) 1692.4 (1039.1-2743.9) 1571.8 (787.9-2608.0) 0.31 
HF (n.u.) 45.2 (24.3-65.2) 33.5 (20.8-58.1) 0.18 
LF (n.u.) 54.8 (34.8-75.7) 66.5 (41.9-79.2) 0.18 
LF/HF 1.2 (0.5-3.2) 2.0 (0.7-3.8) 0.85 
Data presented as median (interquartile range). RMSSD, square root of the mean of the 
sum of successive differences in R-R interval; SDNN, standard deviation of normal to 
normal R-R interval; pNN50%, proportion of successive R-R interval which vary by 
>50 ms; TP, total power (0.0-0.4 Hz); HF, high-frequency power (0.15-0.4 Hz); LF, 
low-frequency power (0.04-0.15 Hz).   
 184 
6.5.2.3. Effect of training on acute response to device-guided slow deep breathing  
 
Respiratory frequency, minute ventilation and PETCO2 responses to acute slow deep 
breathing were not significantly different between the visits. However, increases in tidal 
volume with acute slow deep breathing were slightly but significantly greater during the 
follow up visit, P=0.03 (Table 6.12). During the follow up visit, reductions in BP in 
response to the acute slow deep breathing test were significantly less pronounced 
compared to the first visit, particularly for diastolic BP, P=0.01. The magnitude of the 
device-guided slow deep breathing evoked change in muscle SNA and baroreflex 
control parameters was not significantly different between the two visits.  
 
Increase in HR variability indices were more pronounced during the second visit, in 
particularly TP increased significantly more at the follow up visit (1003.0 (91.5–1861.9) 
vs. 333.6 (-508.0 –946.3), P=0.03) as well as LF power P=0.04, RMSSD, P=0.02, 
SDNN, P=0.002 and pNN50%, P=0.01 in a favor to the follow up visit (Table 6.13). 
However changes in the HF power and LF/HF were not different between the visits. 
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Table 6.12. Effect of training on acute response to device-guided slow deep 
breathing on cardiorespiratory parameters in patients with hypertension before 
(first visit) and after (follow up visit) home-based device-guided slow deep 
breathing 
 First visit Follow up visit P value 
Δ Respiratory frequency (b/min) - 5.8 (- 8.2– -3.3) - 4.9 (- 6.3– -4.2) 0.64 
Δ Tidal volume (L) 0.4 (0.1– 0.8) 0.5 (0.4– 0.9) 0.03 
Δ Minute ventilation (L/min) 0.3 (- 1.4–2.0) - 0.1 (- 0.6–2.2) 0.42 
Δ PETCO2 (mmHg) 0.4 (- 3.8– 2.2) - 0.6 (- 4.7– 1.2) 0.47 
Δ Supine systolic BP (mmHg) - 5.0 (- 8.0– -3.0) - 1.0 (- 5.0– 2.0) 0.03 
Δ Supine diastolic BP (mmHg) -2.0 (-5.0 – -1.0) 0.0 (- 1.0– 1.0) 0.01 
Δ Supine mean BP (mmHg) -3.0 (-5.0 – -2.0) - 1.0 (- 3.0– 2.0) 0.03 
Δ Supine PP (mmHg) -3.0 (-7.0 – 0.00) - 1.0 (- 3.0– 3.0) 0.06 
Δ Heart rate (beats/min) 2.0 (-0.7– 4.0) 1.1 (- 0.9– 4.4) 0.9 
Δ Burst incidence (bursts/100hb-1) - 1.8 (- 9.9– 6.3) - 3.5 (- 6.2– 5.2) 0.67 
Δ Burst frequency (bursts/min) - 1.4 (- 3.6– 4.1) - 1.9 (- 2.5– 2.7) 0.89 
Δ Burst incidence gain 
(bursts/100hb/mmHg) 
-1.3 (- 0.1– 2.0) - 0.2 (- 1.0– 0.6) 0.21 
Δ Total muscle SNA gain 
(AU/beats/mmHg) 
1.0 (- 10.1– 9.9) - 3.6 (- 10.5– 4.9) 0.87 
Systolic BP-RRI gain (ms/mmHg) - 1.5 (- 3.0– 0.4) 0.6 (- 2.9–3.4) 0.15 
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Data presented as median (interquartile range). BP, blood pressure; PETCO2, partial 
pressure of end-tidal carbon dioxide; PP, pulse pressure; SNA, sympathetic nerve 
activity.  
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Table 6.13. Effect of training on acute response to device-guided slow deep 
breathing on HR variability indices in patients with hypertension before (first 
visit) and after (follow up visit) home-based device-guided slow deep breathing 
 First visit Follow up visit P value 
Δ RMSSD (ms) -4.8 (-8.7 – 0.5) 0.9 (-5.6 – 6.7) 0.02 
Δ SDNN (ms) 1.5 (-4.0 – 9.1) 9.6 (4.4 – 19.0) 0.002 
Δ pNN50 (%) -2.3 (-5.9 – -0.03) -0.1 (-5.0 – 3.1) 0.01 
Δ HF (ms2) -146.9 (-434.6 – -54.2) -166.2 (-337.2 – -5.9) 0.17 
Δ LF (ms2) 277.5 (57.1–1177.9) 1009.6 (181.8-1992.0) 0.04 
Δ TP (ms2) 333.6 (-508.0 –946.3) 1003.0 (91.5– 1861.9) 0.03 
Δ HF (n.u.) -26.3 (-49.1 – -13.4) -20.2 (-51.0 – -9.3) 0.40 
Δ LF (n.u.) 24.8 (13.4 – 49.1) 20.2 (9.3 – 51.0) 0.50 
Δ LF/HF 5.4 (1.0 – 24.1) 5.2 (3.9 – 20.3) 0.25 
Data presented as median (interquartile range). RMSSD, square root of the mean of the 
sum of successive differences in R-R interval; SDNN, standard deviation of normal to 
normal R-R interval; pNN50%, proportion of successive R-R interval which vary by 
>50 ms; TP, total power (0.0-0.4 Hz); HF, high-frequency power (0.15-0.4 Hz); LF, 
low-frequency power (0.04-0.15 Hz).   
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There was a strong significant correlation between reduction in the sympathetic nerve 
burst frequency during the acute slow deep breathing at first visit and reduction in office 
diastolic BP after the home-based device-guided slow deep breathing training (r=0.75, 
p=0.008). Similar association was found between acute reduction in the nerve burst 
incidence at the first visit and decrease in office diastolic BP after the slow deep 
breathing training (r=0.62, p=0.04). However acute response to slow deep breathing 
was not predictive of changes in office systolic BP during the follow up (Table 6.14). 
Also there was no significant correlation between the acute response to slow deep 
breathing at first visit and changes in the nerve parameters after the home-based device-
guided training (follow up visit) in hypertensive subjects (Table 6.15). 
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Table 6.14. Correlation between acute response to slow deep breathing (first visit) 
and changes in office BP after the home-based device-guided slow deep breathing 
in hypertensive patients 
Parameters Δ Office systolic 
BP (mmHg) 
Δ Office diastolic 
BP (mmHg) 
r P value r P value 
Δ Supine systolic BP (mmHg) -0.59 0.81 0.01 0.95 
Δ Supine diastolic BP (mmHg) -0.04 0.86 -0.21 0.39 
Δ Burst incidence (bursts/100hb-1) 0.01 0.97 0.62 0.04 
Δ Burst frequency (bursts/min) 0.25 0.46 0.75 0.008 
BP, blood pressure 
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Table 6.15. Correlation between acute response to slow deep breathing (first visit) 
and changes in nerve parameters after the home-based device-guided slow deep 
breathing in hypertensive patients 
Parameters Δ Steady burst incidence 
(bursts/100hb-1) 
Δ Steady burst frequency 
(bursts/min) 
r P value r P value 
Δ Supine systolic BP (mmHg) -0.34 0.41 -0.20 0.64 
Δ Supine diastolic BP (mmHg) -0.16 0.71 -0.05 0.91 
Δ Burst incidence (bursts/100hb-1) -0.38 0.35 -0.48 0.23 
Δ Burst frequency (bursts/min) -0.45 0.26 -0.57 0.14 
BP, blood pressure 
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6.6. Discussion 
 
6.6.1. Cross-sectional assessment of acute device-guided slow deep breathing 
responses in healthy controls and patients with hypertension 
 
Acute device-guided slow deep breathing leads to a significantly greater reduction in 
systolic, diastolic and mean BP in patients with hypertension compared to normotensive 
controls. This observation indicates that acute slow deep breathing may specifically 
target a pathogenic mechanism activated in hypertension. Given that the effects are 
observable within minutes the underlying mechanism must be capable of responding 
promptly to the changes in the triggering stimuli. The sympathetic and parasympathetic 
branches of the autonomic nervous system and peripheral smooth muscle tone are 
plausible candidates.  
 
Baseline muscle SNA burst frequency was higher in the hypertensive group. These 
patients also had reduced baseline spontaneous cardiac baroreflex sensitivity and 
diminished arterial baroreflex control of muscle SNA. However, the BP responses to 
acute device-guided slow deep breathing in the hypertensive subjects occurred despite 
similar magnitude of responses in muscle SNA and baroreflex sensitivity in both 
groups. This suggests that the more prominent BP reduction in the hypertensive subjects 
was not due to inhibition of muscle SNA per se. In a previous studies, acute slow deep 
breathing reduced BP in hypertensive patients,54, 56 increased cardiac baroreflex 
sensitivity,54 and reduced muscle SNA. 33, 44 However, the present study highlights that 
it is important to interpret these changes in the context of responses seen in healthy 
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control participants to delineate existence of different BP lowering mechanisms in 
response to slow deep breathing. 
 
Abnormal (reduced) HR variability was seen in hypertensive patients at rest and this 
group also showed diminished increase in parameters of HR variability in response to 
the acute slow deep breathing compared to the healthy group. Consequently changes in 
parasympathetic nervous system do not appear to be primarily responsible for the 
differences in BP response. In fact the observed changes in parasympathetic parameters 
in HR variability could represent normal response to BP reduction and diminished 
response seen in the hypertensive patients highlights dysfunction of this system in 
hypertension. 
 
It is not thus entirely clear which exact mechanisms are behind the augmented acute 
respiration induced BP reduction in hypertensive patients. 
 
6.6.2. Longitudinal study of patients with hypertension before (first visit) and after 
(follow up visit) home-based device-guided slow deep breathing  
 
The device-guided slow deep breathing training significantly reduced both systolic and 
diastolic BP. The magnitude of the reduction in office BP observed in this study (14/5 
mmHg for systolic/ diastolic BP) was comparable to the results of recent meta-analysis, 
which indicated a reduction in office BP by 13/7 mmHg and net beneficial effect of 4/3 
mmHg (systolic/ diastolic BP) after adjustment for a placebo group.48 Such reductions 
in office BP result in a clinically relevant reduction in incidence of cardiovascular 
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events (stroke, myocardial infarction, heart failure, sudden death, peripheral artery 
disease and end-stage renal disease).60, 582-585 Previously, Viskoper et al found that BP 
reduction in hypertensive patients only occurred if mean BP was 98 mmHg or higher, 
(i.e., in those with likely higher peripheral resistance).42 The present study was 
performed in similar patients. 
 
This study shows for the first time that long-term device-guided slow deep breathing 
evokes sympathetic inhibition in middle age patients with essential hypertension. These 
changes were not associated with any significant modulation of arterial baroreflex 
control of muscle SNA. The sympathetic inhibition was accompanied by the long-term 
improvement in HR variability in response to the acute test. The strong correlation 
between acute reduction in the sympathetic nerve burst frequency and magnitude of the 
diastolic BP after the home-based device-guided slow deep breathing training indicates 
a possibility of utilization of the acute test for selection of patients who are more likely 
to respond to the treatment. 
 
Device-guided slow deep breathing training has been suggested to play a role in 
modulation of autonomic cardiovascular control, likely affecting pulmonary stretch 
receptors, cardiorespiratory reflexes, arterial baroreflexes, chemoreflex and central 
respiratory motor output.26-28, 31, 549, 568-572 Considering the absence of a long-term effect 
of slow deep breathing on parameters of cardiac baroreflex sensitivity, arterial 
baroreflex control of muscle SNA, and PETCO2 the sympathoinhibition could be due to 
enhancement of the central inhibitory rhythms beyond baroreflex and chemoreflex 
mechanism.586 Another possible mechanism is enhancement of the direct sympatho-
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inhibitory effects of lung inflation reflex due to activation of slowly adapting pulmonary 
stretch receptors.576, 587 Furthermore, slower spontaneous respiratory rate is closely 
associated with lower level of sympathetic activation. For instance, in study by 
Narkiewicz at al., respiratory rate was the only independent predictor of muscle SNA in 
young healthy men.130 This study results are consistent with above findings as a long-
term reduction in muscle SNA in this group of hypertensive was accompanied by 
numerically lower respiratory rate. Previously only one study evaluated the training 
effects of the device on muscle SNA and BP and it did not find any effect on either 
parameter.44 
 
Intriguingly, during the follow up visit in the hypertensive group, there was a 
pronounced improvement in HR variability indices of parasympathetic activity during 
the acute slow deep breathing. This indicates that the long-term device-guided slow 
deep breathing training increased the capacity for acute improvement of HR variability, 
in a response to the acute slow deep breathing. This improvement in HR variability may 
be explained by an enhanced increase in tidal volume, but not respiratory frequency or 
minute ventilation. Such improvements in HR variability responsiveness were not 
paralleled by an increase in steady state HR variability at the follow up. In fact, contrary 
to the study hypotheses HR variability indices decreased significantly. This is difficult 
to explain and these observations may indicate involvement of factors responsive to 
respiration and not accountable for in this study. 
 
Previously, the only study that assessed the long-term effect of the RESPeRATE device 
on HR variability, was performed in high risk hypertensive patients, with concomitant 
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diabetes and it showed reduction in BP and increase in LF power, with no effect on HF 
and total power by slow deep breathing but no direct measurements on sympathetic 
nervous system activity were collected.59 
 
6.6.3. Target organ damage 
 
Despite reductions in BP and muscle SNA no significant changes in cardiac structure 
and function, arterial stiffness or renal function were detected after the 8-week use of 
the device. Although previous data showed significant association between high 
sympathetic activity and development of LV hypertrophy in hypertension these changes 
in cardiac structure are reflective of chronic sympathetic hyperactivity.14-16 They take 
years to occur and resolution of LV hypertrophy would require long-term sustained BP 
reduction. Despite significant decrease in BP seen during the 8-week training in this 
study with resulting BP reaching recommended target levels the duration of the 
intervention was probably not sufficient to observe detectable improvement in target 
organ damage. Of note, the patients demonstrated good adherence to the required 
number of sessions, per week and their synchronization was above the previously 
suggested threshold of 65% for achieving significant systolic BP reduction. 497Although 
no significant improvement in the target organ damage was seen the changes were 
clearly in the direction towards such improvement as suggested by pathophysiological 
studies. Indeed, reduced HR variability was associated with LV hypertrophy in 
hypertensive patients17 and high muscle SNA was associated with LV diastolic 
dysfunction and increased arterial stiffness independently of BP levels.18, 19, 238, 580, 581As 
thus longer duration of slow deep breathing training may be needed to elicit befits 
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towards the cardiac structure, but also improvement in arterial stiffness and renal 
function. 
 
6.7. Conclusion 
 
In conclusion, long-term device-guided slow deep breathing training leads to 
sympathetic inhibition in middle age patients with essential hypertension. The 
sympathetic inhibition was associated with longer-term improvement in office BP and 
responsiveness of HR variability. The slow deep breathing training may provide 
therapeutic benefits in essential hypertension via inhibition of excessive sympathetic 
outflow. 
 
Contribution  
For this experimental chapter, I contributed to the study design. I undertook 
identification of the study participants, their screening, recruitment, consent, patient 
follow-up, examination, data acquisition (except for the microneurography, where 
positioning of the electrodes into the peroneal nerve was performed by Dr J. Fisher). I 
performed data analysis, data interpretation and wrote the thesis chapter.  
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CHAPTER VII. SUMMARY AND OVERALL CONCLUSIONS 
 
7.1. Thesis summary 
 
In Chapter 1. (Introduction) a broad introduction to the field with which this thesis is 
concerned was provided along with a rationale for subsequent experimental chapters. 
An overview of our present understanding of autonomic nervous system neuro-anatomy 
and regulation was provided (Chapter 2. Literature review). Following this the 
literature review provides a discussion of the pathways linking dysfunction of 
sympathetic nervous system and pathogenesis of hypertension, along with an overview 
of therapeutic approaches targeting the sympathetic nervous system in order to improve 
BP control. The literature review highlighted the gaps in our present knowledge that this 
thesis sought to address. 
  
Chapter 3 provides a description of the study methods. With the participants in supine 
position, standard microneurography techniques were used to record efferent 
postganglionic multiunit muscle SNA. HR was measured using ECG and beat-to-beat 
arterial BP non-invasively measured from the middle finger using photo-
plethysmography. Respiration related changes in thoracic circumference were measured 
using strain gauge pneumobelt. Participants were fitted with an oro-nasal mask and two-
way valve connected to a heated pneumotachometer to record respiratory parameters. 
Transthoracic echocardiography was used to assess cardiac structure and function to 
establish correspondence to inclusion criteria and effects of the slow deep breathing 
intervention. Arterial stiffness was assessed based on aortic augmentation index. 
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The raw muscle SNA, ECG, BP and respiratory signals underwent analogue-to-digital 
conversion at 10 kHz and were stored for offline analysis. Tidal volume and minute 
ventilation were calculated using the Spirometry module from Labchart 
(ADInstruments, Dunedin, New Zealand). PETCO2 level was derived from the relative 
percentage of expired CO2 waveform as the maximum value. Analyses of steady-state 
muscle SNA and its interaction with respiration were conducted using a custom written 
interactive scoring program (Spike 2, Cambridge Electronic Design, Cambridge, UK). 
The sequence technique was used to determine spontaneous cardiac baroreflex 
sensitivity. Calculations of arterial baroreflex control of muscle SNA were obtained 
from the relationships between diastolic BP vs. burst incidence and total muscle SNA 
by weighted linear regression analysis. 
 
The aim of the first experimental chapter (Chapter 4) was to determine the influence of 
age on respiratory related bursting of muscle SNA and on the association between the 
rhythmic fluctuations in muscle SNA and THW that occur with respiration in humans. 
In this part of the study 10 young and 10 older healthy males participated in the study 
and were investigated during 10 min of uncontrolled spontaneous breathing at a normal 
resting rate and depth.  
 
In contrast to the initial hypothesis, it was observed that the strength of the respiratory 
modulation of muscle SNA parameters (e.g., burst incidence, frequency, amplitude and 
total activity) were preserved in healthy older individuals. A significant association 
between the rMSNA and THW amplitude was identified and this was similar in healthy 
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young and older groups. Collectively, these findings suggest that a potential attenuation 
of inspiratory-linked inhibition of muscle SNA does not appear to explain the elevated 
resting muscle SNA in older individuals, and that central respiratory-sympathetic 
coupling is a component of the THW in both young and older humans 
 
The aim of the second experimental chapter (Chapter 5) was to investigate whether 
slow deep breathing reduces BP and muscle SNA in young healthy individuals, and to 
investigate the underlying autonomic neural control mechanisms. To achieve this, 
microneurographic recordings of muscle SNA were obtained in young healthy men 
during spontaneous breathing and acute device-guided slow deep breathing. Ten young 
healthy, non-smoking males underwent the experimental protocol, which consisted of 
10 min of uncontrolled spontaneous breathing followed by 10 min of slow deep 
breathing. The latter was guided by the RESPeRATE device (InterCure [UK] Limited, 
London, UK), which generates melodic tones to assist the individual in slowing their 
respiratory rate below 10 breaths per minute.  
 
The acute device-guided slow deep breathing led to a reduction of muscle SNA with no 
significant change in BP, arterial baroreflex control of muscle SNA or cardiovagal 
baroreflex regulation. These observations indicate that device-guided reduction in 
central sympathetic outflow are not accompanied by an increase in baroreflex sensitivity 
(cardiac or muscle SNA), but may be attributable to enhanced sympatho-inhibitory 
effects of lung inflation reflex and/or changes in central respiratory-sympathetic 
coupling. 
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The aim of the last experimental chapter (Chapter 6) was to comprehensively evaluate 
the acute and long-term training effects of device-guided slow deep breathing on 
autonomic regulation in hypertension reflected by muscle SNA, arterial baroreflex 
control of muscle SNA and parameters of HR variability effect on hypertension target 
organ damage (e.g. heart, vessels, kidney). To achieve this cardiorespiratory parameters, 
muscle SNA, HR variability and arterial baroreflex function were measured at rest and 
in response to acute slow deep breathing (10 min), both before and after home-based 
long-term device-guided slow deep breathing training (8 weeks). The influence of this 
training regime on cardiac (echocardiography), vascular (arterial stiffness) and kidney 
functions was also determined. 
 
In the cross-sectional study twenty patients with essential hypertension were compared 
with 19 age, sex and BMI-matched normotensive healthy controls. All hypertensive 
patients were clinically stable and treated. In the longitudinal study, 19 of 20 patients 
completed the follow up and were included in the analysis. 
 
In the cross-sectional part of the analysis, acute device-guided slow deep breathing led 
to a significantly greater reduction in systolic, diastolic and mean BP in the 
hypertensive group. The magnitude of the change in muscle SNA and baroreflex 
sensitivity were not different between two groups. Increases in HR variability in 
response to the acute slow deep breathing were more pronounced in the healthy group. 
 
In the longitudinal part of the analysis, after 8 weeks of home-based slow deep 
breathing training, office systolic BP was significantly reduced from 147±18.1mmHg at 
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the first visit to 133±17.0 mmHg at the follow up visit (P=0.001). Office diastolic BP 
was also significantly reduced over the same time period (84±9.5 vs. 79±12.3 mmHg, 
P=0.008). Muscle SNA burst frequency and burst incidence were significantly reduced 
at the follow up. No significant changes were found the clinical biochemistry, 
echocardiography measurements, respiratory parameters and in cardiac and sympathetic 
baroreflex control. RMSSD, SDNN, pNN50%, HF were modestly but significantly 
reduced following home-based slow deep breathing training, whereas TP, LF and 
LF/HF were unchanged. 
 
During the follow up visit, the changes in tidal volume with acute slow deep breathing 
were slightly but significantly greater, whereas reductions in BP reduction were less 
pronounced. No differences in the responses of muscle SNA, baroreflex sensitivity, 
minute ventilation and PETCO2 were observed with slow deep breathing. However, 
increases in indices of HR variability were more at the follow up visit.  
 
The study provides for the first time evidence of sympathetic inhibition by the long-
term device-guided slow deep breathing in middle-aged patients with essential 
hypertension. These changes were not associated with any significant modulation of 
arterial baroreflex control of muscle SNA. The sympathetic inhibition was accompanied 
by the long-term reduction in office BP and an improvement in HR variability in 
response to the acute test.   
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7.2. Study limitations 
 
Studies of respiratory modulation of SNA commonly assess respiration using a strain-
gauge pneumobelt and this practice was followed in the present work. The choice was 
made to avoid participants having to breathe through a mouthpiece and thus minimise 
alteration of breathing pattern and tension of the patient. However, the approach is 
limited by the fact that the time-delay between the occurrence of respiratory related 
events within the central nervous system and changes in thoracic circumference is not 
accounted for. I have assumed that the time-delay is the same in the different study 
groups. It has been previously shown that that there was not significant difference in 
muscle SNA during uncontrolled spontaneous breathing and controlled breathing at 12 
breaths per minute. 
 
As discussed earlier the processes implicated in regulation of the sympathetic system 
and BP are extremely complex and they interact with virtually all other systems of the 
body including very dynamic ones, such endocrine and immune systems. It is thus 
almost impossible to account for the multitude of factors modulating activity of 
autonomic system.  
 
The study does not provide insight into details of molecular mechanisms linking 
breathing modulation and pathways of sympathetic activation, in peripheral nerves but 
also in the brain, kidneys and blood vessels as well as mechanisms tested. Conduction 
of such studies in this human study was beyond the aims and available budget and the 
presented results should ideally be complimented by further mechanistic investigations. 
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These experiments need to be carefully designed to overcome limitations of available 
technologies. Some experiments, particularly those focusing on brain processes, may be 
unethical to be performed in humans but might be conducted on non-human models. 
Advances in non-invasive imaging technologies need to be fully utilized. 
 
The study measured muscle SNA directed to one region, namely the skeletal muscle 
vasculature. Although this is a standard approach in the field, having data from different 
peripheral nerves/target organs would be desirable. Also giving limitations of any used 
methods of assessment of autonomic nerve function or indirect nature of the 
measurements (e.g., based on HR variability) it would be ideal to use several different 
approaches to quantify each tested process to minimise risk of bias.  
 
Although the study populations is of typical size for this type of study a larger study 
cohort would permit greater confidence in study results and conclusions. 
 
7.3. Overall conclusion 
 
The study confirms links between activity of the sympathetic nervous system and BP 
and provides further insights into the contribution of ageing and respiration into the 
complex interplay between these systems. It shows that despite the presence of age-
related elevation in muscle SNA the strength of the respiratory modulation of muscle 
SNA is similar in young and older adults. This indicates that aging-related increase in 
muscle SNA has no association with a diminished respiratory-sympathetic coupling.  
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Although slow deep breathing does not affect BP or arterial baroreflex control of 
muscle SNA in young healthy men it does reduce muscle SNA burst incidence, 
frequency and total activity. These effects do not appear to be dependent on changes in 
baroreflex sensitivity, but may reflect an increase in lung inflation afferent input and/or 
a reduction in central respiratory-sympathetic coupling.  
 
Long-term device-guided slow deep breathing training in middle age patients with 
essential hypertension leads to significant sympathetic inhibition that was paralleled a 
significant reduction in both systolic and diastolic BP and improvement in 
responsiveness of HR variability. These findings indicate the slow deep breathing 
training may provide therapeutic benefits in essential hypertension via inhibition of 
excessive sympathetic outflow. 
 
Undoubtedly, complexity of regulatory mechanisms implicated in the processes studies 
leaves a possibility for alternative contributing factors, and certainly further research is 
essential to understand intimate details of the phenomenon tested in my study. 
 
7.4. Future research and implication for practice 
  
Given the multitude of interactions between the sympathetic nervous system, 
hypertension, respiration and aging a more detailed analysis molecular and cellular 
changes in each of the comportments of the sympathetic system is essential. This 
information would allow more holistic understanding of the processes involved and 
help finding ways to manipulate them in the desired direction.  
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Neuroimaging is a rapidly developing field. Whilst brain and spine magnetic resonance 
imaging and computer tomography have become standard clinical tools opportunities of 
functional brain imaging, although limited at present, could allow some insight into the 
interaction of the SNA and brain function. For example, Fatouleh at al have recently 
demonstrated linkage between peripheral sympathetic nerve burst size and central 
activation before and after 6 month treatment with continuous positive airway pressure 
in patients with obstructive sleep apnoea.588 However the currently available methods 
have limited capacity in assessment of brain processes related to SNA at molecular level 
(e.g., tracing neuromediator activity in specific parts of the brain). This may become 
possible in the future. For example, development of magnetic resonance tracking agents 
tagged with monoclonal antibodies can provide insight in processes mediated by 
proteins and containing them cells/organs. The role of non-invasive imaging in 
assessment of central and peripheral nerve activity (i.e., to trace changes in interactions 
of molecules and cells involved in activity of the sympathetic system) function is 
limited at present this may become an option in future.  
 
The present study assessed 8-week effects of slow deep breathing and both statistical 
power and the study duration were designed to establish physiological impact and 
significance of the tested processes in accordance with the study hypotheses. However 
the study was not designed to determine effects of the findings on long-term clinical 
outcomes. Appropriately designed randomized trials are needed to determine clinical 
benefits of this treatment strategy in terms of quality of life, target organ damage (e.g., 
LV hypertrophy, renal function) and outcomes (e.g., risk of stroke or death). Although 
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essential hypertension itself is a primary focus of such interventions the approach could 
also be tested in other disorders where hypertension poses significant risk (e.g., 
ischemic heart disease and heart failure). In order to determine contribution changes in 
the sympathetic system to these outcomes it is essential to include minimally obtrusive 
markers of sympathetic activity as part of the future trials (e.g., plasma catecholamine 
levels). Identification of specific molecular targets able to modulate the SNA in 
desirable direction would help to develop new antihypertensive medicines. 
 
This work suggests that testing of acute response of the muscle SNA to slow deep 
breathing can predict the magnitude of reduction of diastolic BP after 8-week slow deep 
breathing training. In order to optimize utilization of the technique further research into 
the predictors of responsiveness to the intervention would be desirable. This will help 
identify patients who are more likely to gain most benefits from it. Testing the 
predictive value of acute muscle SNA response for establishment of long term effects of 
slow deep breathing intervention would be an option, but it can also be complemented 
by other methods of quantification of acute response of the sympathetic system (e.g., 
measurement of catecholamine levels) and functional neuroimaging. Additionally it 
would be reasonable to compare the effects of different timings of the intervention (e.g., 
10 min vs. 20 min. vs. 30 min) aiming to both optimise the therapeutic effects and 
minimise inconvenience to the patients. 
 
A number of pharmacological agents are routinely used in management of hypertension; 
some are known to interact with the sympathetic system. It would be important to know 
the effects of these agents on respiratory sympathetic coupling with and without 
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application of slow deep breathing techniques. Together all this information would 
facilitate better management of hypertension in the future. 
 
As respiratory disorders are common and they often involve some disturbances of the 
immune system it would be of interested to test changes in SNA and their interaction 
with respiration in patients with hypertension and concomitant lung problems, such as 
asthma and chronic obstructive pulmonary disease.  
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APPENDICES 
 
Appendix 1. List of the study publications 
 
Manuscript: 
Shantsila A, McIntyre DB, Lip GY, Fadel PJ, Paton JF, Pickering AE, Fisher JP. 
Influence of age on respiratory modulation of muscle sympathetic nerve activity, blood 
pressure and baroreflex function in humans.  Exp Physiol. 2015 Sept; 100: 1039-51. 
 
Abstracts presentation: 
Shantsila A, Adlan AM, Lip GYH, Pickering AE, Paton JFR, Fisher JP Does home-
based, slow deep breathing training reduce central sympathetic outflow and enhance 
baroreflex sensivitiy in primary hypertension? BCS Conference 2015, Manchester, June 
8-10. The top scoring clinical abstract award in the Stable 
IHD/Prevention/Hypertension/Lipids category  
 
Shantsila A, Adlan AM, Lip GYH, Pickering AE, Paton JFR, Fisher JP.  Effect of 
device-guided slow deep breathing on central sympathetic outflow and arterial 
baroreflex sensitivity in young healthy individuals. Experimental Biology 2014, San 
Diego, April 26-30. 
 
Shantsila A, Adlan AM, Lip GYH, Pickering AE, Paton JFR, Fisher JP. Device-guided 
slow deep breathing in essential hypertension: is cardiac or sympathetic baroreflex 
sensitivity altered? Experimental Biology 2014, San Diego, April 26-30. 
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Shantsila A, McIntyre DB, Lip GYH, Paton JFR, Fadel PJ, Pickering A E, Fisher JP. 
‘Influence of age on respiratory modulation of muscle sympathetic nerve activity and 
blood pressure in humans’ Experimental Biology 2013, Boston, April 20-24: 
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